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SUMMARY 
Aberant choline  metabolism is a feature shared  by  many tumors. It is  predominantly 
caused  by elevated expression and activation  of choline  kinase alpha (ChoKα),  which 
catalyzes the phosphorylation of choline to phosphocholine in the Kennedy’s pathway for 
membrane lipids synthesis. In this  PhD thesis, the  most  promising symmetrical  ChoKα 
inhibitor  has  been identified from the  novel series  of choline  kinase inhibitors,  designed 
and synthesized  by  Prof.  Lopez-Cara’s  group,  University  of  Granada,  Spain.  The 
therapeutic potential of the selected lead compound was compared to previously reported 
symmetrical  ChoKα inhibitors and evaluated in two  diferent tumoral contexts. 
Furthermore, the  new  ChoKα inhibitor  was  used to investigate for the first time choline 
metabolism deregulation in hematological tumors. 
The  ChoKα inhibitor EB-3D (also  known as compound 10a) was selected as lead 
compound. The crystal structure of ChoKα1 in complex with compound EB-3D (PDB ID: 
5FTG) reveals that the compound efectively binds to the choline-binding site and inhibits 
ChoKα1 with IC50 of 1.00 ± 0.01 µM. EB-3D strongly inhibits cel growth in a panel of 
cancer cel lines with GI50 ranging from 27 to 110 nM for solid tumors and from 0.9 to 479 
nM for  hematological tumors. EB-3D inhibits also the formation  of  phosphocholine and 
reduces the content of choline-containg metabolites in treated cels. 
In triple-negative  MDA-MB-231  breast cancer cels, EB-3D arests cels in the  G0/G1 
phase  of the cel cycle triggering ireversible celular senescence.  Moreover, EB-3D 
potentiates the antitumoral efect of cisplatin and impairs migration and invasiveness of the 
higly metastatic MDA-MB-231 cel line. Lastly, treatment of syngeneic orthotopic EO771-
C57BL/6  mouse  model  with  1mg/kg  of EB-3D i.p. resulted in strong tumour  growth 
inhibition and reduction  of  metastasis formation. Altogether, these  data reveal the 
antitumorigenic and antimetastatic potential of EB-3D in triple-negative breast cancer. 
T acute lymphoblastic leukemia (T-ALL) cel lines exhibit increased levels  of  ChoKα 
compared to  healthy lymphocytes and  higher  ChoKα/β ratio. EB-3D induces  G0/G1 cel 
cycle arest in  T-ALL and, in contrast to  breast cancer cels, induces cel  death  by 
apoptosis. The efect is rapidly triggered and cannot be rescued by compound withdrawal. 
EB-3D modulates the AMPK-mTOR pathway leading to the inactivation of final efectors 
required for  protein synthesis and cel cycle  progression.  On the contrary, the efect 
appears atenuated in  normal lymphocytes  where  other signaling  pathways are involved. 
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Finaly, EB-3D strongly synergizes with L-asparaginase lowering the GI50 and increasing 
cel  death. Taken together, these  data  validate  ChoKα as a  novel atractive therapeutic 
target in T-ALL and justify the further development of EB-3D inhibitor. 
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1. INTRODUCTION 
1.1 Lipid Metabolism: a new halmark of cancer 
The reprogramming  of celular energy  metabolism is required to support exacerbate cel 
growth and  proliferation, replacing the  metabolic  program that  operates in  physiological 
counterpart.  In fact, the “metabolic reprogramming”  has  been introduced as  one  of the 
new halmarks of cancer (Hanahan and Weinberg, 2011). This is especialy true for solid 
tumors where cancer cels are surounded by a totaly diferent microenvironment than that 
of  normal cels, and tumor cels  must exhibit rapidly adaptive responses to  hypoxia and 
hypo-nutrient conditions.  Metabolic reprogramming is also required for  both tumor 
invasion and  metastasis since cels  must adapt to  new  microenvironment condition and 
diferent chalenges. Also in  non-solid tumors  mechanism  of  metabolic switch  have  been 
described (Kishton et al., 2016). 
Changes in lipid  metabolism  during tumorigenesis  have long  been  described  but the 
molecular  mechanisms  underlying these alterations are stil  being  unraveled (Santos and 
Schulze,  2012).  Beyond their important role in  delimiting cel structure and  organeles, 
lipids are also fundamental for cel shape and motility, membrane protein localization and 
generation  of  bioactive signaling  molecules.  Because the  uncontroled  proliferation  of 
cancerous cels requires sustained lipids synthesis,  many  oncogenes  directly  or indirectly 
regulate lipids turnover (Menendez and  Lupu,  2007; Ricoult et al.,  2016).  However, the 
overexpression  of lipid enzymes  generaly is  not suficient to  drive  malignant 
transformation.  A  notable exception is represented  by choline  kinase α (ChoKα;  E.C. 
2.7.1.32). 
1.2 The Kennedy’s Pathway 
Choline  kinase (ChoK) is  one  of the  most important enzymes for the  generation  of two 
major  membrane  phospholipids,  phosphatidylcholine (PtdCho) and sphingomyelin (SM), 
and subsequently for the cel  division.  Free choline (Cho) is transported inside cels  by 
diferent classes  of choline transporters (ChoT).  The choline  kinase catalyses the  Mg2+-
ATP-dependent  phosphorylation  of choline to  phosphocholine (PCho) as the first step in 
the CDP-choline branch of Kennedy’s pathway (Kennedy, 1957) (Figure 1). As a mater of 
fact,  ChoK could also  phosphorylate ethanolamine in the  paralel  CDP-ethanolamine 
branch. The succesive PCho conversion to CDP-choline is the rate-limiting step catalyzed 
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by the phosphocholine cytidylyltransferase (CCT) that becomes active only when recruited 
to the nuclear membrane. The final step of the pathway involves the transfer of 
phosphocholine headgroup from CDP-choline to diacylglycerol (DAG) backbone to form 
PtdCho, catalyzed by choline phosphotransferase (CPT), located predominantly in 
endoplasmic reticulum (ER) and Golgi membranes. 
 
Figure 1: The Kennedy’s pathway 
Simplified scheme of the CDP-choline branch of Kennedy’s pathway. 
Cho, choline. ChoK, choline kinase. PCho, phosphocholine. PtdCho, phosphatidylcholine. 
 
Various phospholipase enzymes can break down PtdCho: phospholipases A1 and  A2 
(PLA1 and PLA2) generate faty acids and lyso-phosphatidylcholine (Lyso-PtdCho), 
which is further metabolized by lysophospholipase (LPL) into faty acids and 
glycerophosphocholine (GPC); phospholipase C (PLC) generates PCho and  DAG; and 
phospholipase D (PLD) generates choline and phospahtidic acid (PA). GPC can be further 
metabolized by glycerophosphocholine phosphodiesterase (GDPD) into choline. 
1.3 Choline Kinase (ChoK) 
In humans, ChoK is encoded by two diferent genes, CHKA and CHKB, located in 
chromosomes 11q13.1 and 22q13.33 respectively. Because of the high sequence similarity 
(~60%) it seems reasonable that the two genes arise from a process of gene duplication 
from a common ancestor. CHKA generates two isoforms by alternative splicing ChoK�1 
(457 aa) and ChoK�2 (439 aa) while CHKB encodes ChoK� isoform (395 aa). The 
functional form of the enzyme is homodimeric or heterodimeric with diferent activity 
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levels: α/α  dimers  have the  highest activity, α/β intermediate and β/β the lowest activity. 
The three isoforms are ubiquitously expressed but their ratio varies widely between tissues. 
Each isozyme can  phosphorylate  both choline and the structuraly similar ethanolamine, 
but  ChoKα  has  higher afinity for choline  whereas  ChoKβ is  more selective for 
ethanolamine substrate. 
The crystal structures of human ChoKα in its apo form, ADP and phosphocholine-bound 
complexes reveal the molecular details of the substrate binding sites (Figure 2). ATP binds 
in a cleft formed by residues from both N and C-terminal lobes, while the choline-binding 
site constitutes a deep hydrophobic groove in the C-terminal domain with a rim composed 
of negatively charged residues.  
 
Figure 2: Crystal structures of human ChoKα monomer with PCho and ADP 
Ribbon diagram of ChoKα monomer with ADP and PCho molecules concomitantly present. Key structural 
elements are colored: the ATP-binding loop in blue, the dimer interface α-helix in cyan, the short β-strand 
that links the N and C-terminal domains in yelow, the Brenner's motif in red, and the choline kinase motif in 
green. Bal-and-stick representation of ADP and PChol molecules are shown with their carbon atoms colored 
in  orange and  green, respectively.  Oxygen,  nitrogen and  phosphate atoms are shown in red,  blue and 
magenta, respectively. Adapted from Malito et al., 2006. 
ChoK can  be considered an atypical  kinase  because it  works  by a two-steps  mechanism, 
without the formation  of a ternary complex (Figure  3).  First,  ATP transfers a  phosphate 
group directly to the enzyme at Asp306 residue and then, only the phosphorylated enzyme 
is able to bind the choline substrate. Choline binding causes a conformational change that 
favours the transfer  of  phosphate  group from the enzyme to choline and the folowing 
release of PCho. 
 
domains, respectively). The most significant difer-
ence centers at residues 262–281 (hCKα2 number-
ing). This segment comprisesanα-hlix i hCKα2
(Figure 1(a) and (b), helix 5) instead of two shortβ-
strands (7 and 8, CKA-2 numbering), and is not part
of any talyticalyrlevantregion. Eachmonomer
Figure 1.Ribbon diagram of apoh Kα2, and wih ADPand PChol mlecules cncomitantly present as modeled on
the basis of the determined hCKADPand hCKPCholcomplex structures. (a) hCKApodimer (gray/yelow ribbon) orientedwith the 2-fold non-crystalographic axes perpendicular to the planeof te page. Dimer fr ation buries 2100 Å2, whe
helix 2 plays a major role. (b) Stereodiagram f ahCKα2 monomer drawn after a vertical rotaton o 90° with respet to
the orientation in (a). Key structural elements are colored: the ATP-binding loop in blue, the dimer interfaceα-helix in
cyan, the shortβ-strand that links the N and C-terminal domains in yelow, the Brenner's motif in red, and the choline
kinase motif in green. In this andthe folowing Figu , bal-ad-stick representatin of ADP and PC l molecules ae
shown with their carbon atoms colored inoangeand green, respectivly.Oxygen,nitrogen and phosphateatom are
shown in red, blue and magenta, respectively. Al structure Figures were made with Pymol. [htp://www.pymol.org].
138 Structure of Human Choline Kinase
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Figure 3: ChoKα phosphorylates choline via an unusual two-steps mechanism 
Unprotonated Asp306 residue in the active site of human ChoKα can accept a phosphate group by a Mg2+ 
coordinated reaction resulting in  protonation  of the amino acid and subsequent ejection  of  ADP.  The 
phosphate-primed enzyme can accept Cho, which induces a conformational shift in the enzyme resulting in 
PCho exit. The deprotonated ChoKα enzyme reverts to its original conformation and is again ready for ATP 
binding. Adapted from Arlauckas et al., 2016. 
 
In mammalian cels,  only the  ChoKα isoforms  play a central role in sustaining  PCho 
biosynthesis.  Knock-out experiments in  mouse  model revealed that  only CHKA deletion 
leads to embryonic lethal phenotype indicating that ChoKβ isoform cannot compensate to 
ChoKα absence (Wu et al.,  2008).  Therefore,  ChoKα is essential for cel  viabily and 
proliferation. 
Most importantly, the  overexpression  of  ChoKα isoform alone is suficient to  drive 
tumorigenesis,  while  ChoKβ is  not (Galego-Ortega et al.,  2009).  To reinforce the 
importance  of  ChoKα isoform and its involvement in  pathogenesis, several studies 
revealed that  ChoKα,  but  not  ChoKβ,  protein expression in inducible  by carcinogenic 
substances, by oncogenes overexpression or mutation and by treatment with other kinase 
inhibitors. In fact, both CHKA and CHKB genes are controled by a constitutive promoter 
but, in CHKA regulatory regions the presence of inducible promoters have been described. 
The hepatotoxin CCl4 increases the expression of ChoKα through the upregulation of c-jun 
transcription factor that binds to the activator protein 1 (AP1) consensus site located in a 
distal  promoter  of  CHKA  gene (Aoyama et al.,  2007).  The induction  of c-myc  proto-
oncogene increases ChoKα expression (Morish et al., 2008) and the consequent increase 
in  PCho levels (Morish et al.,  2009).  Low  oxigen condition also regulates  uniquely 
ChoKα expression  due to the  presence  of  hypoxia-inducible factor  1α (HIF-1α)  binding 
sites in its promoter region (Bansal et al., 2011; Glunde et al., 2008). 
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1.4 The “Cholinic Phenotype” in tumorigenesis 
Alteration in the choline  metabolism, characterized  by  ChoKα  overexpression and/or 
hyperactivation and the resulting increase  of  phosphocholine (PCho) and total choline-
containing compounds (tCho) in general, is refered to as “cholinic phenotype” and it has 
been associate to tumorigenesis. Indeed, high levels of ChoKα were first reported for colon 
cancer and since then for breast, lung, prostate and ovarian tumors. 
PCho  metabolite levels and  ChoKα activity  were  higher in colon cancer than in  normal 
colon tissue (Nakagami et al., 1999). Ramírez de Molina et al. described increased ChoKα 
protein expression in lung,  breast and  prostate cancer compared to their  normal 
counterparts (Ramírez de Molina et al., 2002d).  Toghether with enzymatic expression, it 
has also been reported the augmented ChoKα activity in tumoral biopsies of patients with 
breast cancer and a clear corelation  between  ChoKα activity and  histologic tumor  grade 
(Ramírez  de  Molina et al.,  2002a).  This  work  highlighted for the first time that  ChoKα 
activation could  be considered as a  marker  of  malignancy and  worst  prognosis in  breast 
tumors.  mRNA and  protein expression  of  ChoKα  were found  upregulated in  primary as 
wel as  metastatic  prostate tumors  with an assciation  with tumor  grade and  poor 
recurence-free survival (Asim et al.,  2016) and the immunohystochemical  detection  of 
ChoKα has been proposed for diagnostic purpose (Chalapali et al., 2015). A retrospective 
study indicated the overexpression of ChoKα as an independent predictor factor of relapse-
free survival in early-stage  non-smal-cel lung cancer (Ramírez  de  Molina et al.,  2007). 
Abnormal choline  metabolism  was extensively  described also in  ovarian cancer  with the 
overexpression of PCho in tumor cel lines (Iorio et al., 2005) and the overexpression and 
hyperactivation of ChoKα in both cel lines and patient’s tumor sample (Iorio et al., 2010). 
Recently, a serum  metabolomic  profile analysis revealed  dysregulation  of choline 
metabolism in  patients  with  T cel lymphoma along  with  ChoKα  protein  overexpression 
(Xiong et al., 2015). 
1.5 Diagnostic and prognostic value in cancer 
Tumor imaging plays a significant role in diagnosis, treatment planning, and folow-up in a 
variety of tumors. The search for biomarkers non-invasive cancer detection and to monitor 
the response to treatment has led to several clinical studies evaluating the level of choline-
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containing metabolites in many tumors, including breast, ovarian, lung, colon, prostate and 
brain tumors. 
While  magnetic resonance imaging (MRI) identifies the anatomical location  of a tumor, 
MR spectroscopy (MRS) compares the  diferent  metabolic  profile  between tumor tissue 
and  normal tissue.  Specificaly, 1H-MR spectra alow the  visualization  of tCho  peak 
(consisting of the sum of Cho, PCho and GPC) that is higher in tumoral lesion compared to 
surounding tissues (Figure  4).  The increasing resolution  obtained  by 1H-NMR alows to 
discriminate choline (Cho), phosphocholine (PC) and glycerophosphocholine (GPC) peaks 
from cancer cel extracts. 
 
 
Figure 4: Metabolite analysis by 1H and 31P-MRS. 
a)  Typical  MRS spectra  obtained from in vivo tumour  models and live cancer cels  where total choline-
containing compounds (tCho) signal in is  detected as a single  peak. In cancer cel extracts, the increasing 
resolution alows to  discriminate choline (Cho),  phosphocholine (PC) and  glycerophosphocholine (GPC) 
peaks. b) Structures of the choline-containing metabolites detected by MRS analysis. Adapted from Glunde 
et al., 2011. 
 
To date, MRS is considered the curent clinical gold standard for some tumor (e.g. brain) 
however,  despite  providing superior structural  detail, it features  poor specificity in 
identifying residual tumors, especialy after treatments (Figure  5).  The introduction  of 
positron emission tomography (PET), and its combination  with computed tomography 
(PET/CT), that employs  molecular tracers involved in celular  metabolism significantly 
improved  patients management. [18F]  2-fluoro-2-deoxy-D-glucose (18F-FDG) is the  most 
common radiotracer, unfortunately 18F-FDG PET/CT presents poor specificity such as the 
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high  glucose  uptake  of certain  normal tissue (e.g.  brain cortex), low tumor/background 
signal ratio, and the  high accumulation also in inflammatory sites. Indeed, the recent 
introduction  of 11C-choline PET/CT imaging improved the  diagnosis  of some  borderline 
cases.  A comparison study  between 18F-FDG and 11C-choline  PET in  diferent tumors 
revealed that the two technique are comparable in al cases except for brain tumor where 
choline uptake result more specific (Tian et al., 2004). Indeed 11C-choline PET/CT shows 
higher sensitivity and specificity than 18F-FDG and MRI in brain tumor diagnosis (Tan et 
al., 2011) and higher accuracy for diferentiating radiation necrosis and tumour recurence 
(Giovannini et al., 2015) but also to distinguish tumor lesion from pulmonary tuberculosis 
nodule (Hara et al.,  2003).  Colectively these studies support the relevance  of choline 
metabolism in tumors and that 11C-choline  PET/CT is a compeling alternative to the 
widely used MRI and 18F-FDG PET/CT. 
 
Figure 5: Comparison between 11C-choline PET/CT and 18F-FDG PET/CT scans 
PET/CT scans of a 55-year-old patient with suspected recurrence, >2 years after radical prostatectomy. Focal 
11C-choline  uptake (a) in right (bold arrow) and left (thin arrow) iliac region revealed lymph  node 
involvement,  not  observed  with 18F-FDG  PET (b). Coronal (left), axial (middle), and sagital (right) fused 
image projections of PET/CT scans. Adapted from Richter et al., 2010. 
1.6 Choline Kinase α as therapeutic target 
Altogether, the studies reporting  ChoKα  overexpression and  hyperactivation in tumors, 
suggest  ChoKα as  prognostic  marker for cancer  progression and as a  novel therapeutic 
target to improve cancer treatments. 
siRNA-mediated  knockdown  of  ChoKα induces apostosis in  HeLa cels,  while single 
ChoKβ or simultaneous ChoKα/ChoKβ silencing have no efect on cel viability (Gruber et 
al.,  2012), suggesting that the  balance  between α and β isoforms is important for cel 
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viability.  This finding also emphasizes the concept that  ChoKα is the  only relevant 
isoenzyme for tumor cel survival, although  no evidence suggests a  diferential role for 
ChoKα1  or  ChoKα2. Indeed,  downregualtion  of CHKA  by  RNA interference  has  been 
demonstrated to reduce cel  proliferation and tumor  growth (Glunde et al.,  2005; 
Krishnamachary et al., 2009), prevent mitotic entry (Gruber et al., 2012), induce apoptosis 
(Falcon et al.,  2013), sensitize cancer cels to chemotherapeutics (Granata et al.,  2014; 
Mori et al., 2007) and suppress migration and invasion (Asim et al., 2016; Granata et al., 
2015). 
CHKA silencing  has  been reported to reduce in vitro cel  proliferation in  breast cancer 
(Glunde et al., 2005) and ovarian cancer due to the accumulation of cels in the G1 phase 
of the cel cycle (Granata et al., 2014). On the contrary, ChoKα overexpression is suficient 
to  promote cel  proliferation  of  quiescent  human  mammary epithelial cels (HMEC) 
promoting entry into S phase of cel cycle (Ramírez de Molina et al., 2004a). According to 
these  data,  mitotic  defects  were  observed after CHKA silencing (Gruber et al.,  2012), 
reinforcing the idea that ChoKα is required for cel cycle progression. 
Some researches recently gave insight in signaling pathway modulated by ChoKα specific 
inhibition.  ChoKα  downregulation in  ovarian cancer inhibits cel  proliferation  without 
afecting cel viability, as shown by the absence of changes in the phosphorylation levels 
of AKT, also known as protein kinase B (PKB), and the mitogen-activated protein kinase 
(MAPK) survival signaling  pathways (Granata et al.,  2014).  On the  other  hand, several 
authors  have reported the induction  of cel  death in  CHKA-silenced  HeLa (Falcon et al., 
2013; Yalcin et al.,  2010) and Jurkat cels (Xiong et al.,  2015) along  with the 
dephosphorylation  of  AKT and the extracelular signal–regulated  kinases (ERK).  The 
apoptotic efect of CHKA silencing has been described also for breast cancer model, where 
it seems to be specific for tumoral cels wherease it is not lethal for the quiescent human 
mammary epithelial cels (HMEC) (Bañez-Coronel et al., 2008).  
Although it  has  been reported that  mitogenic and  growth factors (such as  oestrogens, 
insulin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF) as wel as 
Ras protein family members, enhance ChoKα activity, the exact mechanisms stil remain 
unclear. In fact, nowadays litle is known about interaction with other proteins and possible 
phosphorylation sites on human ChoKα. The fact that EGF or insulin stimulation enhances 
choline uptake and PCho production has been described for quite some time ago (Uchida, 
1996) but only recently, the interaction between EGF receptor (EGFR) and ChoKα through 
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c-Src kinase was shown. Indeed EGFR forms a complex with c-Scr, which recruits ChoKα 
to the cel  membrane and  phosphorylates the enzyme at  Tyr197 and  Tyr333 residues 
causing ChoKα activation (Miyake and Parsons, 2012). These data reveal for the first time 
an activating  phosphorylation in  human  ChoKα and  demonstrate a link  between  ChoKα 
and growth factor stimulation. On the other hand, members of the Ras oncogenes family 
are frequently  mutated in  human cancers, and the  overexpression  of either  of the RAS 
genes in fibroblasts results in  ChoKα activation and sensitizes cels to  ChoKα inhibitors 
(Ramírez de Molina et al., 2001). The exact mechanism of Ras-induced ChoKα activation 
remains  unclear  but it  has  been  proposed that  Ral-GDS and  PI3K contribute in  ChoKα 
activation in the Ras-mutated background (Ramírez De Molina et al., 2002c). 
1.7 Choline Kinase α Inhibitors (ChoKαIs) 
In the  past three  decades, there  has  been  growing interest in the “cholinic  phenotype”, 
identifying  ChoKα as a  new atractive therapeutic target.  Despite  ChoKα knock-down 
through RNA interference has largely contributed to our knowledge in the oncogenic role 
of  ChoK isoforms, the  use  of smal  molecules as  ChoK inhibitors remains the  more 
feasible approach for clinical trials.  Thus, the last ten  years  have  witnessed a frantic 
activity in the synthesis  of  new  ChoKα inhibitors  by several research  groups.  The 
determination of the crystal structures of ChoK proteins (Malito et al., 2006; Peisach et al., 
2003) and the localization  of  ATP and choline  binding sites into the crystal structure  of 
human ChoKα have enabled the design and the synthesis of a series of smal molecules as 
potential ChoKα inhibitors and antiproliferative compounds. 
1.7.1 Symmetric ChoKα inhibitors 
The majority of ChoKα inhibitors are derived from the Hemicolinium-3 (HC-3) (Figure 6-
7), the first known ChoKα inhibitor that unfortunately presented high neurotoxicity in vivo 
because its of-target inhibition of the high-afinity choline transporter interfering with the 
cholinergic neurotransmission (Lloveras et al., 1985). 
However, the inhibitory efect of HC-3 was extremely higher toward the ChoKα isoforms 
compared to  ChoKβ, indicating that  HC-3 is a  more  potent and selective inhibitor for 
ChoKα, showing similar activity toward α1 and α2 isoforms (Hong et al., 2010). 
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Figure 6: Crystal structures of ChoK!1 monomer with HC-3 and ADP 
Adapted from Hong et al., 2010. 
The HC-3-based inhibitors present a symmetric  biscationic structure composed by a 
hydrofobical spacer (linker) whose lenght is critical for the proper distance between the 
two cationic heads. Quantitative structure-activity relationship (QSAR) analyses suggest 
that the inhibitor-binding site of ChoK� is highly specific for predominantly hydrophobic 
molecules carying positively charged nitrogens. Depending on their head-groups, that 
always include a positively charged quaternary ammonium, symmetric inhibitors are 
divided in two main classes, bis-pyridinium or bis-quinolinium ChoK� inhibitors. 
The most promising bis-pyridinium compounds is MN58b (Figure 7)  designed  by  Prof. 
Lacal’s group, with a strong improvement in ChoK� inhibition compared to its ancestor 
HC-3. The compound resulted efective in vitro against multiple cancer cel lines  being 
highly selective in tumoral cels kiling through the induction of cytotoxic ceramides and 
endoplasmic reticulum (ER) stress (Al-Safar et al., 2006;  Rodríguez-González et al., 
2004;  Rodríguez-González et al., 2003). MN58b also reduced in vivo tumor growth 
(Hernández-Alcoceba et al., 1999). 
QSAR studies of bis-pyridinium ChoK� inhibitors and the analysis of their interaction with 
the active site, led to the substitution of the pyridine moiety with a quinolinium group, 
increasing compound hydrophobicity. In this category, RSM-932A (named also TCD-717, 
Figure 7) resulted the most important candidate, with further improvement  of  ChoK� 
inhibition and greater antiproliferative activity in vitro (Sanchez-Lopez et al., 2013). This 
compound presented also good in vivo antitumoral activity (Lacal and Campos, 2014) and 
notably it has recently completed Phase I clinical trial for solid tumor treatment 
HC-3 Ineracion with N-ChoK 1—The cystal structur of
theN-ChoK 1ADPHC-3 complex reveals that HC-3 bound
to a groove on the C-terminal lobe near the interlobe cleft in a
manner where one oxazinium ring occupied the choline-bind-
ing pocket, and the other oxazinium ring was partialy exposed
to solvent (Fig. 3A). The HC-3-
binding groove was lined by hydro-
phobic residues (Tyr-354, Phe-361,
Trp-420, Trp-423, Ile-433, Phe-435,
Tyr-437, and Tyr-440), and only one
side of the planar HC-3 molecule
contributed to the hydrophobic
interaction with the groove (Fig.
3B). The HC-3 oxazinium ring
that occupied the choline-binding
pocket could be superimposed onto
the choline moiety modeled from
the crystal structure of ChoK in
complex with Pho-Cho (PDB code
2CKQ) (Fig. 4), providing direct
structural evidence supporting the
idea that HC-3 competes with cho-
line for the same binding pocket on
ChoK (28).
The N-ChoK 1 model showed
that ADP and two magnesium ions
were located at the nucleotide-bind-
ing site of the N-terminal lobe
(supplemental Fig. S1A). In addi-
tion, the extra tetrahedral electron
density was observed close to the
-phosphate of ADP and was
assigned as a sulfate ion originating
from the crystalization bufer
(supplemental Fig. S1A). ADP inter-
acted either directly or indirectly
with multiple residues (i.e.Arg-117,
Arg-146, Asp-306, Asn-311, Asp-
330, and Glu-332) and water mole-
cules, and its phosphate oxygens
coordinated two magnesium ions
(seesupplemental Material IIfor
details and supplemental Fig.
S2A). The N-ChoK 1 structure
further suggested potential struc-
tural roles of some residues near a
nucleotide-binding site that have
not been previously defined. Arg-117
forming a portion of an ATP-binding
loop (residues 117–124) pointed
toward the -phosphate of bound
ADP, thereby positioning the nu-
cleotide for enzymatic catalysis
(supplemental Fig. S1A). Glu-332,
which belongs to the highly con-
served ChoK motif of the C-termi-
nal lobe (9), participated directly in
coordination of the second magne-
sium in (supplemental Fig. S2A).
HC-3 Phosphorylation by N-ChoK —In the crystal struc-
ture of theN-ChoK ternary complex, HC-3 was bound in the
same way as described for the N-ChoK 1 model (Fig. 3C),
which, with one exception (Ile-366), was also reflected in the
FIGURE 3.Overal structures of N-ChoK ternary complexes.A,ribbon diagramsof the crystal structures of
N-ChoK1(pink) and(lime green) ternary complexes. Adenine nucleotides, HC-3, and Pho-HC-3 are shown
within the sigma-weightedFo Fcomit map (blue) contoured at the 2.5 level and indicated byarows. Onemonomer in the dimeric N-ChoK models is indicated.B, close-upstereo viewof the HC-3-binding site in the
N-ChoK1ADPHC-3 complex structure. The diference Fourier map for HC-3 is drawn at a contour level of 2.5
. The HC-3 (yelow) and its surounding hydrophobic residues (pink) are marked and represented instick mode.
C, close-upstereo viewof the HC-3-binding site in the N-ChoK ADPPho-HC-3 complex structure. The difer-
ence Fourier map coresponding to Pho-HC-3 is drawn at a contour level of 2.5. The Pho-HC-3 (yelow) and its
rounding hydrphobic residues (limgreen) aremarkedand shown instck ode. Theinsetdisplays the
phosphorylated region of Pho-HC-3 at a slightly diferent angle. Al of the figures were generated using PyMOL
(DeLano, W. L. (2002)Te PyMOL Mlecular Graphics System, DeLano Scientific LL, San CarlosCA).
Crystal Structures of ChoK Isoforms in Complex with HC-3
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(NTC01215864) but preclinical data are undisclosed. As described for MN58b, also RSM-
932A induces  ER stress response along  with the activation  of the transcription factors 
CCAAT-enhancer-binding protein (C/EBP) and its homologous protein (CHOP), causing a 
pronounced apoptotic response restricted to cancer cels and  not  observed in  normal 
counterparts (Sanchez-Lopez et al., 2013). 
 
 
Figure 7: Symmetric ChoKα inhibitors 
General structure  of each symmetric inhibitor class (left column) and their most representative compound 
(right column). Adapted from Arlauckas et al., 2016. 
1.7.2 Non-symmetric ChoKα inhibitors 
Generations of half-inhibitor fragment were right after tested to understand if the symmetry 
was a necessary feature for ChoKα inhibition, but the first results were disappointing, with 
lower inhibitory  property and  higher toxicity.  These  data, togheter  with the crystal 
structure of inhibitors docked at the ChoKα active site, discredited the hypothesis that each 
cationic  head  of symmetric compounds interacts  with the active site  of  one  of the two 
monomers (Lacal, 2001). In fact, it is now clear that the two choline-binding sites are too 
far for the symmetric inhibitors to span  between the  ChoKα  dimers (Hong et al.,  2010). 
What remained to be elucidated is the possibility that the un-bound head interacts with the 
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ATP-binding site.  Pursuing this conjecture, researchers lately atempted to  design  dual 
inhibitors composed by one choline-like group while the other mimics the ATP structure 
(Schiafino-Ortega et al.,  2013; Trousil et al.,  2013).  The results  unfortunately suggested 
that the asymmetrical conformation of inhibitors potentialy interferes with the interaction 
between the second molecule of inhibitor and the coupled monomer (Sahún-Roncero et al., 
2013). 
Recently,  based  on the crystal structure  of  ChoKα,  Clem et  al. conducted an in silico 
screening  of smal  molecules identifying CK37 (Figure  8) as  new  potential  ChoKα 
inhibitor. Despite the novelty of lacking the quaternary ammonium that certainly improve 
compound  hydrophobicity, CK37 resulted in lower afinity for  ChoKα compared to the 
symmetrical inhibitor while displaying antiproliferative activity both in vitro (Clem et al., 
2011) and in vivo (Xiong et al., 2015). 
Finaly, compound V-11-0711 (Figure  8) is the  only  ATP competitive  ChoKα inhibitor 
developed to date by a structure-directed optimisation approach (Falcon et al., 2013). The 
compound resulted a potent ChoKα inhibitor causing a strong dose-dependent reduction of 
PCho levels. V-11-0711 shows  good antiproliferative activity  but failed to induce cel 
death in MDA-MB-231 triple-negative breast cancer cel line (Mori et al., 2015). 
 
 
Figure 8: Non-symmetric ChoKα inhibitors 
Structure  of the two  most relevant asymmetric  ChoKα inhibitors. Adapted from Arlauckas et  al.,  2016.
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2. AIM OF THE STUDY  
Given the extensively characterised deregulation of choline  metabolism in cancers, the 
main goal of this project is to identify a novel choline kinase � inhibitor, developed by the 
group of Prof. Lopez-Cara (University of Granada, Spain) for cancer treatment. 
The folowing milestones were set: 
1. Preliminar biological evaluation of a novel series of symmetrical ChoK� inhibitors in a 
panel of diferent tumor cel lines, in order to identify one lead compound for further 
studies. 
2. Comprehensive in vitro and in vivo pharmacological evaluation of the most promising 
compound EB-3D (named also 10a, Figure 9) in triple-negative breast cancer (TNBC) 
model, including data on antiproliferative, antitumour and antimetastatic efects. 
3. Elucidation of the mechanisms leading to cel proliferation arest induced by EB-3D. 
4. To investigate for the first time the choline metabolism in pediatric T cel acute 
lymphoblastic leukemia (T-ALL) and the possibility to use ChoK� inhibitor EB-3D to 
reduce lymphoblasts viability. 
 
 
 
 
Figure 9: EB-3D structure 
Structure of EB-3D (10a), the most promising compound selected from the new series of symmetrical 
biscationic ChoK� inhibitors synthesized by Prof. Lopez-Cara’s group. 
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3. RESULTS  
 
 
3.1 Design, synthesis, crystalization  and  biological evaluation  of  new symmetrical 
biscationic compounds  as selective inhibitors  of  human  Choline  Kinase α1 
(ChoKα1) 
 
 
Santiago  Schiafino-Ortega*,  Eleonora  Baglioni*, Elena  Marioto,  Roberta  Bortolozzi, 
Lucía  Serán-Aguilera,  Pablo  Ríos-Marco,  M.  Paz  Carasco-Jimenez,  Miguel  A.  Galo, 
Ramon  Hurtado-Guerero,  Carmen  Marco,  Giuseppe  Basso,  Giampietro  Viola, Antonio 
Entrena, Luisa Carlota López-Cara 
* Equal contributing authors 
 
 
 
 
Scientific reports. 2016, 6: p. 23793. DOI: 10.1038/srep23793, PMID: 27029499  
 20 
 21 
3.1.1 ABSTRACT 
A  novel family  of compounds  derivative  of  1,1'-((ethane-1,2-diylbis(oxy)bis(4,1- 
phenylene)bis(methylene)-bispyridinium  or  –bisquinolinium  bromide (10a-l) containing 
a pair of oxygen atoms in the spacer of the linker between the biscationic moieties, were 
synthesized and evaluated as inhibitors  of choline  kinase against a  panel  of cancer-cel 
lines.  The  most  promising compounds in this series  were  1,1'-((ethane-1,2-diylbis 
(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(dimethylamino)pyridinium)bromide (10a) 
and  1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)-  bis(7-chloro-4-
(pyrolidin-1-yl)quinolinium)  bromide (10l),  which inhibit  human choline  kinase 
(ChoKα1)  with IC50 of  1.0 and  0.92  µM, respectively, in a range similar to that  of the 
previously reported biscationic compounds MN58b and RSM932A. Our compounds show 
greater antiproliferative activities than  do the reference compounds,  with  unprecedented 
values  of  GI50 in the  nanomolar range for several  of the cancer-cel lines assayed, and 
more importantly they present low toxicity in non-tumoral cel lines, suggesting a cancer-
cel-selective antiproliferative activity. Docking studies predict that the compounds interact 
with the choline-binding site in agreement  with the  binding  mode  of  most  previously 
reported  biscationic compounds.  Moreover, the crystal structure  of  ChoKα1  with 
compound 10a reveals that this compound  binds to the choline-binding site and  mimics 
HC-3 binding mode as never before. 
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3.1.2 INTRODUCTION 
Cancer is a worldwide health threat and the second leading cause of mortality in developed 
countries (Adjei and  Rowinsky,  2003; Neidle and  Thurston,  2005).  Since  many  of the 
curent treatments stil prove toxic and/or lead to drug resistance, there is a strong demand 
for the discovery and development of efective new cancer therapies (Kamb et al., 2007). 
Protein kinases have emerged as one of the most important types of targets in cancer- drug 
discovery  due to their  major roles in regulating cel  growth and survival and  many  other 
cel functions (Brognard and  Hunter,  2011; Reimand et al.,  2013).  An abnormal  kinase 
signaling  network  underlies the  development and  progression  of tumors, and thus the 
targeted inhibition of protein kinases has become an atractive strategy in cancer treatment 
(for a recent review see Gross et al. (Gross et al., 2015) and in the last decade the intense 
development in the field has led to diferent kinase inhibitors that have been approved for 
use in clinical therapy. 
Choline kinase (ChoK) (EC 2.7.1.32) catalyzes the phosphorylation of choline by ATP in 
the  presence  of  Mg2+ to  yield  phosphocholine (PCho) and  ADP (Aoyama et al.,  2004; 
Ishidate,  1997).  This step introduces choline to the so-caled  Kennedy  or  CDP-choline 
pathway for the biosynthesis of phosphatidylcholine, which represents the most abundant 
class  of  phospholipids in eukaryotic cels, constituting  40–60%  of the  phospholipids 
content in cel  membranes (Kent,  1990). In addition to forming the  major structural 
component of the membrane bilayer, phosphatidylcholine also serves as a precursor for the 
production of lipid second messengers (Exton, 2000). 
Mammalian ChoK exists as three isoforms, encoded by two separate genes (Aoyama et al., 
1998a; Aoyama et al., 1998b). In humans, ChoKα1 (457 amino acids) and ChoKα2 (439 
amino acids) derive from a single gene (CHKA) by alternative splicing, while ChoKβ (395 
amino acids) is the product of a diferent gene (CHKB). The amino acid sequence identity 
is 56% between ChoKα and ChoKβ, and both CHKB and CHKB mRNAs, as wel as their 
encoded protein 3 isoforms, are ubiquitously expressed in diverse tissues (Aoyama et al., 
2002).  Each isoform is  present as either  dimers (homo-  or  hetero-)  or as tetramers in 
solution and is not active in monomeric form (Ishidate, 1997), suggesting that, for higher 
eukaryotes, dimeric ChoK is the minimum functional form. 
Choline  kinase is  overexpressed in  many tumors such as  breast, lung,  bladder, colon, 
prostate,  ovary, and liver carcinomas (Granata et al.,  2014; Hernández-Alcoceba et al., 
1999; Ramírez de Molina et al., 2002d) and recently elevated enzymatic activity has also 
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been shown in  T-lymphoma (Xiong et al.,  2015).  This increasing expression leads to 
abnormal choline metabolism, resulting in higher phosphocholine levels, which refer to a 
cholinic  phenotype associated  with  oncogenesis and tumor  progression (Glunde et al., 
2011). As a result, ChoKα, has become an atractive target for novel anticancer therapies. 
The determination of the crystal structures of ChoK proteins from Caenorhabditis elegans 
and human, in which two monomers were dimerized in each asymmetric unit (Malito et al., 
2006; Peisach et al., 2003) and the corect identification of ATP and choline binding sites 
into crystal structure of human ChoKα2 isoform, have enabled the design and the synthesis 
of a series  of asymmetrical  molecules as  potential  ChoK inhibitors and antiproliferative 
compounds (Rubio-Ruíz et al., 2012; Schiafino-Ortega et al., 2013). Figure 1 shows HC-
3, the first inhibitor of choline kinase described, MN58b and RSM923A, which belong to 
the first generation of ChoK inhibitors (Al-Safar et al., 2006; Hernández-Alcoceba et al., 
1999; Lloveras et al.,  1985; Ramírez  de  Molina et al.,  2004a; Ramírez  de  Molina et al., 
2004b; Rodríguez-González et al.,  2003), and the  most  promising compounds  developed 
by  our  group.  Note that RSM932A (also caled TCD-717)  has evidenced a low-toxicity 
profile with improved tolerability in mice (Lacal and Campos, 2014) and a Phase I clinical 
trial  has just  been completed for the treatment  of advanced solid tumors 
(htp:/clinicaltrials.gov/ct2/show/NCT01215864). 
For compounds 1 and 2,  we identified the adenine and  1-benzyl-4- 
(dimethylamino)pyridinium as the  most eficient fragments  of these  molecules  by the 
deconvolution approach based on the ChoKα1/1 (PDB ID: 3ZM9) (Sahún‐Roncero et al., 
2013) and  ChoKα1/2 (PDB ID:  4BR3) (Sahún-Roncero et al.,  2013) crystal structures, 
demonstrating that the adenine fragment  occupies the  ATP  binding site and that the 
pyridinium fragment, through its  positive charge  delocalized  over the  nitrogen atom, 
mimics the positive charge present in choline or in HC-3. 
The second  generation  of inhibitors (compounds 3 and 4), asymmetrical  bispyridinium 
compounds,  proved to  be  good inhibitors and  provide the  discovery  of a  new inhibitory 
binding site  on  ChoKα1  Compound 4 (Figure  10),  which induced the  opening  of  new 
adjacent binding site where the 4-Chloro-N-methylaniline fragment is located, adopting an 
unprecedented modality of binding to ChoKα1 (ChoKα1/4 PDB ID: 4CG8) (Rubio-Ruiz 
et al., 2014), while compound 3 (with biphenyl group as a linker) adopts a binding mode 
similar to the one observed for compound 2. 
In an efort to produce additional highly active compounds, we focused on longer spacers 
between  biphenilic  or  bipyridinic rings,  which  have electron  donor  or acceptor  groups 
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necessary to increase the  binding to the enzyme through  of  hydrogen  bonds and the 
solubility, while retaining some inhibition properties. 
Deep modeling and virtual screening studies (Serán‐Aguilera et al., 2015) have suggested 
the interaction with the choline binding site in the ChoKα1/4 complex while keeping the 
biscationic structure  unchanged.  Thus a classical  bioisosteric exchange  between carbon 
and  oxygen atoms could increase,  on  one  hand, the  polarity and the solubility  of these 
compounds and,  on the  other  hand, the afinity for the enzyme  due to the synclinal 
conformation  of the linker  of these  molecules. In this  way, in the  present study,  we 
reconfigured the substitution  patern around linker  moiety  by the  preparation  of  1,1'-
((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)-bis[4-pyridinium  or 
quinolinium] bromide derivatives with general structures 10a-l. MN58b, RSM932A, 1, 2, 
3, 4,  our recently  published compound 5 (Castro-Navas et al.,  2015) (Figure  10) and the 
most active compounds  described  by  S.  Trousil (Trousil et al.,  2013),  were taken as 
paterns to improve the  polarity and solubility,  while also improving inhibition  by the 
enzyme and consequently enhancing the antiproliferative efect. This series was obtained 
by interchanging the substitution patern of linker by the introduction of two oxygen atoms 
in the linker, in  order to  determine the influence  of these  groups  on the antiproliferative 
and inhibitory activity of ChoKα1, using various cationic heads previously synthesized by 
our  group in similar compounds.  We fixed the  most successful cationic  heads  described 
previously (pyridinium and  quinolinium salts) (Campos et al.,  2002; Castro-Navas et al., 
2015; Conejo-García et al.,  2003b; Gomez-Perez et al.,  2012; Rubio-Ruiz et al.,  2014; 
Sánchez-Martín et al., 2005; Trousil et al., 2013) and examined several 4-substitutions with 
alkylamines or phenylamines on the arylmoiety. Also, we introduced a quinuclidinium salt, 
which mimics the trimethylammonium of the choline, but potentialy prevents interactions 
with the cholinergic system. 
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Figure 10. Structure of choline kinase α inhibitors 
Structures  of symmetrical and  non- symmetrical inhibitors  of choline  kinase  previously  published (HC-3, 
MN58b, RSM-932A and compounds 1–5) and the general structure  of compounds 10a-l described in this 
paper.  
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3.1.3 RESULTS 
Chemistry 
Microwave-assisted (MW) reactions  present several advantages, such as a remarkable 
reduction in reaction times compared to those of the conventionaly heated reactions and 
often lead to improved yields (Kappe, 2004). In the present work, we describe the use of 
microwave iradiation as an energy source for the synthesis of the intermediate (7 and 8) of 
twelve  1,2-bis(p-methylphenoxy)ethane  derivatives 10a-l, substituted in the 
methylphenoxy group with diferent cationic heads as moieties. These compounds can be 
also considered as more polar analogues of choline kinase inhibitor derivatives than those 
previously synthesized. 
The synthesis of compounds 10a-l is shown in Figure 11, and folows three easy steps. The 
first is the treatment of the 4-methylphenol (6) in ethanol with NaOH (1.1 equiv) stiring at 
room temperature for 30 min, folowed by the addition of 1,2-dibromoethane (0.5 equiv), 
under  microwave iradiation (130°C,  28  min) to  provide the  1,2-bis(p- 
methylphenoy)ethane (7) (Cantril et al., 2000; Xiao et al., 2007). Then, bromination in the 
methylene of 7 with NBS and dibenzoylperoxide in CCl4 also under microwave iradiation 
(120°C,  21  min), to  give the  1,2-bis(4-bromomethylphenoy)ethane (8) (Cabezon et al., 
2000). In comparison with conventional (thermal) heating, the microwave heating reduced 
the reaction time in both reactions (30 min vs. 8 h and 21 min vs. 5 h, respectively), but we 
also  noted some  yield improvement (35%  vs.  21% and  65%  vs.  39%, respectively).  We 
conducted diferent experiments to achieve these successful results with MW. Although in 
the second step,  we  were restricted  by the  quantity to  use, since  using  only  100  mg  of 
derivative 7 gave the best yields, while more quantity of 7 led to diminished yields. This 
result was due to the volume of the reactor, which alows only 5 mL of the mixture, while 
more than 100 mg of 7 derivative would need more solvent to dissolve it. Finaly, the last 
step is the introduction  of cationic  heads (previously synthesized  using the  procedure 
reported (Campos et al.,  2002; Castro-Navas et al.,  2015; Conejo-García et al.,  2003b; 
Gomez-Perez et al., 2012; Rubio-Ruiz et al., 2014; Sánchez-Martín et al., 2005; Trousil et 
al., 2013), by means of a simple SN2 reaction in acetonitrile under argon atmosphere for 72 
h at reflux  of  1,2-bis(4-bromomethylphenoxy)ethane (8) and the  4-substituted  pyridine 
derivative (9a-c), quinuclidine derivative (9d-e) or 4-substituted quinoline or 7-Chloro-4-
substituted quinoline (9f-l) to aford 10a-l (Figure 11 and Table 1) with moderate or good 
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yields. 
 
Figure 11: General synthetic pathway folowed in the preparation of compounds 10a-l 
 
10a     10b     10c  10d   10e 
   
  
10f     10g    10h 10i 
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Table 1: Cationic head residues (R) of compounds 10a-l 
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Docking studies 
Docking studies  were  made in  order to  design the  new  ChoK inhibitors.  The crystal 
structures  of  greatest interest for  docking studies are those  of  ChoKα1 isoenzyme in 
complex with compounds 2 (PDB ID: 4BR3) (Sahún-Roncero et al., 2013) and 4 (PDB ID: 
4CG8) (Rubio-Ruiz et al., 2014), since the cationic heads of compounds described in this 
paper are similar to those of compounds 2 and 4. 
Figure  12A shows compound 2 (carbon atoms in  yelow color) inserted into the  Cho 
binding site,  being stabilized  by cation-π interactions  with  Tyr333,  Tyr354,  Tyr440, 
Trp420,  Trp423, and  Phe435 (carbon atoms in cyan color). In  particular, the  biphenyl 
group shows  optimal  paralel  hydrophobic stacking interactions  with  Tyr354, and the  4- 
(dimethylamino)pyridinium  moiety interacts through  paralel cation-π interaction  with 
Trp420. The orientation of this compound inside the Cho binding site was accommodated 
by a conformational change of Tyr333, which moved back to create an extra space (Sahún-
Roncero et al., 2013; Sahún‐Roncero et al., 2013). The adenine fragment of compound 2 
inserted into the Cho binding site was outside the enzyme and showed no interaction with 
the protein, 1-(biphenyl-4-ylmethyl)-4-(dimethylamino)pyridinium being the key fragment 
of this compound for the interaction at the Cho binding site. Figure 13A shows compound 
4 (carbon atoms in  orange color) inserted into the  ChoKα1 crystal structure.  This 
compound adopts a  new  diferent  binding  mode, inducing a conformational change in 
some amino acids.  Tyr256,  Tyr333, and  Trp420 are the residues that  undergo the  major 
changes, and the rotation  of these side chains is critical to alow the insertion  of the  4-
chloro-N-methylaniline fragment into an additional binding site (carbon atoms in magenta 
color), being stabilized by hydrophobic interactions with Trp248, Tyr256, Tyr333, Leu419, 
Trp420, and  Trp423.  The rest  of the  molecule is located inside the  Cho  binding site 
(carbon atoms in cyan color), the  pyridinium  moieties  being stabilized through cation-π 
interactions  with  Tyr333,  Tyr354,  Trp420, and  Tyr440 (Rubio-Ruiz et al.,  2014). 
Compound 4 is more inserted into the Cho binding site in comparison to compound 2 since 
this compound makes the complete opening of this site. 
Docking studies  have  been  performed in  both crystal structures and the analysis  of the 
resulting  poses indicates  which compounds could  be similar to compound 2  or to 
compound 4. In fact, compounds 10a, 10b, 10d, and 10e  have shown  good  poses in the 
crystal structure  of compound 2 (Figure  12),  while the corect  poses  of compounds 10c, 
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10f, 10g, 10h, 10i, 10j, 10k, and 10l resulted in the crystal structure of compound 4 (Figure 
13). 
Figure 12 shows the resulting pose of compounds 10a, 10b, 10d, and 10e. Compound 10a 
(carbon atoms in  green color)  has two  4-(dimethylamino)pyridinium cationic  heads, 
similarly to compound 2 (Figure  12B).  One  1-benzyl-4-(dimethylamino)pyridinium 
fragment is inserted in a  way  very similar to that  of compound 2: i) the cationic  head is 
situated close to  Trp420,  being stabilized  by π-cation interactions  with  Trp420,  Tyr333, 
and  Trp423; and: i) the  benzyl fragment is also  optimized  by  hydrophobic stacking 
interactions with Tyr354. The linker of compound 10a is extremely long, and the second 1-
benzyl-4- (dimethylamino)pyridinium fragment is situated  outside  of the enzyme, an 
additional  hydrophobic interaction  occuring  between the second  phenyl fragment and 
Ile433. The pose of compound 10b is very similar to that of compound 10a, the pyridinium 
moiety  being slightly  more separated from  Tyr333  due to the  higher  volume  of the 
pyrolidine fragment, but the interaction of the whole molecule with the Cho binding site is 
very similar to that of compound 10a. Compound 10d shows also a similar pose to that of 
compound 10a, though slightly more inserted into the Cho binding site due to the smaler 
volume  of the  quinuclidine cationic  head.  The resulting  pose  of compound 10e is also 
similar,  being slightly  outside compound 10a  due to the establishment  of two  H-bond 
between the 3-OH groups and Asn305 and Glu434, respectively. 
Figure  13 shows the resulting  pose  of compounds 10c and  10f-l.  Compound 10l (carbon 
atoms in  orange color)  has two  7-chloro-4-(pyrolidin-1-yl)quinolinium) cationic  heads, 
one  of  which is inserted  very similarly to compound 4 (Figure  13I): the  4-pyrolidin 
fragment is inserted into the additional  binding site and stabilized  by  hydrophobic 
interactions, while the 7-chloroquinolinium moiety is situated into the Cho binding site and 
stabilized  by cation-π interactions.  The second cationic  head is also inserted into the 
protein and stabilized by hydrophobic interactions with Ile433 and Arg117, and the phenyl 
group connected to this cationic head is also stabilized by cation-π interaction with Phe435. 
The most notable efect in these molecules is the conformation of the linker, since the 1,2-
dioxoethane fragment adopts a synclinal conformation due to the gauche efect of the O-C-
C-O  bonds.  This conformation  of the linker alows the total insertion  of compound 10l 
inside the Cho binding site, and also favors the insertion of compound 10a. 
Compounds 10f-k have shown a pose very similar to that of compound 10l (Figure 13D), 
one of the cationic heads being inserted inside the additional binding site and into the Cho 
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binding site. The second cationic head is also inserted into the protein being stabilized by 
hydrophobic interactions  with  Arg117 and Ile433, and the  phenyl  group  of this cationic 
head is also stabilized  by π-cation interaction  with  Phe435.  The resulting  pose  of 
compound 10c shows a slight  diference.  This compound  has two  4-(4-
chlorophenyl)(methyl)amino)pyridinium cationic heads. One cationic head is also inserted 
into the additional binding site and into the choline binding site, as in compound 4, and the 
second cationic  head is also inserted into the enzyme,  but  with a  diferent  orientation. 
Nevertheless, the most noteworthy efect is that in the resulting pose of these compounds 
the  1,2-dioxoethane fragment also adopted a synclinal conformation and, for this reason, 
al these compounds should  be completely inserted into the enzyme and  probably  wil 
show good ChoKα1 inhibition. 
 
Figure 12: Resulting pose of compounds 10a-b and 10d-e in the crystal structure of ChoKα1/2 complex 
(A) Crystal structure of ChoKα1/2 complex (PDB ID: 4BR3). Compound 2 (carbon atoms in yelow color) is 
inserted into the Cho binding site (carbon atoms in cyan color). Resulting pose of compound 10a (B, carbon 
atoms in light green color), 10b (C, carbon atoms in yelow color), 10d (D, carbon atoms in purple color) and 
10e (E, carbon atoms in green color) inside the Cho binding site of ChoKα1/2 complex. 
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Figure 13: Resulting pose of compounds 10c and 10f-l in the crystal structure of ChoKα1/4 complex 
(A) Crystal structure of ChoKα1/4 complex (PDB ID: 4CG8). Compound 4 (carbon atoms in orange color) is 
inserted into the  Cho  binding site (carbon atoms in cyan color) and in an additional  binding site (carbon 
atoms in magenta color). Resulting pose of compound 10c (B, carbon atoms in orange color), 10f (C, carbon 
atoms in yelow color), 10g (D, carbon atoms in purple color), 10h (E, carbon atoms in brown color), 10i (F, 
carbon atoms in  dark  green color), 10j (G, carbon atoms in  yelow color), 10k (H, carbon atoms in  dark 
green color) and 10l (I, carbon atoms in yelow color) inside the Cho binding site of ChoKα1/4 complex. 
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Figure S3. Poses resulting in the docking studies of compounds 10f (A, carbon atoms in yelow color), 
10g (B, carbon atoms in blue-slate color), 10h (C, carbon atoms in reddish-salmon color), 10i (D, carbon 
atoms in blue color), 10j (E, carbon atoms in yelow color), 10k (F, carbon atoms in blue color) and 10c 
(carbon atoms in orange color) inside the Cho binding site of ChoKα1/4 complex (PDB ID: 4CG8). 
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Inhibition of ChoK!1 enzymatic activity  
It has been reported that a potent anticancer efect inducing maximal apoptosis is achieved 
only when ChoK�1 expression is specificaly knocked down, without afecting ChoK� 
levels (Gruber et al., 2012). Thus, in an initial step we evaluated whether these compounds 
have a selective behaviour on ChoK�1. 
We selected the most representative compounds of each family, (10a for pyridinium 
compounds and 10f, 10g, 10k, and 10l for quinolinium compounds) and, since selectivity 
may be explained by a reduced flexibility of Trp353 in ChoK� compared to its homologue 
Trp420 in ChoK�1, as proposed for HC-3 (Sahún-Roncero et al., 2013), tryptophan 
fluorescence assays were performed. As expected from their chemical structures similar to 
that of compound 4, the results of the spectroscopy analysis, depicted in Table 2, showed 
that the Kd values of these compounds for ChoK�1 were in the low µM range (0.241-0.700 
µM), indicating high afinity for the enzyme. These results agree with the first 
experimental validation of the docking studies described above. 
 
Table 2: Kd values of selected compounds evaluated by tryptophan fluorescence quenching 
aKd values of indicated compounds for ChoK�1 are expressed as mean ± SD of at least three independent 
experiments.  
Of al tested compounds, the ones that present an alkylamine or a cycloalkylamine 
substituted at position 4 of the pyridinium or quinolinium system, 10a-b and 10j-l, ofer 
the best results in terms of enzyme inhibition and antiproliferative assays. 
Regarding ChoK�1 inhibitory efect, al compounds showed a micromolar activity, 
comparable to that of the two reference compounds RSM932A and MN58b. The docking 
studies indicated that al compounds could be inserted into the choline binding site and 
could be grouped into two families on the basis of their diferent insertion modes. 
Compounds 10a, 10b, 10d, and 10e could be inserted similarly to compound 2. Compound 
10a showed good ChoK�1 inhibition (IC50 = 1.0 µM), thanks to the presence of the 1-
��������������������������
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comparison to compound 2 (Figure S1 of Supplementary Information) since this compound makes the complete 
opening of this site.
Docking studies have beenperfrmed in boh crystl structures and th analysis of the resulting poses indi-
cates which compounds could be similar to compound 2 or to compound 4. In fact, compounds 10a, 10b, 10d, 
and 10e have shown good poses in the crystal structure of compound 2, while the correct poses of compounds 
10c, 10f, 10g, 10h, 10i, 10j, 10k, and 10l resulted in the crystal structure of compound 4.
As an example, Fig. 3C,D show the reulting poseof ompunds 10a and10l. Compound 10a (carbon atoms 
in green color) has two 4-(dimethylamino)pyridinium cationic heads, similarly to compound 2 (Fig. 3A). One 
1-benzyl-4-(dimethylamino)pyridinium fragment is inserted in a way very similar to that of compound 2: i) 
thectionic head isitated close to Trp420,bing stabilized by π-caio interactions with Trp420, Tyr333, and 
Trp423; and: i) the benzyl fragment is also optimized by hydrophobic stacking interactions with Tyr354. he 
linker of compound 10a is extremely long, and the second 1-benzyl-4-(dimethylamino)pyridinium fragment 
is situated outsidef the nzym, an additionalhydrphobicinteractio occurring between the second phe-
nyl fragment and Ile433. Compound 10l (carbon atoms in orange color) has two 7-chloro-4-(pyrrolidin-1-yl)
quinolinium) cationic heads, one of which is inserted very similarly to compound 4 (Fig. 3B): the 4-pyrrolidin 
fragment is inserted into the additional binding site and stabilized by hydrophobic interactions, while the 
7-chloroquinolinium moiety is situated into the Cho binding site and stabilized by cation-π interactions. he 
second cationic head is also inserted into the protein, being stabilized by hydrophobic interactions with Ile433 
and Arg117, and the phenyl group connected to this cationic head is also stabilized by cation-π interaction with 
Phe435. he most notable efect in these molecules is the conformation of the linker, since the 1,2-dioxoethane 
fragment adopts a synclinal conformation due to the gauche efect of the O-C-C-O bonds. his conformation of 
the linker alows the total insertion of compound 10l inside the Cho binding site, and also favors the insertion of 
compound 10a.
Figure S2 of Supplementary Information shows the resulting pose of compounds 10b, 10d, and 10e. he pose 
of compound 10b is very similar to that of compound 10a, the pyridinium moiety being slightly more separated 
from Tyr333 due to the higher volume of the pyrrolidine fragment, but the interaction of the whole molecule with 
the Cho binding site is very similar to that of compound 10a. Compound 10d shows also a similar pose to that of 
compound 10a, though slightly more inserted into the Cho binding site due to the smaler volume of the quinu-
clidine cationic head. he resulting pose of compound 10e is also similar, being slightly outside compound 10a 
due to the establishment of two H-bond between the 3-OH groups and Asn305 and Glu434, respectively. Figure 
S3 of Supplementary Information shows the resulting pose of compounds 10f-k and 10c. Compounds 10f-k have 
shown a pose very similar to that of compound 10l (Fig. 3D), one of the cationic heads being inserted inside the 
additional binding site and into the Cho binding site. he second cationic head is also inserted into the protein 
being stabilized by hydrophobic interactions with Arg117 and Ile433, and the phenyl group of this cationic head 
is also stabilized by π -cation interaction with Phe435. he resulting pose of compound 10c shows a slight dif-
ference. his compound has two 4-((4-chlorophenyl)(methyl)amino)pyridinium cationic heads. One cationic 
head is also inserted into the additional binding site and into the choline binding site, as in compound 4, and the 
second cationic head is also inserted into the enzyme, but with a diferent orientation. Nevertheless, the most 
noteworthy efect is that in the resulting pose of these compounds the 1,2-dioxoethane fragment also adopted a 
synclinal conformation and, for this reason, al these compounds should be completely inserted into the enzyme 
and probably wil show good ChoKα 1inhibition.
�������������α It has been reported that a potent anticancer efect inducing 
maximal apoptosis is achieved only when ChoKα 1expression is speciicaly knocked down, without afecting 
ChoKβ levels47. hus, in an initial step we evaluated whether these compounds have a selective behaviour on 
ChoKα 1.
We selected the most representative compounds of each family, (10a for pyridinium compounds and 10f, 
10g, 10k, and 10l for quinolinium compounds) and, since selectivity may be explained by a reduced lexibility 
of Trp353 in ChoKβ compared to its homologue Trp420 in ChoKα 1, as was proposed for HC-331, tryptophan 
luorescence assays were performed (Figure S4 of Supplementary information). As expected from their chemical 
structures similar to that of compound 4, the results of the spectroscopy analysis, depicted in Table 1, showed 
that the Kd values of these compounds for ChoKα 1were in the low μM range (0.241± 0.700 μM), indicating high ainity for the enzyme. hese results agree with the irst experimental validation of the docking studies described 
above.
Compound HsChoKα1 Kd (μM)a
10a 0.700 ± 0.080
10f 0.295 ± 0.127
10g 0.517 ± 0.099
10k 0.241 ± 0.03
10l 0.357 ± 0.039
4 0.110 ± 0.01
HC-3 0.18 ± 0.03
Table 1.  Kd values of selected compounds evaluated by tryptophan luorescence quenching. aKd values of 
indicated compounds for ChoKα 1are expressed as mean ± S.D. of at least three independent experiments.
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benzyl-4-(dimethylamino)pyridinium fragment,  which  performs a strong π-cation 
interaction with the Cho binding site (Figure 12B), this having been described as one of the 
most eficient  moieties for  ChoKα1 inhibition (Serán-Aguilera et al.,  2015).  Compound 
10b showed a reduced ChoKα1 inhibition (IC50 = 9.56 µM) atributable to the volume of 
the  4-(pyrolidin-1-yl)pyridinium cationic  head, causing a  decrease in the π-cation 
interaction (Figure  12C). In this family, compound 10d showed  very  poor  ChoKα1 
inhibition (IC50 = 37.54 µM). This result may be due to the presence of the quinuclidine 
and the consequently low lipophilicity (clogP  = -1.01) cationic  head that  probably 
prevented the interactions  with  Tyr333,  Tyr354,  Trp420, and  Tyr440 (Figure  12D). 
However, although compound 10e had a  3-hydroxyquinuclidine cationic  head and low 
lipophilicity (clogP  = -2.42), it showed  beter  ChoKα1 inhibition (IC50 =  9.51  µM) than 
what could be explained by the establishment of two additional H-bonds with the enzyme 
(Figure 12E). 
In summary, when compounds bind to choline site, such as compound 2 (compound 10a-b, 
d-e), low lipophilicity values are suficient to achieve good inhibition of the enzyme, the 
pydidinic ring being the most appropriate moiety, and the quinuclidine ring decreases the 
activity unless the lack of aromatic ring is ofset by the formation of a H bond provided by 
the hydroxyl group. 
The second group interacted with the choline binding site as compound 4. Compounds 10c 
and 10j-l showed a  good  ChoKα1 inhibition (IC50 =  1.63,  1.66,  2.02 and  0.92  µM 
respectively), while compounds 10f-i showed a slightly reduced ChoKα1 inhibition (IC50 = 
6.85, 3.27, 2.79 and 16.22 µM, respectively). Al these compounds had a 4-substituted and 
7-substituted  quinolinium cationic  head, 10f-l, except 10c,  which  had the rest  of the  N-
methylanilino at the  4  position  of the  pyridinium cationic  head.  The structure  of the  4-
substituted fragment conditions the inhibitory activity  of these  molecules. In fact, 
compounds 10j-l had a 4-cycloalkylamino fragment, while compounds 10c and 10f-i had a 
4-N-methylanilino substituent.  The resulting IC50 values indicated that the  4-
cycloalkylamino favored the  ChoKα1 inhibition,  probably  promoting a  more efective 
insertion into the additional  binding site. In this  group the chloro atom increased the 
volume of molecule and the lipophilicity. Thus, the compound 10l ofered the right balance 
between volume and lipophilicity. The perhydroazepine group (10i) provided the volume 
to  be inserted into the choline  binding site  properly and the addition  of a choro atom 
slightly depressed the activity (10j). 
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Conversely, the compounds  with an  N-methylanilino system at the  4  position  of the 
pyridinium  or  quinolinium cationic  heads showed lower IC50 than  did those in the 
alkylamine system. In these compounds, the chloro atom in  para  position  of  4- 
(methyl(phenyl)amino)quinolinium  or  pyridinium fragment (10c, 10g and 10i)  or in 
position  7  of the  quinolinium ring (10h and 10i) seemed to  play an essential role in the 
enzyme inhibition. In fact, the presence of the chloro atom alowed the cationic head to be 
accommodated at the choline-binding site, likely  by an increase in the lipophilicity 
provided by the halogen atom, regardless of where the halogen was located (10c, 10g, and 
10h IC50 =  1.63,  3.27, and  2.79  µM, respectively).  A  direct corelation  between  volume-
lipophilic activity  was found in these compounds (10c, 10f-i), so that the less  bulky and 
lipophilic compounds  ofered the  best  values (10c, IC50 =  1.66µM, clogP=  1.8)  while 
adding a second aromatic ring slightly diminished the activity of 10f-h. On the other hand, 
the two chloro atoms present in compound 10i made the molecule too bulky to bind to the 
choline site, lowering its inhibition activity (IC50 = 16.22 µM), and raising its lipophilicity 
(clogP  =  4.23).  However, the absence  of chloro atom in 10f also considerably  decreased 
ChoKα1 inhibition (IC50 = 6.85 µM), highlighting the important role of the chloro atom. 
Regardless the binding mode to the enzyme, the best inhibitory activities were found when 
a fragment of alkylamine or cycloalkylamine was present at the 4 position in pyridinium or 
quinolinium cationic heads, such as 10a, 10j, 10k, and 10l (IC50 = 1.0, 1.66, 2.02, and 0.92 
µM, respectively), These results reveal that the volume of the cationic head probably fits 
properly into the choline binding site. The only exception was 10b (IC50 = 9.56 µM), and 
this was a consequence of the higher volume of the 4-(pyrolidin-1-yl)pyridinium cationic 
head that diminished the π-cation interaction (Figure 12C) mentioned above. 
The crystal structure of the complex ChoKα1/10a shows that the compound binds to 
the choline binding site 
Although the  docking studies clearly suggested that the compounds  bind to the choline 
binding site (Figure 12-13) we caried out further crystalization experiments with the most 
active  ChoKα1 inhibitors, 10a and 10l, in  order to compile  more consistent  data 
concerning their  binding  mode.  Despite the large  number  of trials,  we  managed to solve 
only the crystal structure of ChoKα1 in complex with compound 10a at 1.45Å (PDB ID: 
5FTG).  The  other compound (10l)  was too  hydrophobic (clogP  =  2.36) and therefore 
insoluble in the mother liquor. 
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For ChoKα1/10a complex, successive iterative model building and refinement cycles were 
caried  out to  produce a final  model  with  good refinement statistics (R  =  0.197,  Rfree = 
0.218). The structure is a monomer formed by a smal N-terminal and a large C-terminal 
domain. Whereas the ATP binding site is located in a cleft formed by N- and C-terminal 
domains, the choline binding site is found in a deep hydrophobic pocket. One molecule of 
compound 10a was visualized at the choline binding site with good electron density. One 
1-benzyl-4-(dimethylamino)pyridinium fragment was deeply positioned within the pocket 
and established π-cation interactions  with  Trp423 and  Trp420,  whereas it set π-π 
interactions  with  Tyr333,  Tyr354,  Phe435, and  Tyr440.  The second  1-benzyl-4-
(dimethylamino)pyridinium  moiety  was  directed towards the  outside  part  of the choline 
binding site,  where it established π-π and  hydrophobic interactions  with residues  Phe361 
and Ile433, respectively (Figure 14A). 
 
Figure 14: Active site of ChoKα1 in complex with ChoKα inhibitors 
(A) Active site of ChoKα1 in complex with compound 10a (PDB ID: 5FTG) (carbon atoms in green color). 
Unbiased difference electron density maps are shown at 2.2 σ. (B) Superimposition of 10a with HC-3 (PDB 
ID: 3G15) (carbon atoms in cyan color) and compound 2 (PDB ID: 3ZM9) (carbon atoms in yelow color). 
(C) Residues that stabilize the positive charge of the cationic head in the three superimposed ligands (carbon 
atoms in grey color). (D) Residues that undergo the most notable conformational changes when compounds 2 
or 10a bind to the choline binding site. 
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When the crystal  pose  was compared  with the  docked  one, few  diferences  were found 
between the two, especialy regarding the conformation that the first  1-benzyl-4- 
(dimethylamino)pyridinium fragment adopted (Figure  15).  This  moiety  was completely 
superimposed in the two  poses, indicating the accuracy  of the theoretical  predictions. 
Nevertheless, the second  4-(dimethylamino)pyridinium  moiety  was flipped almost  90° 
towards the residue  Phe361  but  not towards the residue Ile433, as the  docking  had 
predicted.  The reason for this  diference is that the  pyridinium ring set π-π interactions 
with Phe361 in the crystal pose, increasing the stability of the ligand-protein complex. 
 
Figure 15: Comparison between crystal and docking poses of 10a 
Superposition of the docking pose of compound 10a (carbon atoms in green color) with the effective crystal 
pose (carbon atoms in orange color) inserted into Cho binding site. 
Remarkably, the  positive charge  of the  quaternary ammonium  of the first  1-benzyl-4- 
(dimethylamino)pyridinium fragment  was  positioned at the choline  binding site in the 
same  place as  one  of the  previously reported  ChoKα1 inhibitors, such as compound  2 
(PDB ID:4BR3) and HC-3 (PDB ID:  3G15) (Figure  14B).  This indicates that common 
residues should  participate in the  positive-charge stabilization regardless  of the chemical 
nature of the spacer groups. As reflected in Figure 14C, these residues are Tyr333, Tyr354, 
Trp420, and  Trp423,  which set  paralel π-cation and π-π interactions  with the  quaternary 
ammonium and the aromatic rings of the 1-benzyl-4-(dimethylamino)pyridinium fragment. 
Nevertheless,  depending  on the spacer and the cationic  head  of the compounds, some 
conformational changes in some  of these residues  were  observed.  For instance, residues 
Trp420 and Tyr333 underwent a noticeable retraction to open the hydrophobic cavity when 
compound 10a or compound 2  bound the  protein in  order to accommodate the  positive 
charge of the cationic head (Figure 14D). 
 
 S-8 
 
Figur  S6.  Superposition  ofthe resulting  pose  of compound 10a (carbon atoms in  green color)  with 
compound 10a (carbon atoms in  orange color) inserted into  Cho  binding site into the crystal structure 
(PDB ID: 4TST) 
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the
 on
es t
hat 
pre
sen
t a
n al
kyl
am
ine
 or
 a c
ycl
oal
kyl
am
ine
 su
bsti
tut
ed 
at p
osit
io
n 4 
of 
the
 py
rid
ini
um
 or
 qu
in
oli
niu
m s
yst
em
, 1
0a-
b a
nd 1
0j-l
, of
er t
he 
bes
t re
sul
ts i
n te
rm
s of
 en
zy
me i
nhi
biti
on 
an
d 
ant
ipr
olif
era
tiv
e as
say
s.
Reg
ard
in
g C
ho
Kα
 1 i
nhi
bit
ory
 ef
ect,
 all
 co
mp
ou
nds
 sh
ow
ed 
a 
mic
ro
mol
ar 
act
ivi
ty, 
co
mpa
rab
le t
o t
hat 
of 
the
 tw
o re
fer
enc
e c
om
po
un
ds R
SM
932
A 
an
d M
N58
b.
 h
e d
ock
ing
 st
udi
es i
ndi
cat
ed 
tha
t al
l c
om
po
un
ds c
oul
d 
be i
nse
rte
d i
nto
 th
e c
hol
ine
 bi
ndi
ng 
site
 an
d c
oul
d b
e g
ro
upe
d i
nto
 tw
o fa
mili
es 
on 
the
 ba
sis 
of t
hei
r d
if
ere
nt 
ins
erti
on 
mo
des.
 C
om
po
un
ds 1
0a,
 10
b, 1
0d
, a
nd 1
0e 
cou
ld 
be i
nse
rte
d si
mila
rly 
to 
co
mpo
un
d 2.
 C
om
po
un
d 10
a 
sh
ow
ed 
goo
d Hs
Ch
oK
α 1 
in
hib
iti
on 
(IC
50 =
  1.0
 μM)
, t
han
ks t
o t
he 
pre
sen
ce 
of t
he 
1-b
enz
yl-
4-(
di
met
hyl
am
in
o)
pyr
idi
niu
m fr
ag
men
t, 
whi
ch 
per
for
ms 
a st
ro
ng 
π -
cat
io
n i
nte
rac
tio
n w
ith
 th
e C
ho 
bin
din
g si
te 
(Fi
g. 3
C), 
thi
s 
hav
ing
 be
en 
des
cri
bed
 as
 o
ne 
of t
he 
mos
t e
ic
ien
t 
moi
eti
es f
or 
Ch
oK
α 1 
in
hib
iti
on
33 . 
Co
mp
ou
nd 1
0b
 sh
ow
ed 
a r
ed
uce
d C
ho
Kα
 1 i
nhi
biti
on 
(IC
50 =
  9.5
6 μ
M) 
attr
ib
uta
ble 
to 
the
 vo
lu
me 
of t
he 
4-(
pyr
rol
idi
n-1
-yl
)py
rid
in
-
iu
m c
ati
oni
c h
ead
, c
aus
ing
 a 
dec
rea
se i
n t
he π
 -ca
tio
n i
nte
rac
tio
n (
Fig
ure
 S2
A). 
In 
thi
s fa
mily
, c
om
po
un
d 1
0d
 
sh
ow
ed 
ver
y p
oor
 C
ho
Kα
 1 i
nhi
biti
on 
(IC
50 =
  37.
54 
μM)
. 
h
is r
esu
lt 
may
 be
 d
ue t
o t
he 
pre
sen
ce 
of t
he 
qui
-
nuc
lid
ine
 an
d t
he 
co
nse
que
ntl
y l
ow 
lip
op
hili
cit
y (
clo
g P
 =  
−1
.01
) c
ati
oni
c h
ead
 th
at 
pro
bab
ly 
pre
ven
ted
 th
e 
int
era
cti
ons
 wi
th 
Tyr
333
, T
yr3
54, 
Trp
420
, a
nd 
Tyr
440
 (F
igu
re 
S2
B). 
Ho
wev
er, 
alt
ho
ug
h c
om
po
un
d 10
e 
had
 a 
3-h
ydr
oxy
qui
nuc
lid
ine
 ca
tio
nic 
hea
d a
nd l
ow 
lip
op
hili
cit
y (c
log
 P 
=  −
2.4
2), 
it s
ho
wed
 be
tte
r C
ho
Kα
 1 i
nhi
bi-
tio
n (I
C 50 
=  9
.51
 μM)
 th
an 
co
uld 
be 
exp
lai
ned
 by
 th
e es
tab
lis
hm
ent
 of 
tw
o a
ddi
tio
nal 
H-
bo
nds
 wi
th 
the
 en
zy
me 
(Fi
gur
e S
2C)
.
In 
su
mm
ary
, w
hen
 co
mp
ou
nds
 bi
nd 
to 
the
 ch
oli
ne 
site
, s
uch
 as
 co
mp
ou
nd 
2 (
co
mp
ou
nd 1
0a-
b, 
d-e
), l
ow 
lip
op
hili
cit
y v
alu
es 
are
 su
ic
ien
t t
o a
chi
eve
 go
od 
in
hib
iti
on 
of t
he 
enz
ym
e, t
he 
pyd
idi
nic 
rin
g b
ein
g t
he 
mos
t 
ap
pro
pri
ate 
moi
ety,
 an
d t
he 
qui
nuc
lid
ine
 ri
ng 
dec
rea
ses
 th
e a
cti
vit
y u
nle
ss t
he l
ack
 of 
aro
mati
c ri
ng i
s o
fse
t b
y 
the
 fo
rm
ati
on 
of a
 H 
bo
nd 
pro
vid
ed 
by t
he 
hyd
rox
yl g
rou
p.
h
e s
eco
nd 
gro
up i
nte
rac
ted
 wi
th 
the
 ch
oli
ne 
bin
din
g si
te 
as 
co
mp
ou
nd 
4. 
Co
mp
ou
nds
 10
c 1
0j-l
 sh
ow
ed 
a 
go
od 
Ch
oK
α 1 
in
hib
iti
on 
(IC
50 =
  1.6
3, 1
.66
, 2.
02 
an
d 0.
92 
μM 
res
pec
tiv
ely
), 
whi
le 
co
mp
ou
nds
 1
0f-i
 sh
ow
ed 
a 
slig
htly
 re
duc
ed 
Ch
oK
α 1 
in
hib
iti
on 
(IC
50 =
  6.8
5, 3
.27
, 2.
79 
an
d 1
6.2
2 μ
M, r
esp
ect
ive
ly)
. A
ll t
hes
e c
om
po
un
ds 
had
 a 
4-s
ubs
tit
ute
d a
nd 
7-s
ubs
tit
ute
d q
uin
oli
niu
m c
ati
oni
c h
ead
, 1
0f-l
, e
xce
pt 1
0c,
 w
hic
h h
ad 
the
 re
st 
of t
he 
N-
met
hyl
ani
lin
o at
 th
e 4 
pos
iti
on 
of t
he 
pyr
idi
niu
m c
ati
oni
c h
ead
. h
e st
ruc
tur
e o
f t
he 
4-s
ubs
tit
ute
d fr
ag
men
t 
co
ndi
tio
ns t
he i
nhi
bit
ory
 ac
tivi
ty 
of t
hes
e m
ole
cul
es. 
In f
act,
 co
mpo
un
ds 1
0j-l
 ha
d a 
4-c
ycl
oal
kyl
am
in
o fr
ag
men
t, 
whi
le 
co
mpo
un
ds 
10c
 an
d 10
f-i
 ha
d a 
4-N
-m
eth
yla
nili
no 
su
bsti
tue
nt. 
h
e re
sul
tin
g I
C 50
 va
lue
s in
dic
ate
d t
hat 
the
 
4-c
ycl
oal
kyl
am
in
o fa
vor
ed 
the
 C
ho
Kα
 1 i
nhi
biti
on, 
pro
bab
ly 
pro
mot
ing
 a 
mor
e ef
ecti
ve i
nse
rti
on i
nto 
the
 ad
di-
tio
nal 
bin
din
g si
te. 
In 
thi
s g
ro
up 
the
 ch
lor
o at
om
 in
cre
ase
d t
he 
vol
um
e o
f 
mol
ecu
le 
an
d t
he l
ip
op
hili
cit
y. h
us, 
the
 co
mpo
un
d 10
l o
fer
ed 
the
 ri
ght
 ba
lan
ce 
bet
wee
n v
olu
me 
an
d li
po
phi
lici
ty. 
h
e p
erh
ydr
oaz
epi
ne 
gro
up 
(10
i) 
pro
vid
ed t
he 
vol
um
e to
 be
 in
ser
ted
 in
to t
he c
holi
ne 
bin
din
g si
te 
pro
per
ly 
an
d th
e a
ddi
tio
n of
 a c
hor
o at
om 
slig
htly
 
dep
res
sed
 th
e a
cti
vity
 (1
0j).
Co
nve
rse
ly, 
the
 co
mpo
un
ds 
wit
h a
n N
-m
eth
yla
nili
no 
sys
te
m at
 th
e 4 
pos
iti
on 
of t
he 
pyr
idi
niu
m o
r q
uin
oli
n-
iu
m c
ati
oni
c h
ead
s s
ho
wed
 lo
wer 
IC 5
0 t
han
 di
d t
hos
e i
n t
he 
alk
yla
min
e s
yst
em
. I
n t
hes
e c
om
po
un
ds, 
the
 ch
lor
o 
ato
m in
 pa
ra 
pos
iti
on 
of 4
-(
met
hyl
(p
hen
yl)
am
in
o)q
uin
oli
niu
m o
r p
yri
din
iu
m fr
ag
men
t (1
0c,
 10
g a
nd 1
0i) 
or i
n 
pos
iti
on 
7 of
 th
e q
uin
oli
niu
m ri
ng (
10
h a
nd 1
0i) 
see
med
 to 
pla
y a
n es
sen
tial
 ro
le i
n th
e e
nzy
me i
nhi
biti
on. 
In f
act,
 
the
 pr
ese
nce
 of 
the
 ch
lor
o at
om
 all
ow
ed 
the
 ca
tio
nic 
hea
d to
 be
 ac
co
mm
oda
ted
 at 
the
 ch
oli
ne-
bin
din
g si
te, 
lik
ely 
by 
an i
ncr
eas
e in
 th
e li
pop
hili
city
 pr
ovi
ded
 by
 th
e h
alo
gen
 at
om
, re
gar
dle
ss 
of 
whe
re t
he 
hal
oge
n w
as l
oca
ted
 (1
0c,
 
10g
, a
nd 1
0h
 IC
50 =
  1.6
3, 3
.27
, a
nd 
2.7
9 μ
M, r
esp
ecti
vel
y). 
A di
rec
t c
orr
elat
io
n b
etw
een
 vo
lu
me-l
ipo
phi
lic 
acti
vity
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  0.0
62 
0.3
5 ±
  0.0
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n b
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n ±
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r t
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e i
nde
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den
t e
xpe
ri
men
ts.
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Cancer-cel growth inhibition  
Al compounds  were evaluated for their antiproliferative activity against a  panel  of  nine 
diferent human tumor-cel lines (Table 3). Al were given GI50 values generaly lower than 
1 µM, some of them even at nanomolar concentrations. Only two compounds, i.e. 10d and 
10e, registered GI50 values  higher than  10  µM against al tested lines.  Compounds 10a, 
10b, 10f, and 10l ofered the  best antiproliferative activities against al cel lines. In 
particular, 10a  gave GI50 values ranging from  0.027 to  0.12  µM, although the  best  value 
was  by 10f in  MDA-MB-231 cel line (GI50 =  0.001  µM).  Compared to  quinolinium 
derivatives, in general the pyridinium moiety provided beter results in al tested cel lines. 
In the pyridinium family, the best results were found when the substitution was an alkyl or 
cycloalkylamine (10a-b). The switching of dimethylamine to pyrolidine caused a curious 
decline in activity for the  majority  of cel lines (10b, GI50 =  0.042  µM to  4.5  µM).  The 
replacement  of this tertiary amine  by a conjugate aromatic system (4- (4-chloro-N-
methylanilino)pyridinium, 10c) resulted in lower activity (GI50 =  2.1  µM to  7.3  µM). It 
bears  noting that  despite  of their low lipophilicity (10a, clogP  = -0.36 and 10b clogP  = 
0.36), the compounds 10a-b provided beter results than did compound 10c (clogP = 1.8). 
This finding can  be explained  by the  diferent  mode to  bind to enzymes  of these 
compounds, as mentioned above. 
Replacing the  pyridinium system  with  quinuclidine as cationic  head, such as compounds 
10d and 10e, led to a total loss of activity in al cel lines. This result may be due to the 
very low lipophilicity of 10d-e (clogP = -1.01 and -2.42 respectively) and to the low IC50 
value. 
Regarding the  quinolinium family (10f-l), al compounds  had GI50 in the range  of 
submicromolar values, 10l being the best compound (GI50 = 0.007 µM for Jurkat cels). No 
diferences in the activity were detected between the diferent substituents in the 4 position 
upon the quinolinium system, since 10f and 10l (with N-methylanilino and 4- pyrolidine 
in the  4  position, respectively)  ofer the  best antiproliferative activity  over  nearly al the 
cel lines.  However, the  presence  or  not  of a chloro atom  over the  quinolinium system, 
seems to play a crucial role in inhibiting cel growth. The chloro atom provided not only a 
higher lipophilicity to these compounds, improving the  passage through the  plasma 
membrane, but also a larger volume that impaired the insertion in the choline binding site. 
In fact, compound 10f, which has an N- methylanilino group at the 4 position without any 
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chloro atom, exhibited  beter antiproliferative activity than  did compound 10h  or 10g, 
which  have a chloro atom in the  quinolinium.  However, 10f registered a lower  value  of 
ChoKα1 inhibition (IC50 =  6.86  µM) than 10g and 10h (IC50 =  3.27 and  2.79  µM, 
respectively)  with chloro in  para  position  of the  N-methylanilino system (10g)  or in  7 
position of quinolinium fragment (10h). The chloro atom provided lipophilicity and good 
results of enzyme inhibition but this lipophilicity can alow binding to other targets in the 
cancer cels. On the other hand, the presence of two chloro atoms make compound 10i too 
bulky to inhibit the enzyme (IC50 =  16.22  µM), strongly reducing the antiproliferative 
activity, and it is also  more lipophilic (clogP  =  4.23), and thus  does  not  bind to  other 
targets. In conclusion, among the  quinolinium family, the compounds  with an  N-
methylanilino system  upon the  4  position (10f-i), 10f ofers the  best antiproliferative 
values but lower inhibition of the enzyme (6.85 µM). This could be due to a greater afinity 
of 10f by the enzyme in a whole cancer cel while the higher lipophicility of 10g-h could 
help them to be more suitable for binding to other targets. This highlights the need for a 
balance  between lipophilicity, inhibitory activity  of the enzyme isolated (afinity and 
selectivity), and antiproliferative activity for achieving successful results. The insertion of 
chloro in position 7 as in compound 10k improves the activity. This suggests that although 
the enzymatic inhibitory activity is almost the same for these compounds (IC50 from 0.92 
to 2.02 µM), the chloro leads to an appreciable increase in the antiproliferative activity (10j 
vs. 10k) in nearly al the cel lines. 
Finaly, 10a and 10l were the compounds with the best GI50 values in almost al the cel 
lines.  The two  belong to  diferent subfamilies.  The first  one, 10a,  has a residue  of 
dimethylaminopyridinium as a cationic head which could ofer the best volume to fit in a 
choline  binding site,  while the compound 10l  has a residue  of  7-Chloro-4- 
pyrolidinequinolinium  which  provides  more lipophilicity to the  quinolinium  moiety, 
alowing the compound to cross the plasma membrane more easily. 
Trypan blue exclusion assay 
The cel viability in the presence of 10a was also evaluated by the trypan blue exclusion 
assay. The results depicted in Figure 4 reflect that 10a significantly inhibited cel growth in 
three cel lines (Figure 16, panel A = Jurkat, Panel B = HeLa; panel C = MDA-MB-231) 
tested in a concentration-dependent manner, roughly confirming the results found with the 
MTT test (see Table 3). Notably, we observed that the inhibition of cel proliferation was 
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not  dependent  on the  presence  of the  molecule in the incubation  medium. In fact, 
experiments in  which the cels treated  with 10a  were  harvested,  washed, and incubated 
with fresh medium without 10a proliferation continued to be inhibited, suggesting that the 
catalytic activity of the enzyme may have been ireversibly inhibited (Figure 17). 
 
Figure 16: 10a inhibits cel viability/proliferation 
Cel viability evaluated by trypan blue negative cel count in Jurkat cels (A) HeLa cels (B) and MDA-MB-
231 (C) after incubation  with the indicated concentrations  of compound 10a.  Data are  presented as 
mean±SEM of three independent experiments.  
 
 
Figure 17: 10a inhibits cel proliferation after comcompound removal 
Jurkat cels  were treated  with the indicated concentration  of 10a for  72h and then cels  were  harvested, 
washed, counted, and incubated in a  drug-free  medium.  After further  72h  of incubation, cel  viability  was 
analyzed by trypan blue exclusion assay as described in the experimental section. 
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Figure S5 
Jurkat cels wretreaedwith the ndicated conce  of 10a for72handthencels wer harvestd,
washed, counted, and incubated in a drug-free medium. After a further 72 h of incubation, cel viability 
was analyzed by trypan blue exclusion assay as described in the experimental section. 
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Efect of 10a in non-tumoral cels 
We investigated the efect of the most active compound (10a) in non-tumoral cels, e.g. 
human lymphocytes and human umbilical-vein endothelial cels (HUVEC) from healthy 
donors. As shown in Table 4, in general, in resting lymphocytes, fibroblasts, and HUVEC, 
compound 10a had lower toxicity compared to tumor cels. Instead, in lymphocytes 
stimulated with a mitogen (e.g. phytohematoagglutinin, PHA), the compound had 
cytotoxicity comparable to that seen in tumor cels, indicating a certain preference only 
towards proliferating cels. In this context, it bears noting that other choline kinase 
inhibitors such as MN58b or RSM932A presented low or reduced cytotoxicity in 
oncogene-transformed cels and in tumor cels, in agreement with previously published 
data (Báñez-Coronel, 2004; Cabezon et al., 2000; Cantril et al., 2000; Gruber et al., 2012; 
Xiao et al., 2007). 
 
Table 4: In vitro inhibitory effects of selected compounds in non-tumoral cels.  
aGI50= Compound concentration required to inhibit tumor-cel proliferation by 50% Values represent the 
mean ± SEM for three independent experiments. n.d. not determined. bPha, Phytohematoagglutinin. 
10a induces G1 phase cel-cycle arrest 
Compound 10a induced a G1 arest of the cel cycle, which occured in a concentration-
dependent manner in the three cel lines tested (Jurkat, MCF-7 and MDA-MB-231). 
Together with the G1 increase, a concomitant reduction was found in the S phase (Figure 
18). Notably, cels with hypodiploid DNA content, suggestive of activation of apoptotic 
signaling, were not detected (data not shown). Similar results were also found with the two 
lead compounds RSM932A and MN58b, suggesting a common mechanism of action. Our 
��������������������������
���������������
10a proliferation continued to be inhibited, suggesting that the catalytic activity of the enzyme may have been 
irreversibly inhbited (Figure S5 ofSupplementaryinformation).
We investigated the efect of the most active compound (10a) in 
nn-umoralcls e.g. humanlymphocytesan human umbilical-vein endothelal cls (HUVEC) from healthy 
donors. As shown in Table 3, in general, in resting lymphocytes, ibroblasts, and HUVEC, compound 10a had 
lower toxicity compared to tumor cels. Instead, in lymphocytes stimulated with a mitogen (e.g. phytohematoag-
glutin Pha),thecompound hadcyttoxicty comparable tothatsee in umorcels, indicating a certain pref-
rene only towards proliferating cels.In thi context, it bears notig thatother choline kinase inhibitors such as 
MN58b or RSM932A presented low or reduced cytotoxicity in oncogene-transformed cels and in tumor cels, in 
agreement with previously published data44,48.
α
������������Although the docking studies clearly suggested that the compounds bind to the choline 
Figure 4.  Cel viability evaluated by trypan blue count in Jurkat cels (A) HeLa cels (B) and MDA-MB-231 
(C) ater incubation with the indicated concentrations of compound 10a. Data are presented as mean± SEM of 
three independent experiments.
Antiproliferative activitya GI50 (μM)
Comp PBL(resting) PBL(+Pha)b Human ibroblasts HUVEC
10a 1.5 ± 0.64 0.034 ± 0.007 5.8 ± 1.3 5.1 ± 0.43
10b 34.8 ± 15.6 1.88 ± 0.71 30.5 ± 9.6 n.d.
10f 1.4 ± 0.6 0.10 ± 0.03 9.8 ± 2.5 n.d.
10g 0.98 ± 0.25 0.55 ± 0.11 7.4 ± 2.4 10.4 ± 3.5
10h 1.0 ± 0.42 0.32 ± 0.03 3.7 ± 0.43 16.0 ± 6.6
10j 2.0 ± 0.24 0.095 ± 0.021 14.3 ± 1.2 n.d.
10k 2.1 ± 0.80 0.034 ± 0.007 3.2 ± 0.86 n.d.
10l 3.8 ± 0.55 0.49 ± 0.15 9.6 ± 1.3 11.4 ± 5.9
RSM932A 1.1 ± 0.09 0.23 ± 0.05 n.d 0.46 ± 0.047
MN58b 2.0 ± 0.4 0.15 ± 0.05 n.d. 2.1 ± 0.58
e 3.In vtro nhibitory ef s of selectedcompoundsin non-tumoral cels. aGI50 = Compound concentration required to inhibit tumor-cel proliferation by 50% Values are the mean ± SEM for three 
independenexperimnts.n.d. not determind. bPha, ytoematoag
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results agree  with the  data  of  Granata et al. (Granata et al.,  2014)  which showed that 
ChoKα downregulation in  ovary-cancer cels inhibits cel  proliferation  without afecting 
survival signaling  pathways  whereas, a reduction in the  S-phase,  proportional to  growth 
inhibition, was observed in cels knocked down for ChoKα1. The cel cycle also showed a 
slight  G1 cel-cycle arest in silenced cels compared  with controls.  On the contrary, 
Sanchez-Lopez et al. (Hernández-Alcoceba et al.,  1999) showed that RSM932A and 
MN58b induce a significant  decrease  of the  G1  phase in  breast- and colon-cancer cels 
without any alteration  of the  other  phases  of the cel cycle. It should  be  noted that these 
data corespond to a concentration (15 µM) higher than that used in the present study. 
 
 
Figure 18: 10a induced a G1 arrest of the cel cycle 
Percentage of cels in each phase of the cel cycle in Jurkat (Panels A), MCF-7 (Panel B) and MDA-MB231 
cels (Panels  C-E) treated  with the indicated compounds at the indicated concentrations for  24  h.  Data are 
presented as mean ± SEM of three independent experiments.  
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10a induces low levels of apoptosis 
To evaluate whether 10a causes cel death, we conducted a biparametric cytofluorimetric 
analysis  using  propidium iodide (PI),  which stains  DNA and enters  only  dead cels, 
together with fluorescent immunolabeling of the protein annexin-V (AV), which binds to 
phosphatidylserine in a highly selective manner. Dual staining for AV and with PI enables 
the  discrimination  between live cels (AV-/PI-), early apoptotic cels (AV+/PI-), late 
apoptotic cels (AV+/PI+), and  necrotic cels (AV-/PI+).  For a  positive control,  we  used 
two wel-known anticancer drugs such as Cis-Pt and Etoposide that in al cel lines tested 
induce significant apoptosis (data not shown). As depicted in Figure 19, 10a after 72h of 
incubation induced a modest increment in apoptotic cels only in Jurkat cels while both in 
MCF-7 and MDA-MB-231 the increase appeared not to be significantly diferent from that 
of the untreated cels. 
 
 
Figure 19: 10a induces only a moderate apoptotic effect 
Flow cytometric analysis of apoptotic cels after treatment of Jurkat (panel A), MCF-7 (panel B) and MDA-
MB-231 (panel  C) cels  with 10a at the indicated concentrations after incubation for 72 h. The cels  were 
harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as 
mean ± SEM of three independent experiments. 
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3.1.4 DISCUSSION 
The synthesis  of a  novel family  of  1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene) 
bis(methylene)-bispyridinium or –bisquinolinium bromide (10a-l) and their evaluation as 
inhibitors of choline kinase against a panel of cancer-cel lines are described in this work. 
These compounds  were eficiently synthesized in three steps, starting from the  building 
block 6. The chemistry used was appropriate to obtain the designed target compounds, and 
both the  yield and the time  of reaction  were improved considerably  with  microwave 
iradiation. 
Preliminary  docking studies  performed  on  both crystal structures,  ChoKα1/2 (PDB ID: 
4BR3) and ChoKα1/4 (PDB ID: 4CG8), and the analysis of the resulting poses, indicated 
that these compounds (10a-l) could adopt similar  behaviour to that  of compound 2 or to 
compound 4 thanks to the synclinal conformation of the linker that alowed the insertion of 
these  molecules inside the  Cho  binding site and consequently enhanced the 
antiproliferative efect.  The first experimental  validation  of the  docking studies is shown 
with the results  of tryptophan assays for these compounds,  which  ofer  very  good  Kd 
values.  Among al the compounds, those  belonging to the families  of  pyridinium and 
quinolinium ofered similar or beter IC50 ChoKα1 than did the lead compounds MN58b 
and RSM932A. In fact, the best inhibitors were 10a and 10l, and the crystal structure of 
ChoKα1/10a showed that the compound  binds to the choline  binding site, indicating the 
accuracy  of the theoretical  predictions,  wherein the first  one-benzyl-4-(dimethylamino) 
pyridinium represents the appropriate fragment to inhibit the enzyme. 
Also, we have shown these compounds to have an excelent antiproliferative profile, beter 
than that of the two lead compounds RSM932A and MN58b in a panel of human tumor-
cel lines. More importantly, our compounds presented lower or reduced toxicity in some 
non-tumor-cel lines in comparison to transformed cels. Indeed  our results agree  with 
previous  observations indicating increased  ChoKα1 activity in cel cultures treated  with 
growth factors or insulin (Rodríguez-González et al., 2003; Uchida and Yamashita, 1990; 
Warden and Friedkin, 1985). In this context it is important to note that our results indeed 
confirm these previous findings, and compound 10a in fact presented higher activity only 
in rapidly  proliferating cels such as  mitogen-stimulated lymphocytes in comparison to 
quiescent cels. 
Another important finding is that 10a significantly arested the cel cycle in  G1 together 
 45 
with a sharp reduction  of the  S  phase, confirming their ability to inhibit cel  growth. 
Curiously, despite their ability to block cel proliferation, 10a induced a low proportion of 
cel death, as reflected by a low level of Annexin-V positive cels. Notably, this occured 
also for the two reference compounds RSM932A and MN58b,  which even at the 
maximum concentration used showed a negligible percentage of apoptotic cels, according 
to the analysis  of the cel cycle. It is important to  note that, although some reports 
(Hernández-Alcoceba et al.,  1999) indicate these two compounds  may induce apoptosis, 
this takes place at concentrations much higher than the IC50 (15 µM), which can have an 
of-target efect.  This intriguing aspect is  under active investigation  by  our  group. 
Nevertheless, our data demonstrate that 10a is a highly promising new ChoKα1 inhibitor 
and is worthy of further preclinical evaluation as a potential anticancer drug. 
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RESULTS  
 
 
3.2 The  novel choline  kinase  alpha inhibitor  EB-3D induces celular senescence in 
triple-negative  breast cancer  and reduces tumor  growth  and  metastatic 
dissemination. 
 
 
Elena  Marioto,  Roberta  Bortolozzi,  Roberto  Ronca,  Davide  Carta,  Valentina  Serafin, 
Giuseppe Basso, Luisa Carlota López-Cara, Giampietro Viola. 
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3.2.1 ABSTRACT 
Identification of novel strategies for kinase inhibition is one of the most chalenging goal in 
cancer  pharmacology.  Choline  kinase (ChoK) is the first enzyme  of the  Kennedy’s 
pathway leading to the  biosynthesis  of  phosphatidylcholine (PtdCho), the  most abundant 
phospholipid in eukaryotic cel  membranes.  Compound EB-3D is a  novel  ChoKα1 
inhibitor with a potent antiproliferative activity against a panel of several cancer cel lines. 
ChoKα1 is particularly overexpressed and hyperactivated in aggressive breast cancer. Here 
we report that EB-3D strongly impairs triple-negative  MDA-MB-231  proliferation, 
migration and invasion and the efect is ireversible. Reverse-phase protein aray (RPPA) 
data revealed the activation of the AMP-activated protein kinase (AMPK) metabolic sensor 
causing the  dephosphorylation  of the  mammalian target  of rapamycin complex  1 
(mTORC1)  downstream targets such as  p70 ribosomal  protein  S6  kinase (p70S6K) and 
S6K and the eukaryotic translation initiation factor  4E-binding  protein  1 (4E-BP1), 
suggesting that EB-3D may afect protein synthesis. Moreover we demonstrate that EB-3D 
strongly synergizes  with  drugs  used for triple-negative  breast cancer treatment, in 
particular with cisplatin. The absence of cel death previously reported in MDA-MB-231 
folowing EB-3D treatment is essentialy  due to the induction  of celular senescence. 
Moreover EB-3D-induced senescence significantly sensitizes  MDA-MB-231 cels to the 
apoptotic efect of cisplatin. The antitumorigenic potential of EB-3D was evaluated also in 
vivo in syngeneic  orthotopic  EO771-C57BL/6  mouse  model  of  breast cancer.  The 
compound induces a significant reduction of the tumor mass at low doses. In addition, we 
also tested the possible anti-metastatic efect of EB-3D in both syngeneic EO771-C57BL/6 
and  xenogeneic  NOD/SCID  model engrafted  with  MDA-MB-231. In  both  models we 
observed a significant reduction of lung metastasis. Altogether, our results indicate that the 
novel  ChoKα1 inhibitor EB-3D could  be a  promising  new anticancer agent to improve 
aggressive triple negative breast cancer treatment protocols. 
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3.2.2 INTRODUCTION 
Metabolic reprogramming  has  been recognized as  one  of the ten  halmarks  of cancer 
(Hanahan and  Weinberg,  2011).  Malignant cels  need to change their celular energy 
metabolism in  order to support exacerbate cel  growth and  proliferation and to adapt to 
new  microenvironment conditions and to  diferent chalenges. Lipid  metabolism is  no 
exception: a sustained  biosynthesis  of  membrane  phospholipids is required to  meet the 
demand  of rapidly  proliferating cels. In fact, alteration in choline (Cho)  metabolism  has 
been  observed in  many cancers (Asim et al.,  2016; Iorio et al.,  2010; Nakagami et al., 
1999; Ramírez  de  Molina et al.,  2002d; Ramírez  de  Molina et al.,  2007) and it  has  been 
related to  deregulated cel  proliferation, invasion and  metastasis.  The so-caled “cholinic 
phenotype” consists in increased level  of  phosphocholine (PCho) and in  general  of total 
choline-containing  metabolites (tCho)  mainly  due to the  overexpression and/or 
hyperactivation  of the α1 isoform  of choline  kinase (ChoKα1).  ChoKα1 catalyzes the 
phosphorylation  of choline to  phosphocholine is the first step  of the  Kennedy’s  pathway 
ultimately leading to the synthesis  of  phosphatidylcholine (PtdCho), the  most abundant 
phospholipid  of eukaryotic cel  membrane. Increased expression  of  ChoKα1  has  been 
extensively  described in  breast cancer,  where it corelates  with  histological tumor  grade 
and  poor clinical  outcome (Ramírez  de  Molina et al.,  2002a).  For al these reasons, 
ChoKα1  has  been  proposed as a  new appealing target for cancer therapy and  during the 
past  decades extensive eforts  have  been  made to synthesize and improve  ChoKα1 
inhibitors. 
EB-3D (previously known as compound 10a) is a novel symmetrical biscationic ChoKα1 
inhibitor that was recently shown to impair cel proliferation in a panel of diferent cancer 
cel lines (Schiafino-Ortega et al.,  2016).  Here  we  provide evidence that EB-3D targets 
ChoKα in vitro, reducing  phosphocholine levels  measured  by  magnetic resonance 
spectroscopy (1H-MRS) in cels treated with the compound. The purpose of this study was 
to deeply investigate the efect of EB-3D-mediated ChoKα inhibition both in vitro and in 
vivo in triple-negative  breast cancer (TNBC)  models.  To accomplish this  goal  we  used 
MDA-MB-231  breast cancer cel line,  where the  overexpression  of  ChoKα and its 
consequences are  wel  documented. We examined the effects of EB-3D in vitro  on cel 
viability, cel proliferation, signaling pathways modulation, cel migration and invasion. In 
addition, the ability  of EB-3D to enhance the anti-tumorigenic  potential  of  drugs 
commonly  used in  breast cancer treatment  protocols  was also tested.  We  previously 
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reported that EB-3D has a more potent in vitro cytostatic efect on compared to MN58b 
and RSM932A, chosen as reference compounds for symmetrical  ChoKα1 inhibitors, 
causing a strong reduction of cel proliferation and G0/G1 phase cel cycle arest. In this 
work, we show that EB-3D is less toxic in resting non-tumoral mammary cels compared 
to the stimulated tumor-like counterpart, in agreement to  previously reported compounds 
(Rodriguez-Gonzalez et al., 2004; Trousil et al., 2016). 
Celular senescence is the permanent growth arest that occurs in normal cels to prevent 
unlimited cel proliferation. Neoplastic transformation requires the inhibition of senescence 
machinery, however it has now become clear that tumor cels can be induced to undergo 
senescence  by chemotherapy treatments and treatment-induced senescence  was shown to 
be involved in tumor response to therapies (Achuthan et al., 2011). Indeed, senescent cels 
are able to secrete proteins implied both in tumor suppression and survival (Pérez-Mancera 
et al.,  2014).  Here  we  give  proof that EB-3D is able to induce celular senescence that 
sensitizes resistant cancer cels to chemotherapy. 
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3.2.3 RESULTS 
Inhibition of ChoKα by EB-3D reduces soluble choline metabolites in MDA-MB-231 
To evaluate if EB-3D-mediated ChoKα inhibition efectively reduces choline metabolites, 
1H-NMR spectra  were analyzed after treatment  of  MDA-MB-231  with the  ChoKα1 
inhibitor. The variation of choline metabolites during time is summarized in Figure 20. 
  
 Figure 20: Choline-containing metabolites variations 
Milimolar levels  of  Cho (A),  PCho (B),  GPCho (C) and tCho (D) quantified from 1H-NMR spectra of 
MDA-MB-231 cels treated with 1µM of EB-3D or DMSO for the indicated time points. (E) GPCho/PCho 
molar ratio  normalized to each time-point control. Values represent the mean  ±  SEM  of two independent 
experiments. Differences between each time-point treatement and its control were analyzed using two-way 
ANOVA. (F) Representative 1H-MR spectra from the 3.20–3.25 ppm region of water-soluble extracts from 
MDA-MB-231 cels after 48h of treatment with DMSO (blue line) and 1µM of EB-3D (red line). 
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After  24  h  of treatment  with  1µM  of EB-3D, the  pool  of free  Cho is about two-fold 
compared to control (0.156 ± 0.003 vs. 0.077 ± 0.005 mM) and this gap is mainteined at 48 
h (Figure  20  A).  On the contrary, EB-3D treatment reduces the amount  of the  ChoKα 
reaction  product  over time,  halving  PCho intraceluar level in  48  h (1.62  ±  0.25  mM in 
treated cels  vs.  3.17  ±  0.38  mM in control) (Figure  20  B).  GPCho levels significantly 
increses  only at  48  h (1.47  ±  0.12  vs.  1.18  ±  0.06  mM) (Figure  20  C)  while a  general 
decrease in tCho levels was observed during time (Figure 20 D). Lastly, the GPCho/PCho 
ratio is slighly increased after ChoKα inhibition at al time points but it becomes strongly 
significant  only after  48  h  of treatment (Figure  20  E).  Figure  20  F shows representative 
spectra superimposition of water-soluble extracts of cels treated with 1µM of EB-3D for 
48 h and its control. 
EB-3D irrevesible cytostatic efect 
Our previous data showed that EB-3D is a potent cytostatic agent that causes a G0/G1 cel 
cycle arest in two  diferent  breast cancer cel lines  without afecting cel  viability 
(Schiafino-Ortega et al., 2016). It is worth to add that there is a relevant shift between the 
EB-3D dose-response curves obtained for non-tumoral MCF-10A breast cel line cultured 
in resting condition (minimal medium) and stimulated with mitogenic factors (Figure 21). 
In fact  mitogen-stimulated  MCF-10A respond to EB-3D with two  orders  of  magnitude 
lower GI50. 
 
Figure 21: EB-3D cytotoxicity in non tumoral MCF-10A breast cel line 
MTT cel proliferation assay of non tumoral MCF-10A breast cel line treated with EB-3D in resting (black 
line) and stimulated condition (blue line).  Cel  viability  percentages are  normalized to  untreated cels. 
Symbols and bars represent respectively the mean ± SEM of three replicates. 
In addition,  we report also a significant  dose-dependent reduction  of the relative colony 
formation rate in MDA-MB-231 cels (Figure 22). To investigate deeply the efects of EB-
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3D over time, we treated MDA-MB-231 cels with 0.5 µM of EB-3D up to 6 days and we 
observed a persistent arest in cel proliferation (Figure 23 A), with no significant increase 
in cel death (Figure 23 B). 
        
Figure 22: ChoKα inhibition reduces MDA-MB-231 clonogeneicity 
(A)  Relative colony formation rate  of MDA-MB-231 treated  with the indicated concentration of EB-3D. 
Data are  depicted as  mean  ±  SEM of three independent experiments. Differences  between control and 
treatements were analyzed  using one-way  ANOVA  with  Newman-Keuls correction. (B)  Representative 
pictures of one wel-defined colony (>50 cels) with DMSO and undefined colony in EB-3D-treated cels. 
 
Figure 23: EB-3D irreversible cytostatic effect 
(A) Trypan  blue exclusion assay and (B) flow cytometry analysis  of cel  death. MDA-MB-231 cels  were 
treated  with  0.5  µM  of EB-3D for  72 h and then  medium  were replaced  with fresh  medium  with (EB-3D 
continuous) or without (EB-3D WASHOUT) the ChoKα inhibitor for further 72 h. Data are represented as 
mean ± SEM of three independent experiments. Differences between control and both treatment schedules 
were analyzed using two-way ANOVA with Newman-Keuls correction. There is no significant difference in 
cel proliferation or cel death between EB-3D-continuous exposure (green) and EB-3D-washout (purple) at 
the final time point (144 h). 
 
More interestingly, the removal  of EB-3D from  media culture after  72  h  of exposition 
suggests that the efects of ChoKα1 inhibition led to a ireversible cel growth. In fact we 
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do not observe a proliferation restart or any diferences in cel number between continuous 
exposure  of the  drug and its  withdrawn (Figure  23  A).  This suggest that EB-3D induces 
MDA-MB-231 cel line to enter into an ireversible  quiescent, rather than an apoptotic 
state. 
EB-3D induces celular senescence 
The  prolonged and ireversible efect  of EB-3D treatment could  be explained  by the 
induction  of celular senescence. Indeed,  we  observed a strong increase in senescence-
associated  beta-galactosidase (SA-βgal) activity, a  biomarker  of senescent cels, through 
the conversion of its substrate C12FDG after 72 h of EB-3D treatment (Figure 24 A). The 
analysis  of  mean fluorescence intensity (MFI) indicates that the efect is  dose-dependent 
and, as expected, is ireversible even after EB-3D wash-out (Figure  24  B).  The  onset  of 
senescence is confirmed also by the observation of typical morphological changes: cel size 
and  granularity appear increased in MDA-MB-231 treated  with EB-3D compared to 
control, confirmed also  by the increase in forward scater (FSC) and side scater (SSC) 
observed by flow cytometry (Figure 25). 
 
Figure 25: EB-3D induces celular senescence 
(A) Flow cytometry analysis  of celular senescence  using  C12FDG  probe and (B) representative  histogram 
plot. MDA-MB-231 cels  were treated  with  0.5  µM  of EB-3D for  72h (red color) and then  medium  were 
replaced  with fresh  medium  with (EB-3D continuous,  blue color)  or  without (EB-3D WASHOUT,  green 
color) the  ChoKα inhibitor for further 72h. Data are represented as mean ± SEM of three independent 
experiments. Differences between control and 72 h time point were analyzed using one-way ANOVA with 
Newman-Keuls correction. 
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EB-3D sensitizes triple-negative breast cancer to common chemotherapeutic drugs. 
Since EB-3D induced a strong decrease in cancer cel proliferation, we evaluated whether 
this drug had promise when used in combination with commonly used chemotherapeutics 
in TNBC treatment. To this end, MDA-MB-231 cels were treated for 48 h with EB-3D in 
combination  with selected chemotherapeutic agents, i.e.  doxorubicin (Doxo),  5-
fluorouracil (5-FU) and cisplatin (Cis-Pt). EB-3D was combined with drugs at fixed molar 
ratio, and cel viability was analyzed by MTT assay. As previously described (Schiafino-
Ortega et al.,  2016), EB-3D alone remarkably reduce  MDA-MB-231 cel  viability  when 
used as a single agent,  but  when  used in combination  with chemotherapeutic  drugs,  we 
observed a synergistic increase in cytotoxicity with 5-FU (Figure 26 A), Doxo (Figure 26 
B) and Cis-Pt (Figure 26 C). The synergistic efect is also confirmed by combination index 
(CI) values (Figure 26 D) obtained by the analytic method of Chou (Chou, 2006). For al 
tested combinations, we obtained CI < 0.3 that indicate a strong drug synergism. 
 
 
Figure 26: Drug synergism 
Cel viability was evaluated by MTT analysis, performed after EB-3D (black lines), Doxo (A), 5-FU (B) and 
Cis-Pt (C) single drug treatments (blue lines) and their combination at fixed molar ratios (red lines). Points 
represent the mean ± SEM of three independent experiments. (D) Combination index (CI) values calculated 
at ED50, ED75 and ED90 for each drug combination described above. 
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Given the  highly synergistic efect  obatained  with EB-3D/Cis-Pt,  we then further 
characterized this combination.  The simultaneous addition  of EB-3D (1µM) and  Cis-Pt 
(20µM) significantly increases the  percentage  of apoptotic cels compared to the single 
Cis-Pt treatment (12.8 ± 0.8 vs. 4.8 ± 0.6). Moreover, the pre-treatment with 1µM of EB-
3D for  72h,  which  does  not induce apoptosis itself,  was able to  drasticaly  boost the 
apoptotic response to Cis-Pt in MDA-MB-231 cels (41.8 ± 1.7) (Figure 27).  
 
Figure 27: EB-3D pre-treatment sensitizes MDA-MB-231 cels to cisplatin 
The apoptotic effect  of EB-3D and cisplatin (CisPt)  drug combination was evaluated  by flow cytometry 
using Annexin-V-FITC (AV) and propidium iodide (PI) dual staining. MDA-MB-231 cels were treated for 
72h with CisPt (20µM) alone, the simultaneous addition of EB-3D and CisPt or pre-treated with EB-3D and 
then treated with CisPt for further 72h. Were considered as apoptotic/dead cels al cels being alternatively 
stained for AV, PI or both. Bars represent the represent the mean ± SEM of three independent experiments. 
Differences  between single  CisPt treatment and the two combination schedules  or  within the two 
combinations, were analyzed using two-way ANOVA with Newman-Keuls correction. 
ChoKα1 inhibition afects AMPK-mTOR signaling pathway  
Reverse-phase protein aray (RPPA) enables the measure of protein phosphorylation levels 
with high sensitivity and specificity, using antibodies specificaly validated for RPPA. As 
depicted in  Figure  28, MDA-MB-231 cels show a significant  modulation in  AMPK-
mTOR signaling  pathway folowing EB-3D treatment.  RPPA  data show that the 
treatment with 1 µM EB-3D triggers the activation of the metabolic stress sensor AMPK 
by the increase in  phosphorylation  of residue  T172  of catalytic subunit α.  AMPKα 
represses mTORC1 pathway as shown by mTOR S2448 dephosphorylation. The inhibition 
of mTOR in turn reduces p70S6K S371, 4E-BP1 S65 and S6K ribosomal protein S235/236 
phosphorylations.  Phosphorylation  of  4E-BP1 and  S6K required for the initiation and 
progression of mRNA translation process respectively. 
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Figure 28: EB-3D affects AMPK-mTOR signaling pathway  
MDA-MB-231 cels were treated with 1µM of EB-3D or vehicle for the indicated time points. Cels were 
then lysed and whole cel proteome was subjected to RPPA analysis using validated antibody against 
AMPK�-T712, mTOR-S2448,  4EBP1-S65, p70S6K-S371 and S6-S235/236 phosphorylations. Bars 
represent mean ± SEM of three independent experiments. Differences between control and treated samples 
were analyzed using ANOVA test for repeated measures with Newman-Keuls correction. 
In vivo tumor growth inhibition 
To examine the antitumorigenic potential of EB-3D in vivo, we opted in favour of a 
immunocompetent syngeneic EO771-C57BL/6 mouse model. The fact that there is more 
than 88% of sequence homology between human and mouse ChoK�1 and that al the 
aminoacids shown to be important for interaction with EB-3D or its stabilization 
(Schiafino-Ortega et al., 2016) are perfectly conserved (Supplementary Table 1), suggests 
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that  our compound should inhibits also the  mouse  homolog. EO771, a  mammary 
adenocarcinoma cel line  derived from a  C57BL/6  mouse, are immunohistochemicaly 
classified as  basal-like tumour, a subtype associates  with  poor  prognosis in  humans. 
EO771 are immunosuppressive and  highly aggressive,  giving rise to lung metastasis that 
closely miror those of the human breast tumor (Johnstone et al., 2015). Preliminarly, the 
cytostatic efect of EB-3D was confirmed also in murine cels. EB-3D reduces EO771 cel 
viability  with  GI50  =  0.31 µM and is  more eficient than MN58b (GI50  =  1.65 µM) and 
RSM932A (GI50  =  2.86 µM) (Fig. 29  A) without relevant cytotoxic efects (Fig. 29  B), 
confirming the in vitro data obtained in human MDA-MB-231 cel line. 
 
Figure 29: In vitro cytostatic effect of EB-3D in mouse EO771 breast cancer cel line 
(A) EO771 cel viability  was evaluated  by  MTT assay after  72h  of treatment  with EB-3D, MN58b and 
RSM-932A. (B) Analysis of apoptosis induced by EB-3D at the indicated concentrations for 72h in EO771 
cels.  Apoptosis  was evaluated  by flow cytometry  by staining cels  with Annexin-V-FITC (AV) and 
propidium iodide (PI).  
 
C57BL/6 mice treated with EB-3D displayed a significant reduction in tumor growth at the 
low dose of 1 mg/kg (Figure 30) Interestingly, a significant decrease of the tumor volume 
appears just after the second injection and remain til the completion of the experiment. At 
this point we observed a reduction of about 210% of the tumor volume. Healthy C57BL/6 
mice  were treated  with  2.5  mg/kg  of EB-3D for toxicity and  no significant  weight loss, 
behavioral changes and fur appearance were observed in treated mice compared to controls 
(data not shown). 
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Figure 30: ChoK� inhibition impairs mammary tumor growth in vivo. 
Average mammary EO771 tumor volume of mice injected with either vehicle (DMSO) or 1 mg/kg of EB-3D 
(n = 8/treatment) (A); Average weight (B) and macroscopic images (C) of resected tumors at the conclusion 
of the experiment. Values are depicted as mean ± SEM. Tumors were measured in two dimensions and tumor 
volume V (mm3) was calculated according to the formula V=(D x d2)/2, where D and d are the major and 
minor perpendicular tumor diameters, respectively. Differences between control and treated mice were 
analyzed using Student t test using Bonferroni correction. 
EB-3D suppresses in vitro cel migration and invasion 
Since ChoK� is involved in phosphatidylcholine biosynthesis and the alteration of cel 
membrane structure can reduce motility and invasiveness of tumor cels, we evaluated if 
EB-3D is able to suppress MDA-MB-231 migration and invasion upon treatment. Figure 
31 A shows the representative images of wound-healing assay in MDA-MB-231 cels 
treated with diferent concentration of EB-3D. The inhibition of ChoK! mediated by EB-
3D resulted in a dramatic impairment of migration of MDA-MB-231 cels that are no 
longer able to close the scratch in a concentration dependent manner (Fig 31 B). In 
addition, a cel matrix invasion assay has been performed in  MDA-MB-231 cels pre-
treated with EB-3D for 24 h.  ChoK� inhibition significantly impairs the ability of the 
highly invasive MDA-MB-231 to pass through a basal membrane extract (BME)-coated 
transwel within 24 h (Figure 31 C). 
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Figure 31: EB-3D impairs MDA-MB-231 motility and invasiveness 
Confluent MDA-MB-231 monolayer was scratched and treated with EB-3D at the indicated concentrations 
and monitored at 6, 24 and 48 h. (A) Representative images of wound closure after treatment with EB-3D, 
10X magnification. The distance between the two edges of the scratch is marked in blue. (B) Bar graphs 
showing relative quantification of the distance between scratch edges at the indicated time points. (C) 
Relative quantification of BME-based invasion assays performed with MDA-MB-231 pre-treated with EB-
3D at the indicated doses. Difference between DMSO and treated cels were analyzed using one-way 
ANOVA using Newman Keuls correction. 
Metastasis formation is reduced by EB-3D treatment 
Since we observed that ChoK� inhibition mediated by EB-3D is involved in cel migration 
and invasion, two common features of metastatic cels, we decided to test if EB-3D is able 
to reduce metastasis formation in vivo. The treatment of EO771-C57BL/6 mice after 
primary tumor removal shows only a trend in reduction of the number of spontaneous lung 
macro- and micro-metastasis (Figure 32 A-B). It must be pointed out that the complexity 
of the experimental procedure implies high variability in the number of metastasis within 
controls. However, the observed trend is coroborated by the statisticaly significant 
reduction of experimentaly-induced lung macro- and micro-metastasis (Figure 32 C-D) in 
EB-3D treated mice compared to untreated ones. 
Lastly, EB-3D administration also inhibits the number of experimental lung macro-
metastasis (Figure 32 E) and resected lung weight (Figure 32 F-G) after intravenous 
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injection of MDA-MB-231 cels in xenograft NOD/SCID mice.  Representative 
photomicrographs of lung tissue sections from control and treated xenograft MDA-MB-
231-NOD/SCID mice are shown in Figure 32 H, where the reduction of metastatic lesion 
size between control and EB-3D treated becomes evident. 
 
       
 
Figure 32: ChoK� inhibition reduces lung metastasis formation 
(A)  Number of spontaneous lung macro-metastasis and (B) micro-metastasis after primary EO771 tumor 
removal. Mice were treated i.p. for 4 weeks every other day with either vehicle (DMSO, n=5) or 2.5 mg/kg of 
EB-3D (n=7); (C) Number of experimentaly-induced lung macro-metastasis and (D) micro-metastasis after 
i.v. injection of EO771 cels and 3 weeks treatement with either vehicle (DMSO, n=5) or 2.5 mg/kg of EB-
3D (n=6); (E) Number of experimentaly-induced lung macro-metastasis after i.v. injection of human MDA-
MB-231 cels in NOD/SCID mice and 7 weeks treatement with either vehicle (DMSO, n=3) or 2.5 mg/kg of 
EB-3D (n=3) and (F) average lung weight and (G) macroscopic images of resected lungs at the conclusion of 
the experiment. Values are depicted as mean ± SEM. Differences between control and treated mice were 
analyzed using Student t test using Bonferroni correction. (H) Representative H&E staining performed on 
lung tissue sections from control and treated xenograft MDA-MB-231-NOD/SCID mice. Original 
magnification 10X.  
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3.2.4 DISCUSSION 
In this study we proved that the new choline kinase inhibitor EB-3D, belonging to the class 
of symmetrical biscationic ChoKα inhibitors, is a promising agent for triple-negative breast 
cancer treatment. We observed impaired cel proliferation and clonogenicity as wel as the 
increase in drug sensitivity upon EB-3D treatment in MDA-MB-231 cels. 
Here we demonstrated that the smal molecule EB-3D specificaly targets ChoKα enzyme 
as pointed out by the decrease of PCho and the matched decrease of tCho levels in water-
phase extracts  of treated cels. We also  observed a two-fold increase in  Cho levels after 
treatment that can  be explained as the accumulation  of  ChoKα substrate, supporting the 
enzymatic inhibition. The absence of Cho decrease is reassuring but we cannot rule out the 
possibility  of choline transport inhibition, as this event  was  not examined  here.  The 
increase in  PCho level is required for  G1-S transition (Rodriguez-Gonzalez et al.,  2004) 
and its reduction is consistent with the previously reported cycle arest in G0/G1 phase due 
to EB-3D (Schiafino-Ortega et al.,  2016).  Blockade  of cel  proliferation is  maintained 
even after compound removal suggesting that  ChoKα inhibition is ireversible  or at least 
that the damages caused by EB-3D are permanent. Indeed, to our knowledge we proved for 
the first time that celular senescence can  be induced  by targeting choline  metabolism in 
TNBC. The pharmacological inhibition of ChoKα with EB-3D significantly increases the 
activity of the senescent marker SA-βgal in MDA-MB-231 breast cancer cels and EB-3D 
removal  does  not lead to  growth recovery, conversely to  what  has  been reported for the 
novel non-symmetrical ChoKα inhibitor V-11-0711 (Falcon et al., 2013). In addition, the 
two-fold increase  of  GPCho/PCho ratio  observed  has also  been  described as a feature  of 
senescent cels, independently from the type of senescence (Gey and Seeger, 2013). The 
induction  of celular senescence in triple-negative MDA-MB-231 is also in  perfect 
agreement  with the absence  of cytotoxicity  observed in this cel line compared to  other 
tumor cels treated with EB-3D, such as Jurkat and HeLa (Schiafino-Ortega et al., 2016). 
The absence of apoptosis is in contrast to published data for MN58b (Rodriguez-Gonzalez 
et al., 2005; Rodriguez-Gonzalez et al., 2004) and RSM-932A (Lacal and Campos, 2014), 
whereas similar behavior has been reported for V-11-0711 (Falcon et al., 2013; Mori et al., 
2015). It has been described that in MDA-MB-231 cels the gain-of-function mutant p53 is 
stabilized by phospholipase D preventing cel death during starvation (Hui et al., 2006) and 
excessive/uncontroled  p53 activation  has  been associated to aging (Rufini et al.,  2013). 
Thus, the overexpression and stabilization of p53 protein could explain the peculiar non-
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lethal response to EB-3D observed in MDA-MB-231 compared to p53 wild-type cel lines 
(e.g. HeLa) or p53-nul cel lines (e.g. Jurkat). 
Whilst celular senescence is  known to  be a  permanent and ireversible  process, the 
senescence-associated secretory  phenotype (SASP)  has  been  pointed  out as a  potential 
strategy to  promote tumor  progression (Pérez-Mancera et al.,  2014) and  drug resistance 
(Canino et al., 2011). Thus, the induction of celular senescence could be a double-edged 
sword in cancer.  On the contrary, we demonstrated that EB-3D-induced senescence 
sensitizes MDA-MB-231 cels to the apoptotic efect of cisplatin. This result reveals that 
the onset of celular senescence in tumoral cels might be advantageous in this case.!EB-3D 
also enhances the chemotherapeutic efects of 5-FU and doxorubicin significantly lowering 
their  GI50  values. Al together, these  data suggest that  ChoKα inhibition could  be a 
potential  neoadjuvant and could augment the efects  of conventional chemotherapy for 
TNBC, pointing towards its potential clinical utility although if further studies are needed 
to beter understand the molecular mechanism(s) involved in the synergistic efect. 
To investigate the  mechanisms  underlying cel cycle arrest and celular senescence 
induced  by EB-3D, we adopted a phosphoproteomic approach  using reverse-phase 
protein array (RPPA).  RPPA  data  highlighted a  modulation of the AMPK-mTOR 
metabolic pathway. Indeed, Trousil et al. recently described that the ChoKα inhibitor 
ICL-CCIC-0019 reduces mitochondria respiration and ATP production, leading to AMPK 
activation,  without increasing  ROS species  production (Trousil et al.,  2016) revealing a 
non-canonical  mitochondrial  damage response (Houweling et al.,  2002).  We report the 
activation of AMPK stress sensor, that causes the reduction of mTOR phosphorylation and 
its downstream targets 4E-BP1, p70S6K and S6K. The dephosphorylated form of 4E-BP1, 
which sequester the eukaryotic translation initiation factor  4E (eIF4E), together  with the 
absence  of the active  hyperphosphorylated form  of  S6K,  prevent that initiation and 
progression  of  mRNA translation  process.  Colectively, these  data suggests that  ChoKα 
inhibition by EB-3D is sensed like a metabolic insult in MDA-MB-231 cels causing the of 
mTORC1 final efectors required for protein synthesis. These observations coroborate the 
observed reduction in cel  proliferation and  G0/G1 cel cycle arest folowing EB-3D 
treatment. In this context it is interesting to note that increased AMP-ATP ratio and AMPK 
activity  were  observed  during celular senescence in fibroblasts (Wang et al.,  2003). 
Consistently, sustained  AMPK activation  was  observed  during radiation-induced 
senescence (Liao et al.,  2014) although  other research  groups report that activation  of 
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AMPK prevents  H2O2-induced senescence (Han et al.,  2016; Ido et al.,  2012) triggering 
autophagy (Guo et al.,  2012).  Therefore, the induction  of  AMPK activation  by EB-3D 
could be involved in celular senescence in MDA-MB-231 cels. Thus it wil be important 
to demonstrate through future experiments the possible relationship and the link between 
the inhibition  of choline  kinase α and the activation  of  metabolic stress, consequently 
leading to celular senescence. 
In this work we have also demonstrate the eficacy of EB-3D as potent antitumor agent in 
vivo in a syngeneic mouse model. It is worth to note that the efect of the drug is evident 
already after the second administration at low  dose (1  mg/Kg i.p.), indicating a  potent 
antitumor efect and a favourable  pharmacokinetics. Importantly  we  did  not  observe any 
sign of apparent toxicity. 
Since  ChoKα is the first enzyme involved in  phosphatidylcholine  biosynthesis, the  most 
abundant membrane lipid, is reasonable to assume that ChoKα plays an important role in 
cel  membrane stability and therefore in  migration and invasion  processes. Indeed it  has 
been recently reported that ChoKα inhibition suppresses epithelial-to-mesenchimal (EMT) 
transition in  glioblastoma (Koch et al.,  2016). EB-3D-mediated  ChoKα inhibition 
drasticaly reduces tumor cel  motility and invasiveness in vitro in the  highly aggressive 
MDA-MB-231. 
The high mortality rate associated with TNBC is due primarily to the onset of metastases, 
mainly targeting lung, liver, bones and brain. Hence, research eforts should focus also on 
the  development  of  new therapies for secondary  metastatic lesions  prevention.  For this 
reason, the anti-metastatic effect of EB-3D was tested also in vivo  using  both alogeneic 
and  xenogeneic  models. Indeed, an essential component for  new  pharmacological agents 
testing is the assessment  of their eficacy in  preclinical setings.  However,  very few 
preclinical models that incorporate  the  relevant  features  of  human  metastatic disease 
are available. We were able to provide preliminary evidence of reduction of spontaneous 
lung metastatic nodules in mice treated with EB-3D after primary tumor resection, but the 
efect become more evident when tumor cels were injected intravenously. 
To conclude, the new ChoKα a inhibitor EB-3D provided excelent antiproliferative efects 
in vitro and resulted to be an efective antitumoral agent in preclinical TNCB model. For 
these reasons, we claim that EB-3D is worthy of further studies in breast cancer as wel as 
in other tumors.  
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3.3.1 ABSTRACT 
Aberant choline  metabolic  profile and concomitant  ChoKα  overexpression  have  been 
described in most human tumors, including lung, breast, and prostate cancer. Very litle is 
known about the role  of  ChoKα and choline  metabolism in  hematological  malignancies. 
With this  purpose  we investigated the efect  of a  novel and selective  ChoKα inhibitor 
namely EB-3D in T acute-lymphoblastic leukemia (T-ALL). We first demonstrate that, as 
occurs in  other tumors,  ChoKα is  upregulated also in  T-ALL cel lines in comparison to 
healthy lymphocytes, suggesting a  potential role  of this enzyme in tumor  growth and 
proliferation. The drug exhibits a potent antiproliferative activity in a panel of T-leukemia 
cel line with a GI50 ranging from 0.9 to 479 nM and it also displays a significant activity 
in primary cultures derived from pediatric T-ALL patients. The antiproliferative activity is 
likely due to a remarkable decrease of phosphocholine levels observed upon treatment of 
CCRF-CEM cels  with EB-3D indicating that  ChoKα  may  be essential in  T-ALL cel 
survival and proliferation. Moreover, the drug strongly induces apoptosis as evidenced by 
the appearance  of  Annexin-V  positive cel  upon treatment and,  more importantly, it 
enhances T-leukemia cel sensitivity to chemotherapeutic and biotherapeutic agents, such 
as dexamethasone and L-asparaginase. In addition we also evaluated in detail, by means of 
Reverse  Phase  Phosphoproteomic  Analysis (RPPA), the initial alterations of  protein 
phosphorylation levels in T-ALL cels upon treatment with the purpose to investigate 
the  mechanism  of action.  The results show that the compound is able to induce an 
early activation of AMP-activated protein kinase (AMPK), the main regulator of celular 
energy homeostasis, by its phosphorylation at residue T712 of catalytic subunit α. This in 
turn represses the  mammalian target  of rapamycin complex  1 (mTORC1)  pathway as 
shown by mTOR S2448 dephosphorylation. The inhibition of mTOR afects the activity of 
several known downstream targets, such as 4E-BP1, p70S6K, S6K and GSK3, ultimately 
leading to a reduction  of  protein synthesis and cel cycle arest. Interestingly, EB-3D 
induces only a modest activation over time of AMPK-mTOR in healthy lymphocytes that 
does  not impact  on  downstream efector inactivation, suggesting  other  pathways 
intervention.  Taken together,  our findings suggest that targeting  ChoKα  may  be an 
interesting  option for treating  T-ALL and that EB-3D, could represent a  valuable 
therapeutic tool, although further experiments are needed. 
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3.3.2 INTRODUCTION 
T cel acute lymphoblastic leukemia (T-ALL) is an aggressive  hematologic  disorder 
resulting from the malignant transformation of T cel progenitors. T cel transformation is a 
multi-step  process in  which  diferent  genetic alterations cooperate to alter the  normal 
mechanisms that control thymocytes  development.  T-ALL accounts for about  15%  of 
pediatric ALL cases. The overal 5-year survival rate for children with T-ALL is now more 
than  75% (Schrappe et al.,  2011),  however the  outcome  of  T-ALL  patients  with  primary 
resistant or relapsed leukemia remains poor (Locateli et al., 2012). For this reason, there is 
stil an intense efort in finding new therapeutic strategies to improve protocols for high-
risk leukemic patients. 
Dysregulation  of specific tyrosine  kinases in sustaining  T-ALL pathogenesis  has  been 
described (Kruse et al., 2010; Roberts et al., 2012). However, although a low percentage of 
patients are successfuly treated with kinase inhibitors, most of them do not take advantage 
from this form  of therapy.  Starting from the evidence that signal transduction  proteins 
regulate nearly al aspects of cel life and death by the phosphorylation of proteins which is 
catalyzed by protein kinases and that their deregulation plays a critical role in hematologic 
disorders,  kinases are the first choice  druggable targets as they are enzymes,  whose 
biological activity can be therefore turned of by drugs that block their catalytic site. 
Choline kinase α1 (ChoKα1) has recently become an interesting therapeutic target since its 
overexpression has been associated to tumorigenesis in many cancers (Granata et al., 2014; 
Hernández-Alcoceba et al., 1999; Ramírez de Molina et al., 2002d). In particular ChoKα 
expression has been extensively described in breast cancer, where it corelates with tumor 
grade and  poor clinical  outcome (Ramírez  de  Molina et al.,  2002a).  ChoK catalyzes the 
phosphorylation of choline (Cho) to phosphocholine (PCho) in the first step of the CDP-
choline  branch  of  Kennedy’s  pathway for  phosphatidylcholine (PtdCho) synthesis. In 
humans, three isoforms of ChoK have been described (Aoyama et al., 1998a; Aoyama et 
al.,  1998b): ChoKα1 (457 amino acids) and  ChoKα2 (439 amino acids) are alternative 
splicing forms generated from a single gene CHKA, and ChoKβ (395 amino acids) encoded 
by CHKB gene. ChoK isoforms are ubiquitously expressed in tissues (Aoyama et al., 2002) 
and isoforms associates to form  homo-  or  hetero-dimers that constitute the active 
enzymatic form (Ishidate, 1997). Despite high gene and protein sequences similarity, only 
ChoKα1 isoform has been proposed as oncogenic promoting factor. Indeed, specific CHKA 
silencing induces apostosis in tumor cels, while CHKB silencing has no efect (Gruber et 
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al., 2012). Besides the overexpression of ChoKα is suficient to drive cel proliferation of 
quiescent  human  mammary epithelial cels  promoting  DNA synthesis and cel cycle 
progression (Ramírez  de  Molina et al.,  2004a).  Thus, the  overexpression and 
overactivation of ChoKα lead to abnormal choline metabolism, resulting in higher levels of 
phosphocholine and total choline-containing compounds (tCho) in  general.  This 
phenomenon has recently been caled “cholinic phenotype” and it has been associated with 
oncogenesis and tumor progression (Glunde et al., 2011) 
As  much as the cholinic  phenotype  has  been  described for  various solid tumors, far too 
litle is known about it in lymphoblastic disorders. Recently, a serum metabolomic study 
performed in  T-cel lymphoma  patients  has  highlighted the  dysregulation  of choline 
metabolism (Xiong et al., 2015). The purpose of this study is to give insight into choline 
metabolism in  T acute lymphoblastic leukemia and to accomplish this  goal  we inhibited 
choline kinase with the recently described ChoKα1 inhibitor EB-3D. 
EB-3D (also refered as 10a) is a symmetrical  biscationic  ChoKα1 inhibitor reported to 
strongly impair cel  proliferation in a  variety  of  diferent cancer cel lines (Schiafino-
Ortega et al., 2016). In triple-negative breast cancer, EB-3D induced the ireversible arest 
of cel  proliferation  prompting cels to celular senescence, inhibited  both cel  migration 
and invasion and  modulated the  AMPK-mTOR signaling  pathway  ultimately leading to 
protein synthesis blockade (Marioto et al., unpublished data). In addition, EB-3D showed 
good antitumoral and antimetastatic activity in vivo. 
The efects of EB-3D in vitro  on cel  viability, cel  proliferation and cel  death  were 
evaluated in this  work. In addition,  we  performed a  phosphoproteomic analysis  by 
Reverse-Phase Protein Aray (RPPA) which pointed out a relevant diference in pathway 
modulation between tumoral cel lines and normal lymphocytes. Lastly, the ability of EB-
3D to enhance the anti-tumorigenic potential of drugs commonly used in pediatric T-ALL 
protocols was also tested. 
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3.3.3 RESULTS 
ChoKα is overexpressed in T-ALL cel lines 
Since ChoKα is overexpressed in many tumors but very litle is known about its expression 
in haematological malignancies, ChoKα expression levels were evaluated in a panel of T 
leukemic cel lines. Figure 33 shows the colective overexpression of ChoK isoforms in T-
ALL cel lines compared to  peripheral  blood lymphocytes (PBL) colected from  healthy 
donor,  PBL stimulated  with  phytohemagglutinin (PHA)  or  CD3-positive (CD3+)  T 
lymphocytes (Figure 3). ChoKα isoforms are strongly overexpressed in T-ALL cel lines 
while their expression is almost undetectable in controls. In particular, it is worth to note 
that the  oncogenic isoform  ChoKα1 (457 aa) is expressed at  higher levels than  ChoKα2 
(439 aa) in al  T-ALL cel lines.  The  predominant isoform  of choline  kinase in  normal 
lymphocytes appears to  be the  ChoKβ isoform,  wherease the  ChoKα/ChoKβ ratio is 
weighted in favour ChoKα in T-ALL. 
 
Figure 33: ChoKα is overexpressed in T-ALL cel lines  
(A) Immunoblot analysis  of  ChoK isoforms in  different  T-ALL cel lines and  healthy controls and (B) 
densitometry analysis of  ChoKα/β ratio. PBL,  peripheral  blood lymphocytes.  PHA,  phytohemagglutinin. 
CD3+, T lymphocytes 
EB-3D antiproliferative activity in T-ALL cel lines and primary cels  
As shown in  Table  5, EB-3D  displays excelent antiproliferative activity against a  wide 
cohort of T leukemic cel lines, with GI50 values in the nanomolar range and resulting more 
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cytotoxic compared to the reference compounds RSM932A and MN58b.  The  most 
sensitive cel line is  MOLT-16  with  GI50  of  0.9  ±  0.6  nM  whereas  CCRF-CEM  was the 
less sensitive  with  GI50  of  479  ±  152  nM.  However there is  no corelation  between  GI50 
and ChoKα expression level nor ChoKα/β ratio. In addition the novel ChoKα inhibitor EB-
3D shows lower cytotoxicity in PBLs (GI50 1500 ± 640 nM) compared to leukemic T cel 
lines (Table  6).  On the  other  hand, the treatment results  more toxic  when  PBLs are 
stimulated  with  PHA (GI50  34  ±  10  nM), indicating a certain  preference toward cels in 
active phase of proliferation (Figure 34 A). 
 
ChoKα1'
Inhibitor!
Antiproliferative'activity''
GI50'(nM)!
JURKAT!CCRFBCEM! HSBB2! MOLTB16! DNDB41! LOUCY! PEER! ALLBSIL!
EBB3D! 136.2'±'36.2!
478.8'±'
152.5!
17.7'±''
1.8'
0.9'±''
0.6!
60.6'±''
28.6!
200.0'±'
51.6!
265.0'±''
31.9!
132'±''
101!
MNB58b! 634.8!±!226.4!
214.6!±!
89.1!
138.0!±!
24.8!
19.7!±!!
3.7!
443.4!±!
112.4!
236.8!±!
118.4!
496.7!±!!
46.3!
336!±!!
102!
RSMB932A! 563.6!±!163.9!
608.9!±!
146.4!
173.3!±!
20.3!
171.1!±!!
82.2!
152.7!±!
70.5!
1016.7!±!
370.5!
386.7!±!!
37.6!
295!±!!
125!
Table 5: EB-3D antiproliferative activity in T-ALL cel lines 
In vitro antiproliferative effect  of EB-3D, RSM932A and MN58b in  T leukemia cel lines. b GI50 = 
Compound concentration required to inhibit tumour cel proliferation by 50%. Values are the mean ± SEM 
for three independent experiments. 
 
ChoKα1'
Inhibitor'
Antiproliferative'activity''
GI50'(nM)!
PBL''
resting!
PBL!
+'PHA!
EBB3D! 1500'±'640! 34'±'10!
MNB58b! 2000!±!420! 150!±!30!
RSMB932A! 900!±!210! 230!±!50!
Table 6: EB-3D antiproliferative activity in primary normal lymphocytes 
In vitro antiproliferative effect of EB-3D, RSM932A and MN58b in healthy peripheral blood lymphocytes 
(PBL) in resting condition and stimulated with phytohemagglutinin (PHA). b GI50 = Compound concentration 
required to inhibit tumour cel proliferation by 50%. Values are the mean ± SEM for three different donors. 
The antiproliferative efect  of EB-3D was confirmed also in  primary  T-ALL colected 
from  pediatric  patients at  diagnosis. As depicted in  Figure  34  B, there is a certain 
variability of response to the treatment between diferent patients that could be due to the 
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diferent sub-classes of T-ALL. In particular, two patients who were diagnosed as Early T 
cel  Precursor (ETP) leukemia, characterized  by  poor response to standard intensive 
chemotherapy and very high risk of relapse, appear quite resistant to EB-3D compared to 
later phenotype stage T-ALLs (T-II). 
 
Figure 34: EB-3D cytotoxicity in healthy PBLs and primary T-ALL pediatric samples 
(A) MTT cel proliferation assay carried out after 72 h in peripheral blood lymphocytes (PBL) colected from 
healthy  donors treated  with EB-3D,  with  or  without  phytohemagglutinin (PHA) stimulation. (B) MTT cel 
proliferation assay in  primary  T-ALL treated  with EB-3D and carried  out after  48  h  of treatment. Cel 
viability percentages are normalized to untreated cels. Symbols and bars represent respectively the mean ± 
SEM of three different donors (A) or experimental triplicate of the same T-ALL patient (B). ETP, Early T 
cel Precursor. T-III, cortical T-ALL. 
The cytotoxic efect caused by EB-3D is irreversible 
We previously reported that EB-3D treatment significantly inhibits cel growth in diferent 
tumoral cel lines, including Jurkat cels, in a concentration  dependent  manner,  due to a 
strong G0/G1 arest of the cel cycle (Schiafino-Ortega et al., 2016). Contrary to what we 
observed in  breast cancer (Marioto et al.,  unpublished  data), EB-3D induces a  dose-
dependent increase in apoptotic cels in T-ALL cel lines after 72 h of treatment (Figure 35 
A).  Moreover, the  mechanisms activated  by  ChoKα inhibition that trigger apoptosis are 
rapid and ireversible since  wash-out experiments  demonstrate that  24  h  of exposure to 
EB-3D (that causes  only a slight increase  of apoptosis) are suficient to induce a strong 
apoptotic response 72 h after compound withdrawal (Figure 35 B).  
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Figure 35: EB-3D-induced apotosis increases after drug removal 
Flow cytometric analysis of apoptotic cels after treatment of Jurkat, CCRF-CEM and HSB-2 cels with 
compound EB-3D at the indicated concentrations after 72 h of incubation (A) or after 24h of EB-3D treatment 
and then after 72h from EB-3D wash-out (B). The cels were harvested and labeled with annexin-V-FITC 
(AV) and propidium iodide (PI) and analyzed by flow cytometry. Data are represented as mean ± SEM of three 
independent experiments. Differences between WASH OUT and pre-treatements were analyzed using one-way 
ANOVA with Newman-Keuls correction. 
 
EB-3D targets ChoK! in leukemia cel line 
To assess the efective ChoK� inhibition in the leukemic model, we measured choline 
metabolites by high-resolution  nuclear magnetic resonance (1H-NMR) spectroscopy. The 
pediatric T leukemia cel line CCRF-CEM treated with two doses of EB-3D for 48  h 
showed a significant  dose-dependent reduction of PCho and the subsequent reduction of 
total choline-containing compounds (tCho), indicating that EB-3D is able to enter inside 
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cels and inhibit the specific target (Figure 36). We observed no relevant changes in Cho 
and GPCho levels. 
 
Figure 36: EB-3D targets ChoKα in T-ALL cels 
Milimolar levels of Cho, PCho, GPCho and tCho quantified from 1H-NMR spectra of water-soluble extracts 
from CCRF-CEM cels treated with DMSO and two different doses of EB-3D. Differences between control 
and treatements were analyzed using two-way ANOVA with Newman-Keuls correction. 
ChoKα inhibition afects AMPK-mTOR signaling pathway 
Reverse-phase  protein array (RPPA) is a  high-throughput technology enabling the 
measure  of  protein expression and  phosphorylation levels  on a  multitude  of samples 
simultaneously.  Protein lysates are arrayed as  microspots  on  nitrocelulized coated 
glass slides and  probed  with  highly specific antibodies that  have  been  validated for 
RPPA. Each microspot contains the whole proteome repertoire of the cel.  
RPPA analysis  was  performed  on lysates  of Jurkat,  CCRF-CEM,  HSB-2 and  PEER 
leukemic cel lines treated with about two-fold the GI50 dose (0.3 µM, 1 µM, 50 nM and 
0.5  µM respectively) for  1  h and  6  h to  be able to  observe the starting changes in 
phosphorylation levels  while avoiding the cytotoxic efect  of EB-3D.  As  depicted in 
Figure 37, ChoKα inhibition causes the activation of AMPK metabolic stress sensor by the 
phosphorylation at residue  T712  of its catalytic subunit α, as  previously  described for 
triple-negative  breast cancer (Marioto et al.,  unpublished  data).  AMPK activation 
represses mTORC1 pathway as shown by mTOR S2448 dephosphorylation. The inhibition 
of mTOR in turn afects the activity of several known downstream target, such as 4E-BP1, 
p70S6K,  S6K and GSK3.  4E-BP1 results  dephosphorylated at  S65, expecialy in  CCRF-
CEM. The p70S6K S371 dephosphorylation is even stronger and significant in al tumoral 
cel lines and increases  over time.  The  phosphorylation at  S235/236 residues  of  S6K is 
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notably reduced at al time points, expecialy in CCRF-CEM cels, while HSB-2 seems to 
be more refractory compared to other cel lines. 
The  dephosphorylated form  of  4E-BP1 sequesters the eukaryotic translation initiation 
factor  4E (eIF4E)  which is required to start  mRNA translation together  with the active 
(phosphorylated) form of S6K that is necessary to progress through the translation process. 
Colectively the  RPPA  data suggests that  Chokα inhibition  by EB-3D is sensed like a 
metabolic insult in leukemic cels, causing the activation  of  AMPK,  which in turn 
represses the  downstream efectors  of  mTORC1 required for  protein synthesis.  These 
observations are in agreement with the observed reduction in cel proliferation. In fact the 
phosphorylation of both 4E-BP1 and S6K becomes almost undetectable at 48h, despite the 
variations of mTOR activity during time (Figure 39). 
The glycogen synthase kinase-3 (GSK-3) has been described as a target of both mTOR and 
p70S6K. The activity of GSK-3 is silenced by phosphorylation at S21 in the α subunit, and 
by  phosphorylation at  S9 in the β subunit.  Folowing EB-3D treatment,  we  observed a 
strong reduction of GSK-3α/β S21/S9 phosphorylations, in particular in CCRF-CEM and 
HSB-2 where the reduction of these phosphorylations is more than 50% (Figure 37). 
The inhibition of mTOR pathway is atenuated in normal lymphocytes 
For comparative purposes, the same RPPA analysis has been performed also in quiescent 
PBL and  PHA-activated colected from  healthy  donor.  PBL  were treated  with the  higher 
dose of EB-3D used for T-ALL cel lines, coresponding to 1 µM used for CCRF-CEM. It 
is worth to note that while this dose is very close to GI50 value of PBL resting, it is 30-fold 
higher than GI50 value of PHA-stimulated PBL. PBL were also treated with 0.1 µM of EB-
3D (data  not shown) and  no significant  diferences  were  observed comparing the two 
doses. 
EB-3D induces a modest activation over time of AMPK in resting PBL and its activation 
leads to a temporary inhibition of mTOR that is then hyperphosphorylated at 6 h. On the 
other hand, AMPK activation strongly occurs at 1 h in proliferating lymphocytes and then 
returns to  basal level, while  mTOR  phosphorylation is significantly reduced at later time 
compared to the resting counterpart (Figure 37). Surprisingly, the inhibition of mTOR has 
no impact on the downstream efectors 4E-BP1, p70S6K and S6K. In fact we observed the 
hyperphosphorylation  of  p70S6K  S371 and  S6K  S235/236 in stimulated  PBL, and the 
temporary increase of both S6K and 4E-BP1 phosphorylations in resting PBL (Figure 37). 
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On the contrary  GSK3α/β stil results strongly  dephosphorylated in lymphocytes,  only 
temporary in  PBL resting  while augmenting  over time in  proliferating  PBL.  These  data 
suggest that  other  mechanisms contribute to  healthy lymphocytes response to  ChoKα 
inhibition. Indeed  we  observed the activation  of  AKT  by the increase  of  T308 and  S473 
phosphorylations,  which are  both required for its activation,  occuring  only in  normal 
lymphocytes. Moreover, also the activation of MAPK signaling occurs only in PBL while 
in  T-ALL cel lines remains  unchanged  or its even  downregulated. EB-3D treatment 
causes the significant phosphorylation of MEK1/2 S271/S221 and ERK1/2 T202/Y204 that 
increase 2-fold and 10-fold respectively in PBL resting after 6 h of treatment (Figure 38). It 
must  be said that augmented  AKT  S473 and  ERK1/2  T202/Y204  phosphorylations  has 
been observed also in Jurkat cels treated with EB-3D but only at later time (Figure 39). 
 
 
Figure 39: EB-3D induces complete dephosphorylation of m TOR downstream targets 
Time-course immunoblot analysis of Jurkat cels treated with a sub-lethal dose of EB-3D (0.3 µM). 
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Figure 37: ChoKα inhibition affects AMPK-mTORC1 signaling pathways  
RPPA analysis of T-ALL cel lines (left panel) treated with EB-3D (Jurkat 0.3 µM, CCRF-CEM 1 µM and 
HSB-2 50 nM, PEER 0.5 µM) or vehicle (CTR) for the indicated time points. PBL colected from healthy 
donor (right panel) were treated with 1 µM of EB-3D. Data are represented as mean ± SEM of three independent 
experiments. Differences  between control and treatment were analyzed  using  ANOVA test for repeated 
measures.
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Figure 38: ChoKα inhibition affects MAPK signaling pathways in normal lymphocytes 
RPPA analysis of T-ALL cel lines (left panel) treated with EB-3D (Jurkat 0.3 µM, CCRF-CEM 1 µM and 
HSB-2 50 nM, PEER 0.5 µM) or vehicle (CTR) for the indicated time points. PBL colected from healthy 
donor (right panel) were treated with 1 µM of EB-3D. Data are represented as mean ± SEM of three independent 
experiments. Differences  between control and treatment were analyzed  using  ANOVA test for repeated 
measures. 
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EB-3D strongly synergizes with L-asparaginase 
We also tested EB-3D in combination with two chemotherapeutic drugs used routinely for 
leukemia treatment, dexamethasone (DEX) and L-asparaginase (L-ASP), to test if ChoKα 
targeting could increase sensitivity to standard treatments. Indeed, cel  viability assay  of 
1:1 fixed-molar ratio combination drugs indicates that EB-3D significantly lowers the GI50 
of both single DEX and L-ASP treatments. These data pointed out that EB-3D synergizes 
with  DEX, except for Jurkat that are  glucocorticoid-resistant, and even strongly  with  L-
ASP, as confirmed by combination index (CI) much lower than 1 (Figure 40), where CI<1 
indicates drug synergism according with the model proposed by Chou (Chou, 2006). Thus, 
the combination  of the  ChoKα inhibitor EB-3D and standard chemotherapies could  be 
beneficial in the management of leukemia cel burden. 
Figure 40: EB-3D synergizes with common leukemia treatments 
MTT cel proliferation assay in T-ALL cel lines treated with EB-3D in combination with L-asparaginase (L-
ASP) (A) or dexamethasone (DEX) (B) and Combination Index (CI) calculated at the respective ED50, ED75 
and ED90 for L-ASP (C) and DEX (D) combination. Cel viability percentages are normalized to untreated 
cels. Symbols and bars represent the mean ± SEM of triplicates. 
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We then further characterized the synergistic efect of the EB-3D/L-ASP combination. The 
simultaneous addition  of EB-3D and  L-ASP increases the  percentage  of apoptotic cels 
compared to the single treatments (Figure 41). 
Since  L-ASP also interferes  on leukemia cel  metabolism  by asparagine aminoacid 
deprivation,  we  hypothesized that the synergic efect  of the EB-3D/L-ASP combination 
relies on targeting the same signaling pathway. Indeed the combination of EB-3D and L-
ASP caused a stronger dephosphorylation of S6K compared to the single treatments that is 
completely abolished after 24 h of co-treatment (Figure 42). 
 
 
Figure 41: EB-3D boosts the apoptotic effect of L-ASP acting on the same signaling pathway 
Flow cytometric analysis  of apoptotic cels after treatment  of Jurkat (A),  CCRF-CEM (B) and  HSB-2 (C) 
cels with EB-3D, L-ASP or the combination of the two drugs at the indicated concentrations for 48 h. The 
cels  were  harvested and labeled  with annexin-V-FITC and  PI and analyzed  by flow cytometry. Data are 
represented as mean  ± SEM  of three independent experiments. Differences  between EB-3D/L-ASP combination 
and single treatments were analyzed  using one-way ANOVA test  with  Newman  Keuls correction. (D) 
Immunoblot analysis  of EB-3D, L-ASP and EB-3D/L-ASP combination treatment for the indicated time 
points in Jurkat (1:1), CCRF-CEM (2.5:1) and HSB-2 (1:1). 
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3.3.4 DISCUSSION 
 
Despite significant improvements have been achieved for a more reliable stratification and 
treatment of childhood T-ALL however, relapse stil remains a frequent feature (Nguyen et 
al., 2008; Schrappe et al., 2011) and most children die after relapse (Locateli et al., 2012; 
Schrappe et al.,  2011).  Moreover, the increasing evidence that relapses  may arise from 
selection of pre-existing drug resistant clones (Kunz et al., 2015) or from acquired reduced 
sensitivity to chemotherapeutic agents (Pui,  2015), suggests the  urgent  need  of  new 
strategies for  T-ALL treatment.  Since  many  years, abnormal choline  metabolism  has 
become an important  halmark  of tumor  metabolism that characterized  diferent  kind  of 
tumors and, in many cases, it has been associated to oncogenesis and tumor progression. In 
this context  we  wanted to assess the in vitro efects  of a  new and selective inhibitor  of 
choline kinase namely EB-3D in T-ALL cels. 
To investigate a  possible implication  of  ChoKα in  T-ALL  pathogenesis,  we  measured 
ChoKα  protein levels in a  panel  of  T-ALL cel lines  with respect to their corespondent 
non-tumorigenic  primary lymphocytes.  As in  many  other tumors,  ChoKα  was found 
upregulated respect normal lymphocytes suggesting that Chokα may have a role also in T 
cel leukemia  development. Interestingly the expression levels  of the enzyme are similar 
within T-ALL cel lines irespective of their genetic characteristics. 
We also evaluated the ratio  between  ChoKα and  ChoKβ isozymes and  we  observed that 
the ratio is shifted toward ChoKα in T-ALL cels in contrast to normal lymphocytes where 
the  predominant isoform is the  non tumorigenic  ChoKβ.  These findings supported the 
concept that higher level of ChoKα and especialy high ChoKα/ChoKβ ratio, are required 
for the  proliferation  of leukemia cels. Indeed  Gruber et  al. reported that silencing,  by 
specific siRNA, of ChoKα alone induced cel cycle arest ultimately leading to apoptosis, 
while the  double  knockdown  of  both  ChoKα and  ChoKβ isoforms rescued cels from 
undergoing apoptosis (Gruber et al.,  2012).  Therefore, these  observations  point  out that 
choline kinase inhibition as an anticancer strategy, must focus on the specific inhibition of 
ChoKα,  without afecting the activity  of  ChoKβ, in  order to induce  maximum apoptosis 
only in target cancer cels. Indeed we previously demonstrated a high selectivity of EB-3D 
toward  ChoKα suggesting that this smal  molecule could  be a  valuable  pharmacological 
tool (Schiafino-Ortega et al., 2016). 
As expected, the drug exhibits a remarkable potency in inhibiting T-ALL cel lines growth 
with GI50 in the nanomolar range and lower respect the two reference drugs RSM932A and 
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MN58b. Moreover EB-3D also demonstrates a good eficacy in inhibiting cel growth in 
primary cel cultures  derived from  pediatric  T-ALL  patients. Importantly, the  drug is 
endowed  with lower toxicity in  healthy lymphocytes and showed an antiproliferative 
activity only in cels in active phase of proliferation. We also observed that the compound 
induces a block of the cel cycle in G0/G1 with a concomitant decrease of the S phase that 
ultimately leads to apoptotic cel death. 
We also investigated the efects  of the simultaneous treatment  of T leukemia cels  with 
dexamethasone and  L-asparaginase, two  drugs commonly  used in the  T-ALL therapeutic 
protocols.  Our results show that EB-3D enhanced the chemotherapeutic efects  of these 
drugs, significantly lowering their  GI50. In  particular the  most  prominent efect  was 
observed with L-asparaginase. Indeed we give evidence that both L-asparaginase and EB-
3D impact  on the same  metabolic  pathway thus explaining the synergistic efect.  On the 
light that a consistent percentage of T-ALL patients relapse, with leukemic cels becoming 
resistant to treatments, our results suggest that ChoKα inhibition could augment the efects 
of conventional chemotherapy for T-ALL and pointed towards the potential clinical utility 
of choline  kinase inhibitors, although further studies are  needed to  beter  understand the 
molecular mechanism(s) involved in the synergistic efect. 
In this context we evaluated by mean of RPPA analysis the signaling pathways that could 
be activated by EB-3D in T-ALL cel lines. Interestingly we observed the rapid activating 
phosphorylation  of  AMPK folowed  by a  deregulation  of the  mTOR  pathway.  AMPK is 
the  main regulator  of energy  homeostasis in eukaryotic cels and  under  metabolic stress 
conditions it  becomes activated  by a  double  mechanism.  Under conditions that lowered 
intracelular ATP levels, such as during nutrient deprivation or hypoxia, AMP or ADP can 
directly bind to the γ regulatory subunit, leading to a conformational change that favours 
the  phosphorylation  of  T172 in the activation loop  of  AMPKα, strictly required for its 
activation.  The liver  kinase  B1 (LKB1) is the  major  kinase  phosphorylating  T172  of 
AMPKα activation loop  under conditions  of energy stress.  We  observed a slight 
phosphorylation of LKB1 in Jurkat and CCRF-CEM cel lines that, in our opinion, is not 
suficient to explain the remarkable activation of AMPK. Indeed, in al the four leukemic 
cel lines investigated (Jurkat,  CCRF-CEM,  HSB-2 and  PEER), the  AMPK  T172 
phosphorylation  occurs just after  one  hour  of treatment suggesting a rapid efect  of the 
drug. If this efect is directly linked to the inhibition of ChoKα remain to be evaluated and 
wil be the object of future studies. It would be interesting to investigate alteration in the 
AMP/ATP ratio to beter characterize the link between EB-3D and AMPK activation. 
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The activation  of  AMPK resulted in  down regulation  of  mTOR  S2448 and its target 
p70S6K T371. The mammalian target of rapamycin (mTOR) kinase is a master regulator 
of many celular processes, including cel proliferation and survival. mTOR is downstream 
of the  PI3K/AKT  pathway and this axis is  often  deregulated in  many cancers,  making 
mTOR as an atractive target for cancer therapy.  AKT can activate  mTOR indirectly 
promoting the dissociation of the tuberous sclerosis complex 2 (TSC2), which sequesters 
mTOR.  AKT is  partialy activated through an initial  phosphorylation at  T308  by  PDK-1 
and then fuly activated  by the subsequent  phosphorylation at  S473  by several  kinases. 
Since  we  do  not  observe any relevant changes in  both  AKT  T308 and  S473 
phosphorylation sites,  we can assert that  AKT is  not involved in the initial  mTOR 
inhibition observed after EB-3D, which is mainly controled by AMPK activation. On the 
other hand, only at later time we observed the increase in AKT S473 suggesting that other 
mechanisms intervene to the modulation of ChoKα inhibition efects. The involvement of 
PI3K/AKT/mTOR  pathway in choline  metabolism  has already  been reported although 
more studies are needed to understand the mechanisms more deeply since it is involved at 
many levels. Indeed the uptake of choline into cancer cels is positively regulated by the 
PI3K/AKT/mTOR  pathway (Wang et al.,  2007)  while  ChoKα  hyperactivation  has  been 
associated  with  overactive  RAS signaling,  mediated through  both the  PI3K/AKT/MTOR 
and MAPK pathways (Ramírez de Molina et al., 2002b). Contrary to what we observed in 
Jurkat cel line after  48  h  of EB-3D treatment,  phosphorylation  of  AKT  S473,  but  not 
T308, can be reduced by inhibition of ChoKα via siRNA or smal molecule inhibitors, in 
PI3K-independent way (Chua et al., 2009). 
We  would like to  point  out that that the  AMPK/mTORC1 axis represents a recently 
identified  promising therapeutic target in  diferent tumors (Shaw,  2009; Sujobert and 
Tamburini, 2015) as its activity is frequently deregulated in cancer cels including T-ALL. 
In fact constitutive activation  of  mTORC1 is a common event in  T-ALL,  which 
emphasizes the  potential  of  using  mTORC1-targeting  drugs as therapeutic agents in this 
disorder.  Among these  drugs rapamycin, an  mTORC1 inhibitor  has showed a  modest 
eficacy in preclinical models of T-ALL while more encouraging results come from studies 
in which an activator of AMPK, such as metformin, was tested (Shi et al., 2012). At the 
present stage, how EB-3D targets AMPK-mTOR pathway remains to be explored although 
a recent  work showed, through a  metabolomic approach, that the  ChoKα inhibitor ICL-
CCIC-0019 leads to a metabolicaly stressed phenotype and AMPK activation (Trousil et 
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al.,  2016).  Thus, in  wel agreement  with  our findings, the  pharmacological inhibition 
choline pathway seems to criticaly afect cel metabolic function beyond the reduction os 
phospholipids synthesis. 
In  paralel  manner  we studied in  both  normal  quiescent lymphocytes and  PHA-activated 
the efect of treatment on the AMPK-mTOR pathways. Contrary to what was observed in 
T-ALL cel lines EB-3D induces a  modest activation  over time  of  AMPK in  quiescent 
lymphocytes and its activation leads to a temporary inhibition  of  mTOR that is then 
hyperphosphorylated at later times. A similar behavior was observed also in proliferating 
lymphocytes.  Surprisingly, the inhibition  of  mTOR  does  not afect the  downstream 
efectors 4E-BP1, p70S6K and S6K. These data suggest that other mechanisms contribute 
to the response of healthy lymphocytes to ChoKα inhibition. A recent study in fact pointed 
out that diferent metabolic features exist between normal and T-ALL cels (Kishton et al., 
2016). Thus it is possible that normal lymphocytes utilize a distinct metabolic program in 
comparison to  T-ALL in response to  ChoKα inhibition that  may  be  due, as  described 
above, to the remarkable  diference  of  ChoKα enzyme level  between  normal and 
transformed lymphocytes. 
Another interesting  observation is that activation  of  MAPK signaling  occurs  only in 
normal lymphocytes while in T-ALL cels remains unchanged or its even downregulated. 
In  particular  MEK1/2  S271/S221 and  ERK1/2  T202/Y204  were found  phosphorylated 
after EB-3D treatment in  quiescent lymphocytes. Indeed, the accumulation  of  PCho  has 
shown to  be essential for the constitutive activation  of  MAPK and  PI3K/AKT/mTOR 
signaling  pathways since siRNA-mediated and  pharmacological inhibition  of  ChoKα 
atenuate both survival pathways (Clem et al., 2011; Yalcin et al., 2010), demonstrating the 
existence  of a reciprocal relationship  between  oncogenic signal transduction and choline 
metabolism.  Several studies  have  demonstrated that  AMPK activators can  modulate the 
MAPK pathway. Huai et al. reported that metformin activates ERK in the human leukemia 
cel line NB-4 (Huai et al., 2012) and an independent group found that the AMPK activator 
AICAR stimulates MAPK pathway in a diferent leukemia cel lines (Lalic et al., 2014). It 
is therefore  possible that the  diference in the  metabolic response to treatment exhisting 
between  healthy and leukemic cells wil also  be reflected  on  MAPK  pathway activation. 
However, further experiments are needed to clarify this point. 
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In conclusion, in this study  we clearly showed that choline  kinase inhibition could  be a 
valuable therapeutic strategy in  T-ALL treatment and EB-3D can  be considered a an 
interesting  new  molecule  worthy  of further evaluation as a  potential chemotherapeutic 
agent. 
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4. CONCLUSIONS 
In this thesis,  novel  ChoKα inhibitors  were tested in vitro for their antiproliferative 
activity. The most promising compound EB-3D was chosen as lead compound for further 
in vitro and in vivo studies and used to characterise choline metabolism in hematological 
tumor. 
The compound exhibited  high antiproliferative activity against a  panel  of solid and 
hematological cancer cell lines,  while  normal  quiescent cels  were less sensitive to 
treatment compared to their  proliferating counterpart.  ChoKα inhibition  decreased  PCho 
and subsequently tCho levels and caused the accumulation of Cho substrate. In both triple-
negative  breast cancer and  T acute lymphoblastic leukemia, EB-3D triggered AMPK 
activation leadind to downregulation of pro-survival mTOR pathway. The inactivation of 
mTOR  downstream targets  4E-BP1,  p70S6K and  S6K is  known to cause the arest  of 
mRNA translation  processes.  Thus, the inhibition  of  protein synthesis could explain the 
striking reduction of cel proliferation induced by EB-3D. In contrast, normal lymphocytes 
were less afected  by EB-3D treatment, showing reduced  dephosphorylation  of  mTOR 
efectors, presumably via the activation of MAPK alternative pathway. 
The final  macroscopic efect, in  both tumor contexts,  was a strong reduction  of cel 
proliferation and G0/G1 cel cycle arest. Surprisingly, while EB-3D caused cel death in 
al tested  T-ALL cel lines, it  was  unable to induce cel  death in  MDA-MD-231 triple-
negative breast cancer cels. The explanation for this diferent behavior is the onset of early 
and ireversible  of celular senescence in  MDA-MB-231 that  prevents cel  death  but stil 
sensitizes cel to subsequent exposure to chemotherapy. Colectively, the results obtained 
in vitro highlighted potential opportunities for targeted combination therapies. 
Last,  pre-clinical in vivo experiments indicated a strong antitumoral efect  of EB-3D in 
aggressive  breast cancer  model,  with strong reduction  of tumor  growth at low  dose.  The 
ChoKα inhibitor also reduced cel migration and invasion of the higly invasive MDA-MB-
231 cels. The antimetastatic power of EB-3D was confirmed in vivo by reduction of lung 
metastatic foci and metastasis size. Taken together, these data indicates a potent antitumor 
and antimetastatic effect of EB-3D and a favourable pharmacokinetics. Importantly we did 
not observe any sign of apparent toxicity. 
To conclude, this work has given a proof that ChoKα is a novel atractive therapeutic target 
in T-ALL and justify the further development of EB-3D ChoKα inhibitor. 
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MATHERIALS AND METHODS 
Chemistry 
General procedure C for the synthesis of the final compounds 10a-l 
A solution  of  1eq  1,2-bis(4-bromomethylphenoy)ethane (8) in   dry  CH3CN  was added 
drop to drop to a solution of 9a-l (2 eq) in dry CH3CN under argon conditions. The mixture 
was heated under reflux for a further 3 days and, after cooling down to room temperature, 
washed with diethyl ether and hexane, filtered and dry to vacuum to aford 10a-l as a solid 
product. Characterization data for final products are described below. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-
(dimethylamino)pyridinium)  bromide (10a).  Folowing  general  procedure  C furnished 
10a as a yelow solid, yield 42%, mp: 62-63°C. 1H NMR (300 MHz, CD3OD) δ: 8.20 (d, J 
= 7.86 Hz, 4H), 7.35 (d, J = 8.73 Hz, 4H), 7.02 (d, J = 8.73 Hz, 4H), 6.99 (d, J = 7.86 Hz, 
4H), 5.30 (s, 4H), 4.33 (s, 4H), 3.24 (s, 12H). 13C RMN (75 MHz, CD3OD) δ: 161.80 x 2, 
158.87 x 2, 143.76 x 4, 131.98 x 4, 129.20 x 2, 117.30 x 4, 109.93 x 4, 68.86 x 2, 62.22 x 
2, 41.20 x 4. HRMS (m/z): [M]2+ calcd for C30H36N4O2: 242.1419, found: 242.1409. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(pyrrolidin-
1-yl)pyridinium)  bromide (10b).  Folowing  general  procedure  C furnished 10b as a 
brown solid, yield 48%, mp: 129-130°C. 1H NMR (300 MHz, CD3OD) δ: 8.17 (d, J = 7.77 
Hz, 4H), 7.34 (d, J = 8.73 Hz, 4H), 7.01 (d, J = 8.73 Hz, 4H), 6.84 (d, J = 7.77 Hz, 4H), 
5.28 (s, 4H), 4.32 (s, 4H), 3.54 (t, J = 6.84 Hz, 8H), 2.11 (t, J = 6.86 Hz, 8H), 13C NMR 
(75 MHz, CD3OD) δ: 161.79 x 2, 156.05 x 2, 143.68 x 4, 131.92 x 4, 129.31 x 2, 117.29 x 
4,  110.51  x  4,  68.86  x  2,  62.26  x  2,  50.28  x  4,  26.98  x  4.  HRMS (m/z): [M]2+ calcd for 
C34H40N4O2: 2681576, found: 268.1568. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(4-
chlorophenyl)(methyl)amino)pyridinium)  bromide (10c).  Folowing  general  procedure 
C furnished 10c as a white solid, yield 30%, mp: >300°C. 1H NMR (600 MHz, CD3OD) δ: 
8.28 (d, J = 8.5 Hz, 4H), 7.58 (d, J = 8.5 Hz, 4H), 7.37 (m, 8H), 7.02 (d, J = 8.4 Hz, 4H), 
6.92 (m,  4H),  5.35 (s,  4H),  4.33 (s,  4H),  3.53 (s,  6H). 13C  NMR (75  MHz,  CD3OD) δ: 
160.85 x 2, 158. 31 x.2 143.52 x 4, 135.52 x 2, 131.94 x 4, 131.13 x 4, 129.28 x 4, 127.95 
 92 
x 2, 116.27 x 8, 110.27 x 2, 67.81 x 2, 61.64 x 2, 30.55 x 2. HRMS (m/z): [M]2+ Calcd for 
C20H19N2OCl: 338.1186, found: 338.1194. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-
phenylene)bis(methylene)bis(quinuclidinium)  bromide (10d).  Folowing  general 
procedure C furnished 10d as a white solid, yield 56%, mp: > 300°C. 1H NMR (300 MHz, 
CD3OD) δ: 7.47 (d, J = 8.78 Hz, 4H), 7.13 (d, J = 8.78 Hz, 4H), 4.43 (s, 4H), 4.35 (s, 4H), 
3.48 (m,  12H),  2.18 (dt, J  =  6.44,  3.23  Hz,  2H),  2.01 (dt, J =  8.23,  3.23  Hz,  12H). 13C 
NMR (75 MHz, CD3OD) δ:  162.80 x 2, 136.48 x 4, 121.54 x 2, 117.14 x 4, 69.52 x 2, 
68.87  x  2,  56.39  x  6,  25.81  x  6,  22.33  x  2.  HRMS (m/z) [M]2+ calcd for  C30H42N2O2: 
231.1623, found: 231.1628. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(3-
hydroxyquinuclidinium) bromide (10e). Folowing general procedure C furnished 10e as 
a white solid, yield 63%, mp: 268-270°C. 1H NMR (300 MHz, DMSO-d6) δ: 7.48 (d, J = 
8.66 Hz, 8H), 7.13 (d, J = 8.66 Hz, 8H), 4.43 (s, 8H), 4.41 (s, 8H), 4.08, 3.64, 3.35, 3.04, 
2.27, 2.10 (6m, 52H), 13C NMR (75 MHz, DMSO-d6) δ: 159.52 x 4. 134.43 x 8, 119.63 x 
4, 114.77 x 8, 65.61 x 4, 62.26 66.37, 63.27, 53.46, 52.52, 26.83, 20.87, 17.29 x 4. HRMS 
(m/z) [M]2+ calcd for C30H42N2O4: 247.1572, found: 247.1565. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-
(methyl(phenyl)amino)quinolinium)  bromide (10f). Folowing  general  procedure  C 
furnished 10f as a yelow solid, yield 64%, mp: 169-170°C. 1H NMR (300 MHz, CD3OD) 
δ: 8.86 (d, J = 7.44 Hz, 2H), 8.13 (d, J = 8.37 Hz). 7.81 (dt, J = 5.57, 1.43 Hz, 2H), 7.62 
(dd, J = 8.8, 1.3 Hz, 2H), 7.53 (m, 4H), 7.46 (t, J = 7.36 Hz, 2H), 7.40-7.29 (m, 12H), 7.03 
(d, J = 8.76 Hz, 4H), 5.89 (s, 4H), 4.33 (s, 4H), 3.84 (s, 6H). 13C NMR (75 MHz, CD3OD) 
δ: 161.47  x  2,  160.80  x  2,  150.14  x  2,  148.54  x  2,  141.68  x  2,  135.51  x  2,  132.75  x  4, 
130.63 x 4, 130.28 x 2, 130.15 x 2, 128.64 x 2, 127.85 x 2, 127.73 x 4, 122.29 x 2, 120.97 
x 2, 117.30 x 4, 107.73 x 2, 68.85 x 2, 59.94 x 2, 46.75 x 2. HRMS (m/z) [M]2+ calcd for 
C48H44N4O2: 354.1732, found: 354.1736. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(4-
chlorophenyl)(methyl)amino)quinolinium) bromide (10g). Folowing general procedure 
C furnished 10g as a yelow solid,  yield  70%,  mp:  178-180°C. 1H  NMR (400  MHz, 
CD3OD) δ: 8.90 (d, J = 7.40 Hz, 2H), 8.16 (dd, J = 8.9, 0.6 Hz, 2H), 7.84 (dt, J = 5.64, 
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1.36 Hz, 2H), 7.67 (dd, J = 8.8, 1.2 Hz, 2H), 7.52 (d, J = 8.91 Hz, 4H), 7.41-7.37 (m, 8H), 
7.33 (d, J = 8.77 Hz, 4H), 7.03 (d, J = 8.77 Hz, 4H), 5.91 (s, 4H),  4.33 (s, 4H). 3.82 (s, 
6H), 13C  NMR (75  MHz,  CD3OD) δ:  161.48  x  2,  160.92  x  2,  148.81  x  2,  148.77  x  2, 
141.68 x 2, 135.68 x 2, 135.58 x 2, 132.72 x 4, 130.69 x 4, 130.00 x 2, 129.28 x 4, 128.52 
x 2, 128.20 x 2, 122.41 x 2, 121.13 x 2, 117.30 x 4, 108.36 x 2, 68.84 x 2, 60.09 x 2, 46.53 
x 2. HRMS (m/z) [M]2+ calcd for C48H42N4O2Cl2: 388.1342, found: 388.1338. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(7-chloro-4-
(methyl(phenyl)amino)quinolinium)  bromide (10h).  Folowing  general  procedure  C 
furnished the crude residue  which  was  purified  by flash chromatography  using  CH2Cl2: 
MeOH (9:1  v/v) as eluent to  obtain  10h as a yelow-green solid,  yield  61%,  mp:  181-
183°C. 1H NMR (300 MHz, CD3OD) δ: 8.82 (d, J = 7.50 Hz, 2H), 8.15 (d, J = 1.89 Hz, 
2H), 7.56-7.53 (m, 6H), 7.47 (t, J = 7.4 Hz, 2H), 7.41-7.40 (d, J = 7.48 Hz, 4H), 7.34-7.31 
(m, 6H),  7.29 (dd, J = 9.3, 1.9 Hz, 2H), 7.06-7.03 (d, J = 8.70 Hz, 4H), 5.85 (s, 4H), 4.34 
(s, 4H), 3.82 (s, 6H, CH3). 13C NMR (75 MHz, CD3OD) δ: 161.58 x 2, 160.51 x 2, 149.76 
x 2, 148.95 x 2, 142.51 x 2, 141.90 x 2, 132.92 x 4, 131.80 x 2, 130.77 x 4, 130.59 x 2, 
128.35 x 2, 128.24 x 2, 127.72 x 4, 128.24 x 2, 120.68 x 2, 120.45 x 2, 117.41 x 4, 107.93 
x  2,  68.86  x  2,  59.91  x  2,  46.87  x  2.  HRMS (m/z): [M]2+ calculado for  C48H42N4O2Cl2: 
388.1342, found: 388.1331. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(7-chloro-4-(4-
chlorophenyl)(methyl)amino)quinolinium) bromide (10i). Folowing general procedure 
C furnished the crude residue which was purified by flash chromatography using CH2Cl2: 
MeOH (9:1 v/v) as eluent to obtain 10i as a yelow solid, yield 39%, mp: 185-186°C, 1H 
NMR (300 MHz, CD3OD) δ: 8.87 (d, J = 7.46 Hz, 2H), 8.20 (d, J = 1.93 Hz, 2H), 7.63 (d, 
J = 9.31 Hz, 2H), 7.55 (d, J = 8.78 Hz, 4H), 7.42 (d, J = 8.78 Hz, 4H), 7.40 (d, J = 1.96 Hz, 
2H), 7.38 (d, J = 7.47 Hz, 2H), 7.35 (d, J = 8.73 Hz, 4H), 7.06 (d, J = 8.73 Hz, 4H, H-2), 
5.88 (s, 4H), 4.35 (s, 4H), 3.82 (s, 6H, CH3). 13C NMR (75 MHz, CD3OD) δ: 161.59 x 2, 
160.65 x 2, 149.22 x 2, 148.45 x 2, 142.50 x 2, 142.06 x 2, 135.92 x 2, 132.88 x 4, 131.68 
x 2, 130.85 x 4, 129.33 x 4, 128.71 x 2, 128.15 x 2, 120.82 x 2, 120.61 x 2, 117.40 x 4, 
108.57 x 2, 68.85 x 2, 60.05 x 2, 46.69 x 2. HRMS (m/z) [M]2+ calcd for C48H40N4O2Cl4: 
422.0953, found: 422.0952. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(azepan-1-
yl)quinolinium) bromide (10j). Folowing general procedure C furnished 10j as a yelow 
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solid, yield 67%, mp: 75-77°C. 1H RMN (300 MHz, CD3OD) δ: 8.54 (d, J = 7.73 Hz, 2H), 
8.42 (dd, J = 8.62, 1.28 Hz, 2H), 8.05 (dd, J = 8.83, 1.05 Hz, 2H), 7.90 (dt, J = 5,67, 1,33 
Hz, 2H), 7.66 (dt, J = 5.77, 1.15 Hz, 2H), 7.27 (d, J = 8.80 Hz, 4H), 7.10 (d, J = 7.74 Hz), 
7.00 (d, J = 8.80 Hz, 4H), 5.74 (s, 4H), 4.30 (s, 4H), 4.09 (m, 8H), 2.09 (m, 8H), 1.75 (dt, J 
= 5.40, 2.54 Hz, 8H), 13C NMR (75 MHz, CD3OD) δ : 161.91 x 2, 161.34 x 2, 146.48 x 2, 
142.10 x 2, 135.52 x 2, 130.48 x 4, 130.44 x 2, 128.98 x 2, 127.04 x 2, 121.41 x 2, 120.33 
x 2, 117.22 x 4, 104.55 x 2, 68.84 x 2, 58.99 x 2, 56.06 x 4, 29.37 x 4, 29.23 x 4. HRMS 
(m/z) [M]2+ calcd for C46H52N4O2: 346.6700, found 346.2039. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(4-(azepan-1-
yl)-7-chloroquinolinium)  bromide (10k).  Folowing  general  procedure  C furnished the 
crude residue which was purified by flash chromatography using CH2Cl2: MeOH (8:1 v/v) 
as eluent to  obtain  10k as a white solid,  yield  41%,  mp:  87-88°C. 1H  RMN (400  MHz, 
CD3OD) δ: 8.51 (d, J = 7.75 Hz, 2H), 8.40 (d, J = 9.21 Hz, 2H), 8.07 (d, J = 1.82 Hz, 2H), 
7.29 (d, J = 8.64 Hz, 4H), 7.65 (dd, J = 9.2, 1.9 Hz, 2H), 7.11 (d, J = 7.78 Hz, 2H), 7.03 (d, 
J = 8.64 Hz, 4H), 5.72 (s, 4H), 4.33 (s, 4H), 4.08 (m, 8H), 2.08 (m, 8H), 1.74 (m, 8H). 13C 
NMR (75 MHz, CD3OD) δ :161.56 x 2, 161.44 x 2, 146.77 x 2, 142.95 x 2, 141.82 x 2, 
132.31 x 2, 130.59 x 4, 128.57 x 2, 127.45 x 2, 119.88 x 2, 119.78 x 2, 117.32 x 4, 105.00 
x 2, 68.85 x 2, 59.00 x 2, 56.12 x 4, 29.28 x 4, 29.16 x 4. HRMS (m/z) [M-Br]+ calcd for 
C46H50N4O2Cl2Br : 839.24949, found: 839.2494. 
1,1'-((ethane-1,2-diylbis(oxy)bis(4,1-phenylene)bis(methylene)bis(7-chloro-4-
(pyrrolidin-1-yl)quinolinium)  bromide (10l). Folowing  general  procedure  C furnished 
the crude residue which was purified by flash chromatography using CH2Cl2: MeOH (9:1 
v/v) as eluent to  obtain  10l as a white solid,  yield  48%,  mp:  118-120°C. 1H  RMN (300 
MHz, CD3OD) δ: 8.63 (d, J = 9.23 Hz, 2H), 8.51 (d, J = 7.69 Hz, 2H), 8.04 (d, J = 2.02 
Hz, 2H), 7.66 (dd, J = 9.2, 2.0 Hz, 2H), 7.27 (d, J = 8.75 Hz, 4H), 7.01 (d, J = 8.75 Hz, 
4H), 6.90 (d, J = 7.69 Hz, 2H), 5.71 (s, 4H), 4.32 (s, 4H), 4.02 (m, 8H), 2.20 (m, 8H). 13C 
NMR (75 MHz, CD3OD) δ:  161.37 x 2, 157.92 x 2, 146.91 x 2, 142.45 x 2, 141.76 x 2, 
131.76 x 2, 130.45 x 4, 128.68 x 2, 127.71 x 2, 120.16 x 2, 119.73 x 2, 117.29 x 4, 104.64 
x  2,  68.83  x  2,  59.06  x  2,  55.43  x  4,  24.64  x  4.  HRMS (m/z) [M]2+ calcd for 
C42H42N4O2Cl2: 352.1337, found: 352.1353. 
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Docking Studies 
Molecular-modeling studies  were  performed  by  using  Sybyl  program [51].  Crystal 
structures  of  human  ChoKα1 in complex  with compounds 2 (PDB entry  4BR3) and 4 
(PDB entry  4CG8)  were  used for  docking studies. In  both cases,  using the  Structure 
Preparation  Tool  module  of  Sybyl refined  protein structure.  Missing side chains  of those 
residues situated far away from the binding sites were added and protein N- terminal and 
C-terminal were fixed with ACE and NME, respectively. Hydrogens and charges were also 
added and protonation type of Glu, Asp, Gln and Asp was analyzed and fixed. Hydrogen 
orientations were also checked in order to maintain intramolecular hydrogen bonds within 
the protein. Finaly, the molecules of compounds 2 and 4 inserted into the ATP binding site 
were carefuly checked to assure the corection  of these  molecules.  Structures  of 
compounds 10a-l were constructed from standard fragments of the Libraries of the Sybyl 
program, and used as ligands for docking studies. As previously described (Conejo-García 
et al., 2003a), a new type of atom was necessary to define in order to build the molecules: 
N.ar4, the  quaternary  nitrogen  of the  pyridinium fragments.  Additional  parameters  were 
also  developed from initio calculations to  optimize the  geometry  of these  molecules 
Atomic charges  were calculated  by  means  of  Gaussian  Program [53] and  optimizations 
were undertaken using the BFGS method. 
The  Surflex-Dock (Jain,  2007),  module implemented in the  Sybyl  program  was  used for 
docking studies. Surflex Dock Protomol was prepared using compound 2 or 4 inserted into 
the  ChoK  binding site,  with a threshold  value  of  0.5 and a  Bloat  of  0  A.  Surflex-  Dock 
GeomX (SFXC)  protocol  was  used, the search  grid  was expanded in  5  Å,  50 additional 
starting conformations  were  used for each  molecule and  30 conformations  per fragment. 
The results  were analyzed  using the  Sybyl  program and the  most stable  pose for each 
molecule  was chosen as the  prefered  one inside the  ChoK enzyme.  Figures  were  built 
using the PyMOL program. 
Determination of human choline kinase α1 (ChoKα1) activity 
The inhibitory efect of the diferent compounds was assayed in human ChoKα1 purified 
enzyme as  previously  described (Rubio-Ruiz et al.,  2014). In each experiment  DMSO-
assays were always run in paralel as a control. DMSO in no case exceeded a concentration 
of  0.1% in  order to avoid  unspecific  ChoKα inhibition.  ChoKα1 activity  was assayed  by 
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measuring the rate of incorporation of 14C from [methyl-14C]choline into phosphocholine 
both in the  presence  or absence  of  diferent inhibitor concentrations.  Briefly, the final 
reaction mixture contained 100 mM Tris (pH 8.5), 10 mM MgCl2, and 10 mM ATP, and 
20  ng  of  purified  ChoKα1.  After the samples  were  preincubated at  37°C for  5  min, the 
reaction was initiated with 1 mM [methyl-14C]choline (4500 dpm/nmol) and incubated at 
37°C for 10 min, the final volume being 55 µl. The assay was stopped by immersing the 
reaction tubes in boiling water for 3 min. Aliquots of the reaction mixture were applied to 
the origin of Silica Gel plates in the presence of phosphocholine (0.1 mg) and choline (0.1 
mg) as cariers. The chromatography was developed in methanol/0.6% NaCl/28% NH4OH 
in  water (50:50:5,  v/v/v) as solvent.  Phosphocholine  was  visualized  under exposure to 
iodine vapor and the coresponding spot was scraped and transfered to scintilation vials 
for  measurement  of radioactivity  by a  Beckman  6000-TA (Madrid,  Spain) liquid-
scintilation counter.  At least three experiments  were  performed in al assays.  The  50% 
inhibitory concentrations (IC50 values)  were  determined from the  % activity  of the 
enzymes at  diferent concentrations  of synthetic inhibitors  by  using a sigmoidal  dose-
response curve (the ED50plus v1.0 software). 
Tryptophan fluorescence quenching 
Al compounds  were  prepared in  100%  DMSO.  Their  Kds against  human  ChoKα1  were 
measured by monitoring the quenching of tryptophan fluorescence. Al experiments were 
performed in Cary Eclipse spectrofluorometer (Varian) at 25°C with the enzymes at 1 µM, 
and concentrations of compounds varying from 0.1 to 5 µM for ChoKα1 in 25 mM Tris, 
150  mM  NaCl,  pH  7.5.  Fluorescence emission spectra  were recorded in the  300-400  nm 
range  with an excitation  wavelength  of  280  nm,  with slit  width  of  5  nm.  Controls  were 
determined  by incubating the enzymes  with equivalent amounts  of  DMSO.  As indicated 
previously,  data analysis  was  performed in  Prism (GraphPad software) considering a 
model  with a single  binding site (Eq.1),  where  F0 is the intrinsic fluorescence  of the 
enzyme in the absence  of  quencher (Q),  F1 is the  observed fluorescence at a  given 
quencher concentration, fa is the fractional  degree  of fluorescence, and  Kd is the 
dissociation constant. 
Eq 1.           1−!1!0=!
!"!∗![!]
!"!∗![!] 
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Protein crystalography 
ChoKα1 at  20  mg/ml in  bufer  25  mM  Tris/HCl,  150  mM  NaCl  pH  7.5  was  used as the 
protein solution.  The siting-drop  vapor-difusion  method  was  used to  produce apo- 
crystals  by  mixing  0.5  µl  of the  protein solution and an equal  volume  of  mother liquor 
(crystals appeared in  20%  polyethylene  glycol [PEG]  3350 and  0.25M  potassium 
isothiocyanate).  Tetragonal crystals (space  group  P43212)  grew  within in  3-4  days and 
were soaked in 2 µL of the mother liquor with 0.2 µL of a dilution 500 mM of compounds 
10a, 10g, 10h, 10k, and 10l in DMSO (DMSO was at 10% final concentration in the mix 
whereas compounds were at 50 mM) for two days. Only crystals soaked with compound 
10a contained the compound. The crystals used in this study were cryoprotected in mother-
liquor solutions containing 20% ethylenglycol and frozen with nitrogen gas stream cooled 
to  100  K.  Difraction  data  of the  binary complexes  were colected at  beamline I04-1 
(Diamond, Oxford). The data was processed and scaled using the XDS package and CCP4 
software. 
Structure determination and refinement 
The structure of the binary complex was solved by molecular replacement using PDB ID 
3G15 as a template. Initial  phases  were further improved  by cycles  of  manual  model 
building in  Coot and refinement  with  REFMAC5.  The final  model  was  validated  with 
PROCHECK.  Coordinates and structure factors  have  been  deposited in the  Worldwide 
Protein Data Bank (PDB). 
BIOLOGY 
Cel lines and culture conditions 
Human  T-cel leukaemia (Jurkat,  CCRF-CEM, MOLT-3, MOLT-16,  P12-ICHIKAWA, 
DND-41,  KOPTK-1,  HSB-2,  TALL-1,  ALL-SIL,  PEER,  LOUCY),  human  B-cel 
leukemia (RS4;11) and human promyelocytic leukemia (HL-60) cel lines were grown in 
RPMI-1640 medium (Gibco) while human cervix carcinoma (HeLa), human alveolar basal 
epithelial carcinoma (A549) and  human  breast adenocarcinoma (MCF-7 and  MDA-MB-
231) cel lines were grown DMEM medium (Gibco). Both media were supplemented with 
10% fetal bovine serum (FBS), glutamine (2mM), penicilin (100U/ml) and streptomycin 
(100µg/ml) (al from Thermo Fisher Scientific, Waltham, MA) and cultured at 37°C, 5% 
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CO2 in saturated humidity for no longer than 15 passages. 
Non tumoral  MCF-10A  breast cel line  was  grown in  DMEM/F12  medium (Gibco)  with 
5%  horse serum (Invitrogen),  penicilin (100U/ml) and streptomycin (100µg/ml), 
supplemented  with  EGF  20ng/ml (R&D  System),  Hydrocortisone (0.5  mg/ml) (Sigma), 
Cholera  Toxin (100  ng/ml) (Sigma) and Insulin  10µg/ml (Sigma).  For cel  viability 
experiment,  MCF-10A  were also cultured in  minimal  DMEM/F12  medium,  defined as 
“resting”, containing only serum and antibiotics. 
Mouse breast cancer EO771 cels were grown in complete DMEM medium supplemented 
with 20% FBS. 
Al cel lines  were  purchased from the  American  Type  Culture  Colection (ATCC; 
Manassas, VI). For al experiments, mid-log phase cultures were seeded in fresh medium 
24 h before pharmacological treatment. 
Human Umbilical Vein Endothelial cels (HUVEC), were prepared from human umbilical-
cord  veins, as  previously  described (Porcù et al.,  2013).  The adherent cels  were 
maintained in M200 medium added by LSGS (low serum growth supplement), containing 
FBS, hydrocortisone, hEGF, bFGF, heparin, gentamycin/amphotericin (Life Technologies, 
Monza, Italy). HUVEC were used in experiments from the first to sixth passages. 
Human fibroblasts from foreskin were isolated as previously described (Panula and Pera, 
2008) and maintained in DMEM medium with 10% fetal bovine serum added. 
Pediatric T acute lymphoblastic leukemia (T-ALL) patients 
Bone  marow samples from  pediatric  T-ALL  patients  were colected at  diagnosis at the 
Pediatric  Oncohematology  Laboratory  of  Padova (Italy) and enroled in the  ALL2009 
therapeutic  protocols  of the  Associazione Italiana  Ematologia  Oncologia  Pediatrica 
(AIEOP). Diagnosis was made according to standard cytomorphology, cytochemistry, and 
immunophenotypic criteria.  For al selected  patients,  T lymphoblasts  percentage  was 
comprised between 70% and 98%. 
T-ALL bone marow samples were hemolyzed, washed extensively and resuspended in α-
MEM  medium supplemented  with  10%  FBS,  1%  penicilin/streptomycin,  1%  Glutamine 
(al from  Thermo  Fisher  Scientific,  Waltham,  MA),  10%  human  heat inactivated  AB+ 
serum (Sigma-Aldrich S.r.l., Milan, Italy), human IL-7 (R&D Systems, Minneapolis, MN), 
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human SCF, human FLT3-ligand (both from Peprotech, London, UK) and insulin (Sigma-
Aldrich  S.r.l.,  Milan, Italy).  Cels  were immediately seeded at a concentration  of  105 
cels/wel in 96-wel microtiter plates and exposed to the test compound and, after 48h, cel 
viability was evaluated by MTT assay. 
Isolation of peripheral blood lymphocytes and T cels from healthy donors 
Blood samples from healthy donors were colected from the blood bank of the Hospital of 
Padova (Italy). Peripheral blood lymphocytes (PBL) were isolated from heparinized whole 
blood  using a density  gradient centrifugation using  Lymphoprep (Fresenius  KABI  Norge 
AS) solution at  2000 rpm for  20  min.  PBL  were then carefuly recovered,  washed 
extensively, resuspended (106 cels/mL) in  RPMI-1640  with  10%  FBS and incubated 
overnight to remove residual adherent cels.  For MTT cytotoxicity evaluations  of  PBL 
cultures,  non-adherent cels  were resuspended in  growth  medium and stimulated  with 
2.5'µg/mL  phytohematoagglutinin (PHA) (Irvine  Scientific)  or  not (defined as “resting” 
medium). 
Healthy T lymphocytes (CD3+) were isolated from PBL by depletion of non T-cels using 
human  Pan  T  Cel Isolation  Kit I  with a  Miltenyi autoMACS  magnetic cel sorter 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The isolated cels purity was confirmed 
by flow cytometry. 
Cel proliferation assay and drug combination sensitivity assay 
The cytotoxic activity  of selected  drugs  was  determined  using a standard  3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazodium  bromide (MTT)-based colorimetric assay 
(Sigma-Aldrich  S.r.l.,  Milan, Italy).  Briefly, cels  were seeded at a  density  of  5x103 
cels/wel (for adherent cel lines), 2.5x104 cels/wel (for non-adherent cel lines) or 1x105 
cels/wel (for primary PBL or T-ALL) in 96-wel microtiter plates and incubated at 37°C 
in a humidified 5% CO2 incubator overnight prior to the experiments to ensure exponential 
growth.  After  24h,  medium  was replaced  by fresh  medium containing the specific 
treatment or drug combination (fixed combination ratios) at serial diluition (1:10) for 72h. 
MTT was added to each wel at a final concentration of 0.5mg/ml, and incubated for 3h, 
37°C,  5%  CO2.  Viable cels  with active  metabolism convert  MTT into a  purple-colored 
formazan  product,  which is  next solubilized  with equal  volume  of isopropanol-HCl to 
measure the changes in absorbance at  570  nm  using a  plate reading spectrophotometer 
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(Victor,  Perkin  Elmer).  The  GI50 was  defined as the compound concentration required to 
inhibit cel  proliferation  by  50%, in comparison  with cels treated  with the  maximum 
amount  of  DMSO and considered as  100%  viability.  Each  drug concentration  was 
performed in triplicate. To determine the synergistic, additive, or antagonistic efects of the 
drug combinations,  CalcuSyn software (version  2.0,  Biosoft)  based  on the  method  of the 
combination index (CI)  described  by  Chou and  Talalay  was  used (Chou,  2006),  where 
synergism is defined by CI<1. 
Trypan Blue exclusion assay 
The accurate  determination  of the cel  proliferation rate  was  determined  by trypan  blue 
exclusion assay. Cels in exponential growth were treated with diferent concentrations of 
EB-3D (time 0) and then colected at the indicated time points. Cels were diluted 1:1 with 
isotonic solution  of trypan  blue (Thermo  Fisher  Scientific) and counted  on an 
hemacytometer. Only trypan blue negative cels were considered viable cels. 
Cel cycle distribution analysis 
For flow cytometric analysis  of  DNA content,  5x105 cels in exponential  growth  were 
treated  with  diferent concentrations  of EB-3D for  24h.  After the incubation  period, the 
cels  were colected, centrifuged and fixed  with ice-cold ethanol (70%).  The cels  were 
then treated  with lysis  bufer containing  RNAse  A and  0.1%  Triton  X-100, and then 
stained  with  propidium iodide (PI).  Samples  were analyzed  on a  Cytomics  FC500 flow 
cytometer (Beckman  Coulter).  DNA  histograms  were analyzed  using  MultiCycle for 
Windows (Phoenix Flow Systems). 
Annexin-V/PI assay 
Surface exposure  of  phosphatidylserine  on apoptotic cels  was  measured  by flow 
cytometry with Cytomics FC500 (Beckman Coulter) by adding simoultaneously annexin-V 
(AV) conjugated to fluorescein isothiocyanate (FITC) and  propidium iodide (PI) to cels 
according to the  manufacturer’s instructions (Annexin-V-Fluos staining  kit,  Roche 
Diagnostic). 
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C12-FDG senescence assay 
For flow cytometric analysis  of celular senescence,  5x104 cels in exponential  growth 
were treated with diferent concentrations of EB-3D for 3 days and then the medium was 
replaced  with fresh  medium containing EB-3D  or  DMSO for the  next  3  days.  After the 
incubation  period, culture  media  were replaced to remove any  dead cels and remaining 
cels were incubated (1h, 37°C, 5% CO2) with 100 nM of bafilomycin A1 to neutralize the 
acidic  pH  of lysosomes.  Cels  were then incubated (1h,  37°C,  5%  CO2)  with  33  µM  of 
C12FDG (Thermo Fisher Scientific) and then colected by trypsinization, washed once and 
resuspended in  PBS.  Samples  were analyzed  on a  Cytomics  FC500 flow cytometer 
(Beckman Coulter). Mean Fluorescence Intensity (MFI) and graphs overlay were analyzed 
using FlowJo software (Tree Star, La Jola, CA). 
Western blot analysis 
Total celular  proteins  were extracted from cels  using  T-PER lysis  bufer containing 
phosphatase and  protease inhibitors.  The  protein concentration  was  determined  using the 
BCA protein assay reagents (Thermo Scientific Pierce, Waltham, MA). Equal amounts of 
protein (10 µg)  were resolved  using sodium  dodecyl sulphate  polyacrylamide  gel 
electrophoresis (SDS-PAGE) and transfered to  PVDF Immobilon-P  Membrane (Merck 
Milipore, Darmstadt, Germany). Membranes were saturated with BSA 3% for at least 1 h 
at room temperature and then  probed  overnight at  4°C  with  primary antibodies. 
Membranes were then washed and incubated with HRP-labeled secondary antibodies (goat 
anti-rabbit  or anti-mouse IgG;  Perkin  Elmer,  Waltham,  MA) for  60  min,  RT.  Al 
membranes were stained using ECL Select (GE Healthcare, Catania, Italy) and visualized 
with Aliance 9.7 (UVITEC, Cambridge, UK), according to manufacturer’s instruction. To 
ensure equal protein loading, each membrane was reprobed with β-actin antibody (Sigma-
Aldrich S.r.l., Milan, Italy). 
Reverse-phase protein arrays (RPPA) 
Cel lysates  were  diluted to  1  mg/ml in  Tris–Glycine  SDS  Sample  Bufer (Invitrogen) 
containing  5%  of β-mercaptoethanol and  boiled for  5  min immediately  prior to aray 
printing.  Lysates  were loaded into a  384-wel  plate and serialy  diluted  with lysis  bufer 
into four-point dilution curves ranging from undiluted to 1:8. Protein lysates were printed 
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in duplicate in each aray set onto nitrocelulose-coated slides (FAST slides) with the 2470 
Arayer (Aushon BioSystems). Printed slides were stored desiccated at -20°C until use.  
For RPPA analysis, one slide was stained with Fast Green FCF dye (Sigma) according to 
the manufacturer’s instruction, in order to estimate the total protein amount of each printed 
sample. Before antibody staining, the arays were blocked for 3 h RT in blocking solution 
(2% I-Block in  T-PBS).  Arays  were then stained  with the  primary antibodies  on an 
automated slide stainer (Dako Autostainer Plus) using the CSA kit (Dako). Each antibody 
was  previously subjected to extensive  validation for single-band specificity  by  Western 
blot. Slides were air-dried and scanned on a Epson Perfection V300 Photo at 600 dpi. The 
TIF images  of antibody- and  Fast  Green  FCF-stained slides  were analyzed  using 
Microvigene  Software (VigeneTech Inc,  Boston,  MA,  USA) to extract  numeric intensity 
values from the aray images. 
Scratch-migration assay 
Nearly confluent  MDA-MB-231 cels  were  gently  wounded through the  horizontal and 
vertical axis  using a  pipete tip.  Cels  were  washed twice to remove cel  debris and then 
treated with EB-3D at the indicated concentration for 48h. Quantification of cel motility 
was evaluated  by  measuring the  distance  between the invading front  of cels in four 
random selected  microscopic fields for each condition and time  point. Images  were 
captured at 0, 6, 24, and 48 h using an inverted microscope equipped with a CCD camera.  
Cultrex BME Cel Invasion Assay 
To assess the invasive capacity of MDA-MB-231 cels after tretment, cels were added to 
24-wel  Transwel inserts  of the  Cultrex  BME (Basal  Membrane  Extract)  Cel Invasion 
Assay (Trevigen,  Gaithersburg,  MD) according to the  manufacturer’s  manual. Invasion 
was measured  24h after  plating, at  485-520  nm  using the  VICTOR spectrophotometer 
(Perkin Elmer, Milan, Italy). 
Magnetic resonance spectroscopy (1H-MRS) 
MDA-MB-321 breast cancer cels or CCRF-CEM T-ALL cels were seeded and cultured 
for  24h in complete  growth  medium and then treated  with EB-3D  or DMSO for  48h. 
Adherent cels  were colected  by trypsinization,  washed twice and then counted. 
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1x107 cels were used for each cel extraction. Water-soluble as wel as lipid extracts were 
obtained using the dual-phase extraction method (Mori et al., 2015). Briefly, the peleted 
cels  were resuspended  with ice-cold  methanol and  vigorously  vortexed.  Samples  were 
incubated  on ice for  15  min, and then  mixed  with chloroform (1:1),  vortexed  vigorously 
and  kept  on ice for  10  min.  Finaly,  water  were added and shaken  wel.  Samples  were 
stored at 4°C overnight for phase separation and later centrifuged at 15000×g at 4°C for 30 
min. The upper water/methanol phase containing water-soluble celular metabolites (Cho, 
PCho and GPCho) was treated with 50 mg of chelex beads (Sigma-Aldrich) to remove any 
divalent cations.  Beads  were removed  by filtration and  methanol  was evaporated.  The 
remaining  water  phase  was lyophilized.  Cel extracts  were resuspended in  0.7  mL  of 
deuterated  water containing  7.006×10−8 mol  of  3-(trimethylsilyl)propionic-2,2,3,3-d4 acid 
(TSP; Sigma-Aldrich) as an internal standard for MR spectral analysis. Fuly relaxed 1H-
MR spectra  of  water-soluble extracts  were acquired  on a  Bruker  Avance  14.09 T 
spectrometer (Bruker  BioSpin)  with flip angle  =  90°  preceded  by  2.0 s  presaturation for 
water signal suppression), sweep width = 10000 Hz, repetition time = 14.0 s, block size = 
128k, and scans  =128.  Signal integrals  of  N-(CH3)3 of  Cho at about  3.202  ppm,  PCho at 
about  3.224  ppm and  GPCho at about  3.232  ppm in  water soluble extracts  were 
determined, normalized to cel number and cel volume and compared with the standards. 
To  determine intracelular  metabolite concentrations,  peak integration (IPCho) from 1H 
spectra for  PCho  were compared to that  of the internal standard  TSP according to the 
equation [PCho]  =  ATSP * IPCho/ITSP *  N  *  V  where [PCho] represents the intracelular 
concentration of PCho expressed as mmol/L (mM). ATSP is the number of moles of TSP in 
the sample,  N is the cel  number, and  V is cel  volume (MDA-MB-231:  2,050 µm3). 
Because the number of protons contributing to the signal of PCho at ~3.226ppm and the 
TSP peak at 0 ppm is the same, corection for diferences in the number of protons was not 
required. To determine the cel volume, cel size was determined by trypsinizing the cels 
and measuring the diameter (d) of 100 randomly selected cels using an optical microscope 
and calculated as [(4π/3)x(d/2)3].  The resulting  PCho concentrations  were averaged for 
three or four independent experiments. 
In vivo antitumoral assay 
Seven week-old C57BL/6 female mice were orthotopicaly injected into the mammary fat 
pad with 4x105 EO771 mammary carcinoma cels. When tumors were palpable mice were 
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randomized to a control and treated groups. Treatment was performed every other day by 
intraperitoneal (i.p.) injection of EB-3D (0.5 and 1 mg/kg) or vehicle (DMSO) in 100 µl 
final  volume.  Tumors  were  measured in two  dimensions and tumor  volume  V (mg)  was 
calculated according to the formula V=(D x d2)/2, where D and d are the major and minor 
perpendicular tumor  diameters in  mm, respectively.  Diferences  between control and 
treated  mice  were analyzed  using Student t test and  Bonferoni corection.  At the end  of 
the experimental procedure tumors were harvested, weighted, photographed and embedded 
in OCT and frozen for histological processing. 
In vivo metastasis models 
For spontaneous metastases, 5x105 EO771 cels were injected into the mammary fat pad of 
C57BL/6 female mice and tumors were resected when reached the 8 x 13 mm size. After 
one week of recovery mice were treated i.p. every other day for four weeks with vehicle or 
EB-3D (2.5 mg/kg) in 100 µl final volume. 
For experimentaly induced  metastasis,  murine  EO771 (2x105)  or  human  MDA-MB-231 
(8x105) breast cancer cels in 100 µl of PBS were injected intravenously into the tail vein 
of  7  week-old  C57BL/6  or  NOD/SCID female  mice, respectively.  Animals  were treated 
every  other  day  by i.p. injection  with EB-3D (2.5  mg/kg)  or  vehicle (DMSO) in  100 µl 
final volume for 3 weeks (for EO771 cels) or 7 weeks (for MDA-MB-231 cels). 
At the end  of the experimental  procedure  mice  were sacrified, lungs  were  harvested, 
weighted, formalin-fixed and the  number  of  macro-metastases  were counted  under a 
dissecting microscope. Lungs were then embedded in parafin for histological processing. 
Histological analyses 
Parafin-embedded samples were sectioned at a thickness of 5µm, dewaxed, hydrated and 
stained  with  hematoxylin and eosin (H&E) according to  protocol and analysed  by light 
microscopy. Images  were compiled for figures  using  Adobe Ilustrator (Adobe  Systems 
Inc., San Jose, CA) 
Statistical analyses 
Graphs and statistical analyses  were  performed  using  GraphPad  Prism software 
(GraphPad,  La Jola,  CA).  Al  data in  graphs represented the  mean  of at least three 
independent experiments ± standard eror of the mean (SEM). Statistical significance was 
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determined using the two-tailed Student t test or ANOVA (one- or two-way) depending on 
the type  of  data.  For  multiple test comparison,  Bonferoni  or  Newman-Keuls corections 
were applied. Asterisks indicate a significant diference between the treated and the control 
group, unless otherwise specified. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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SUPPLEMENTARY MATHERIALS 
 
CHKA_HUMAN         1 MKTKFCTGGEAEPSPLGLLLSCGSGSAAPAPGVGQQRDAASDLESKQLGG     50  
                     ||||||||||||||||||||||| |:|||.||||||||||.:||||||||  
CHKA_MOUSE         1 MKTKFCTGGEAEPSPLGLLLSCG-GNAAPTPGVGQQRDAAGELESKQLGG     49 
 
CHKA_HUMAN        51 QQPPLALPPPPPLPLPLPLPQPPPPQPP-ADEQPEPRTRRRAYLWCKEFL     99 
                     :..|||||||||.||||    ||||.|| |||||||||||||||||||||  
CHKA_MOUSE        50 RTQPLALPPPPPPPLPL----PPPPSPPLADEQPEPRTRRRAYLWCKEFL     95  
  
CHKA_HUMAN       100 PGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYG    149  
                     ||||||||||:|||||||||||||||||||||:.|::|||||||||||||  
CHKA_MOUSE        96 PGAWRGLREDQFHISVIRGGLSNMLFQCSLPDSIASVGDEPRKVLLRLYG    145  
  
CHKA_HUMAN       150 AILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGI    199  
                     |||:|||||||||||||.|||||||||||||||||||||||||||||:||  
CHKA_MOUSE       146 AILKMRSCNKEGSEQAQNENEFQGAEAMVLESVMFAILAERSLGPKLFGI    195  
  
CHKA_HUMAN       200 FPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWL    249  
                     ||||||||||||||||||||.|||||||||||||||||||||||||||||  
CHKA_MOUSE       196 FPQGRLEQFIPSRRLDTEELRLPDISAEIAEKMATFHGMKMPFNKEPKWL    245  
  
CHKA_HUMAN       250 FGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSP    299  
                     ||||||||.:|||:||:.|:|:::|||:||||||||||||||||:.|.||  
CHKA_MOUSE       246 FGTMEKYLNQVLRLKFSREARVQQLHKILSYNLPLELENLRSLLQYTRSP    295  
  
CHKA_HUMAN       300 VVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCE    349  
                     ||||||||||||||||||:||||::|||||||||||||||||||||||||  
CHKA_MOUSE       296 VVFCHNDCQEGNILLLEGQENSERRKLMLIDFEYSSYNYRGFDIGNHFCE    345  
  
CHKA_HUMAN       350 WMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKS    399  
                     |||||:|||||||||||:|||::|||||||||||..||||||:||:||:.  
CHKA_MOUSE       346 WMYDYTYEKYPFFRANIQKYPSRKQQLHFISSYLTTFQNDFESLSSEEQF    395  
  
CHKA_HUMAN       400 IIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYF    449  
                     ..||:||||||||||||||||||||||||||||||||||:||||||:|||  
CHKA_MOUSE       396 ATKEDMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMEYAQARFEAYF    445  
  
CHKA_HUMAN       450 HQKRKLGV    457   
                     .|||||||  
CHKA_MOUSE       446 DQKRKLGV    453  
 
 
Identity: 402/457 (88.0%)  
Similarity: 433/457 (94.7%)  
Gaps: 6/457 (1.3%)  
 
Supplementary Table 1: ChoKα alignment between human and mouse protein sequences 
Protein sequences alignment  generated  by  EMBOSS  Needle  Global alignment tools 
(htp:/www.ebi.ac.uk/Tools/psa/emboss_needle/).  Residues in  bold (Tyr333,  Tyr345,  Phe361,  Trp420, 
Trp423, Ile433, Phe435, Tyr440) shown to be important for interaction with EB-3D or its stabilization, are 
perfectly conserved. Also Asp306 catalytic base for ATP hydrolysis is conserved. Vertical bar (|) indicates 
fuly conserved residue.  Colon (:) indicates conservation  between groups  of strongly similar properties. 
Period (.) indicates conservation between groups of weakly similar properties. 
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ABBREVIATIONS  
18F-FDG: 18F-fluorodeoxyglucose  
5-FU: 5-fluorouracil 
ATP: adenosine tri-phosphate 
AV: annexin V 
C12-FDG: 5-dodecanoylaminofluorescein-di-β-D-galactopyranoside 
CCT: phosphocholine cytidylyltransferase 
CD3+: cluster of differentiation 3-positive cels 
Cho: choline 
ChoK: choline kinase 
ChoT: choline transporter 
Cis-Pt: cisplatin 
CPT: choline phosphotransferase 
DAG: diacylglycerol 
DEX: dexamethasone 
Doxo: doxorubicin 
EGF: epidermal growth factor 
ER: endoplasmic reticulum 
FBS: fetal bovine serum 
GDPD: glycerophosphocholine phosphodiesterase 
GI50 = compound concentration required to inhibit cel growth by 50% GPC: glycerophosphocholine 
HUVEC: human umbilical vein endothelial cel 
IC50 = compound concentration required to inhibit enzyme by 50% L-ASP: L-asparaginase 
LPL: lysophospholipase Lyso-PtdCho: lyso-phosphatidylcholine 
MRI: magnetic resonance imaging 
MRS: magnetic resonance spectroscopy 
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazodium bromide 
NMR: nuclear magnetic resonance 
PA: phospahtidic acid 
PBL: peripheral blood lymphocyte 
PCho: phosphocholine 
PET/CT: positron electron tomography/computed tomography 
PHA: phytohematoagglutinin 
PI: Propidium iodide 
PLA1/PLA2/PLC/PLD: phospholipases A1/A2/C/D 
PtdCho: phosphatidylcholine 
QSAR: quantitative structure-activity relationship 
shRNA: short hairpin RNA 
siRNA: smal interfering RNA 
T-ALL: T acute lymphoblastic leukemia 
TNBC: triple-negative breast cancer 
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